MDM2との結合競合を介したTLPによるp53の活性化維持機構 by 前田, 亮 & MAEDA, Ryo
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ȆŞ
  ǚǯ²Ēš+Ȗė?> p53 ,ƏĵÖ-ǚǯ,CÖBɌ!8,ĳɞ*ǚǯ
ĴǓÞĴ'	>p53,ƏĵÖ+;=ȻÅ*ǚǯȷëȖė?(=AEzf
WY:ǚǯǩÖ(
$!âȰƺ*ĴǓBȀ!8+-ƏĵÖ p53 ,ƸƫɄǡņ
:ƏĵÖƧĺ,ņǠɂȆ'	>ǚǯ¾+
&p53-MDM2+;=ÄȋÉĮ
Bá&=p53
+MDM2,¤Ʈ<ȯ?> p53,ƏĵÖƧĺǡņ,
!8,Ɇ(*>?6',ǁǌ<TBPrD|+Ě>ȤÀïć'	> TLP 
(TBP-like protein) p53(Ǟåǚǯ²Ēš+ p21,ȤÀƏĵB>(ǅ
?&
!'ũǁǌ'-p53-TLP ƾ¤Ʈ9!<ÔůBŠ<+>
(BƼƺ(ƭÖĉƺǚǯƭƥĉƺȋŮ;/ in silicoȋŮBȀ$!Ǟů(
& TLP-ɨɪɩp53_nQBċčÖ>(ɨɫɩUVƢĖīŦ+
& p53
,ƏĵÖBņǠ>(ɨɬɩp53-MDM2 ǞåBɍĒ>(ɨɭɩp53 ,Ų
þȨȮBŀÉ>(ɨɮɩǲƶ,üƂBŀÉ>(ɨɯɩÖĉƷƋǻÌ+Ĕ
>ĹáĵBş>(Š<+?!,Ǟů+;=TLP-MDM2
+;>Äȋ< p53BĊ>(' p53,ŻǰBªȶ>p53-MDM2ǝȣ,ř!
*ÉĮïć'	>(ǅ?! 
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ģș
 Sk},ĊȜǆ(;.?> p53 -Ÿ*ǋɢ,YfY+ĴǓ&ǚǯü
Ƃ,±ž:EzfWYǚǯǩÖBĥȠħÐ*ȤÀïć'	> [1]p53-
ŕƹ+Ý0ŹƺȽć,ȤÀBÉĮ&
>Ś'ğĝš-ǚǯÄȂ,ĶĝĵBǡ
ņ>!8+ǚǯ¾+¢v'ǡņ?&
> [2], p53,ŀÉÉĮ-+
pOaN\'	>MDM2+;$&ȀA?MDM2- p53, NŨǏg~G
¾,ȤÀƏĵÖg~G+Ǟå>('p53,kpOaÖ;/zp
OaÖBªȶ> [3-5]p53,kpOaÖ-_nQȟ,ÄȋWRh
'	>zpOaÖBĆ×>"'*ŲþȨȮWRh(&Żǰ>
(ƿ<?&
> [6-9]p300 -ǚǯȟ',7 p53 ,pOaN\(&³
*)ǚǯȟ- p53 +($&ÄȋBá:
úľ'	=p53 BŲ+«ņ>
(- p53,ŻǰƏĵÖBǡņ>!8+ɂȆ'	>(Ǫ<?&
> [10] 
  p53-MDM2 ǝȣ- p53 ÉĮŻŷ,ųĠB*ǝȣ'	=66*ïć
p53-MDM2ƾ¤Ʈ+¤Ʈ>('ȻÅ* p53ƏĵÖ,LLrBÅ=ţ&

> [11]ǚǯ²ĒĥȠ?>(6Ç8+ ATM: Chk1/Chk2*),O
h\+;$&p53¾,MDM2Ǟåɟö+Ĉò> 18ƲƼ,YLi( 20
ƲƼ,[ɀÖ?> [12, 13]?+;=p53 - MDM2 <ȋɔ
Ž+ p300/CBP p53+Ǟå& p53, CŨǏg~G¾,XƁøBE[a
Ö>('p53-ÄȋB¸?>((9+ȤÀƏĵÖŻǰBƩĭ> [14, 15]
,ȵ,ÞĴBǝ&p53- p21: PUMA*),ŹƺȽć,ȤÀBƏĵÖǚ
ǯüƂ,ŀÉ:EzfWY,ȖėBȀ,Ś'ǚǯ²Ē+Ĕ>ĴǓÞĴ
ßŬ>(HDAC1/MDM2ȅå£ p531(ǞåǱE[aÖ;/p
OaÖBȌĆ>(' p53,ÄȋBªȶ> [16]6!øũȤÀïć TFIID
,Usibf, 1%'	> TAF1-ǚǯ²Ē,īŦ+
& p53(Ǟå55
ƲƼ,YLiBɀÖ>(ƿ<?&
> [17]?+;= p53 ,
MDM21,ǞåȉìĵüÑp21*),p53ŹƺȽć,t_<p53
ȋɔ> [18],;+p53 -ġÿ,ȅɓ*ïć+;$&,Żǰ:ǚǯ¾
ÕĺȘǖ?&=p53-MDM2 ǝȣ+ĩɜB>řȈ_nQȟBæč
,ŻǰBȋŮ>(-ǚǯ²Ēš, p53 ,ňÕB;=ſƬȋ>'Ŷ
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8&ɂȆ'	>(Ǫ<?> 
  TLP (TBP-like protein)- TBPrD|+Ě>_nQȟ'	=TBP,
CŨǏ«Ĉɟö( 38%,ƾæĵB9% [19, 20]TLP- TBP(-Ƴ*= TATA-less
t_+¤Ʈ>('y]}_nQȟ*),t_+
&
RNAz~\ II+;>ȤÀBªȶ>(ƿ<?&
> [21, 22]ǚǯ²Ē
+
&-TLP- p21: wee1UGQ G2*),ǚǯüƂ¤Ʈïć,ȤÀ
BÉĮ>('ǚǯêŦB±ž> [23, 24]?6',ǁǌ<TLP -
TBP(æŸ+ p53(Ǟåp53§Ĉƺ+ p21t_,ȤÀBƏĵÖ>
(Š<+?&! [25-27]*<
%),;+ p53	>
-
,ŹƺȽć+¤Ʈ&
>,(
$!Ȕǚ*ÉĮŻŷ-Š<+?&
*
$! 
 ũǁǌ'- p53,ÉĮŻŷ+> TLP,ŻǰBŠ<+>(BƼƺ(&
ȋŮBȀ
TLP  p53-MDM2 ƾ¤ƮBɍĒ>(' p53 ,ņǠƺċčÖB
ĥȠ(BŠ<+!TLP BkbQ`H!ǚǯ'-ǚǯ²Ēš+
p53,ƏĵÖšɊǀ*=EzfWY:ǚǯǩÖȖė?+
(ǅ
?!<+E_G}*ŲþȨȮ,ȋŮBȀ$!ǞůTLP-MDM2Ȗė
> p53 ,ŲþȨȮBŀÉ&
>(Š<+*$!ŜĈ,ćđɠCưŭ
, TLPýƳ£'- p53,Ǟåǰ(ǚǯüƂŀÉǰ¢
(ǅ?6!Ǣǥ
ƺ*Cǚǯ,fYQtf}ȋŮ,ǞůTLP,ƸƫɄ- p53ſĝ*
C+
&JfzWg*),ÖĉƷƋǻÌ+Ĕ>Ĺáĵ(ƾɋ>(Š<
+*$!,Ǟů+;=TLP - MDM2 , p53 +Ĕ>ǞåBɍĒǚǯ
²Ēš+
& p53,ɈŦƏĵÖBȖė>(Š<+*$!  
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Ūŗ(ŚƋ
1. ǚǯ÷ɤȽćėº 
 of,÷ɤǚǯ'	> HCT116ǚǯɨɃƭõɱHCT116 WTɲ	>
- p53żŎ
õɱHCT116 p53-/-ɲɩHeLaǚǯBƮ
&ȋŮBȀ$!HeLaǚǯ- DMEM-Low 
glucose (Wako) ÷ó'HCT116ǚǯ- DMEM-High glucose (Wako) ÷óBƮ

& 5% CO237	 '÷ɤ!?<,÷ó+- FBSɨHWǮ¹ǿƗɩB 10%w
iW-Yftf{GW(Gibco) B 100 unit/ml+*>;+Ñ!÷ɤǚǯ
1,Ƚćėº- Lipofectamine 2000 (Invitrogen) BƮ
&čƋȲ=Ȁ$! 
 
2. tY|gsiRNAshRNA 
 ƸƫƮtY|g(& pCI-neo (Promega)BƮ
FLAG_RHA_RBŉº
ī p53TLPMDM2,E|kɀTgɟöBUsQiR!p53, CŨ
Ǐ<ǨȐǠ;+ DronpaBȵǞ?B pTRE3G (Clontech)+UsQ
iR>('dfUGQȖėĵ, p53-DronpaƸƫvQ_B¤Ȅ
!6!Tet Lw_+Ǟå&ȤÀBƏĵÖ>gGm'	>
TET3G ,ƸƫvQ_(&pEF1α-TET3G B¥Ʈ!TLP +Ĕ> siRNA
,ȿÆ-,(='	>5’- UAACAGGGCCCAAUGUAAATT (sense)5’- 
UUUACAUUGGGCCCUAUUATT (antisense)shRNABƸƫ>!8+TLP
ȿÆ#1 (5’- GTAACAGGGCCCAATGTAA)#2 (5’- GGAGCAAATGTAATTTATA)
B pSilencer5.1-U6 retro (Thermo) +UsQiR! 
 
3. TLP shRNAċčƸƫű,àĭ 
 TLP ,ƸƫBċčƺ+ŀÉ>!8+ HCT116ɨɃƭõp53-/-ɩHeLa ǚǯ+
TLP shRNABƸƫ> pSilencerBėº4 µg/µl,q{GW+;>ǻ
ÌȼłīƭĈQBÚɔ!TLP,ƸƫŀÉ,ǊĤ- RT-PCR;/HJ
Y_sbf+;$&Ȓ¨! 
 
4. ǚǯńÃƔ,ȘȄ;/HJY_sbf 
 [YQn'ǚǯBîßī+ LysismbrD (Tris-HCl pH 7.6150 mM 
  6 
NaCl1 mM EDTA10%R[0.1% NP-40PI mix)+Ļƞ!Ɣ£Ǎ
ǘBƮ
&ÁǞǾȋB 3îǣ=Ȭ!,#13000 rpm' 20ÄȺĲÄɔƗB
»ǚǯńÃƔ (WCE)(!UtB 12.5%, SDS zEQE|gSB
Ʈ
&ɕƄƍÕ!9,B PVDF Ǵ+ȤÀPVDF Ǵ+Ǟå!_nQȟB
? ?,ƦƳƺŁ£BƮ
&ŵÃ! 
 
5. RT-qPCR 
  » RNA- RNeasyObf(QIAGEN) BčƋȲ=Ʈ
&îß!Ž+ 0.5 µg,
» RNAB Prime Script II (TaKaRa) BƮ
&ȰȤÀÞĴBȀ$!ĭ<?!ȰȤ
ÀÞĴƥBɅõ(& Thunderbird qPCR Mix (Toyobo)BƮ
&čɄ PCR (qPCR)
BȀ$!¥Ʈ!tG{-ȁ 1+ȏ 
 
6. TirK~WEb[G 
 HCT116ǚǯB 35 mmeFbW+ŏ24šɊī+ 50 J/m2, UVBƢĖ
!7ŝɊ÷ɤ!,#Fix & Staining solutionɨPBSQY_mGLbf
1ɧx}Eeog1%~_kɩ'ñč(ŰǷBȀ
100ǚǯ'Ĩļ
?!ǚǯTiŕBȍƚ! 
 
7. β-NQfW`\ŰǷ 
 UV ²Ē+;>ǚǯǩÖBŵÃ>!8, β-NQfW`\ŰǷ-Cellular 
Senescence Assay Kit (Chemicom)BƮ
&čƋȲ=+Ȁ$!,īɗǷ+èǷ
!ǚǯŕBȍƚ! 
 
8. WrI\Eb[G  
 HCT116ǚǯB 24HItf+ 110ɭ ­%ŏ24šɊī+z_
;/JrIQ_ȽćBėº!, 24šɊī+ Dual-Luciferase Reporter 
Assay System (Promega) BƮ
&čƋȲ=+t_ȋŮBȀ$!ȃſƮt
Y|g(& pRL- TK (Promega)B 5 ngėº! 
 
9. 2-lGsbgEb[G 
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 HCT116 p53-/-ǚǯB 24 HItf+ 110ɭ  ­ŏ24 šɊī+
pBIND-TLP/pACT-p53ƸƫvQ_Bėº!, 24šɊī+Dual- Luciferase 
Reporter Assay System (Promega) BƮ
&ȋŮBȀ$! 
 
10. ǜ7ō_nQȟ,ǗȄ 
 pET-FH-TLPpET-FH-p53pGEX-TLPpGEX-p53 BĀǳǸ BL21 ű+Ĩȟ
Ȥō!Ê÷ɤ(&? ?,ĀǳǸűB LB÷ó+Ōǋ&37	 'Ţ÷ɤ
!ũ÷ɤ,÷ó+Ĕ& 4%Ä,Ê÷ɤƔBÑ27	 ' OD600 0.5+*>6
'÷ɤ!Ž+isopropyl-1-thio-β-D- galactoside (IPTG) BǛƟĤ 0.5 mM+*
>;+Ñ<+ 3šɊ÷ɤ!ɒǸīPBS(-)'ƎƑĀǳǸƝȋmbr
DBÑƅ' 20ÄɊɘǤ!,( FHǞå_nQȟƮƝȋmbrD
(PBS(-)500 mM NaCl10% R[1% Triton X-10010 mM G|`
^tdE\Gop_ɍĒÌ (PI mix; 1 mM vZE| HCl1 
µg/ml 3tY_a A0.5 mM rIi~aYrKirLGg1 µg/ml 
Gwta ) ) (GSTǞå_nQȟƮƝȋmbrD (PBS(-)500 mM NaCl
10% R[0.5 mM EDTA1% Triton X-100PI mix) B¥
Ä!ȡ
ɛƌ' 30ǈÂƬī+ƅ' 1ÄɊɘǤ>ő¤BƝȋƔ,ƞ=**>6'Ȁ$
!	(9,500 rpm4	 ' 20ÄɊȺĲÄɔƗBĀǳǸńÃƔ(! 
 FHǞå_nQȟƸƫĀǳǸƝȋƔ+-Ni-NTA  Agarose pZ (NipZ
QIAGEN)BÑ4	 ' 1šɊȤ¯ƕì!FHǞå_nQȟƮƝȋmbrD
' 4îƎƑīFHǞå_nQȟƝÃmbrD(PBS(-)500 mM NaCl10% R
[1% Triton X-100500 mM G|`^PI mix) BpZ(ǒɄÑ
 4	 ' 10ÄɊȤ¯ƕì!2,000 rpm30ǈ,ȺĲīƗBɒ8!ƝÃ,
ő¤-ǣ=Ȭ& 3îȀ$!ɒ8! FHǞå_nQȟ-Ⱦ+ 5 Ut
RmbrDBÑŹƜ_nQȟ(&HWǿƗEs|(BSA)BƮ
&
SDS- PAGEBȀ
CBBŰǷ+;$&čɄ! 
 GST Ǟå_nQȟƸƫĀǳǸƝȋƔ+ Glutathione Sepharose 4B (GE 
Healthcare Bioscience)BÑ4	 ' 1šɊȤ¯ƕì!GSTǞå_nQ
ȟƮĀǳǸƝȋmbrD' 5îƎƑī+10%ĻƞƔ+*>;+ƎƑmbrD
BÑ!GST Ǟå_nQȟ,Ʉ9 FH Ǟå_nQȟ(æŸ+,ȾB¥
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$&čɄ! 
 
11. GSTt`HEb[G 
 TNEmbrD(50 mM Tris- HCl (pH 7.9)150 mM NaCl1 mM EDTA10% 
R[0.1% NP- 40PI mix) + FH_RǾå_nQȟ;/R_
aLpZ+Ǟå! GST Ǿå_nQȟBÑ4	 ' 3 šɊȤ¯ƕì
!TNEmbrD' 3ĤƎƑ2SDS UtRmbrDBÑ98	 
' 5ÄɊƣƈ!,UtBƮ
& SDS-PAGEBȀ
_nQȟBHJY
_sbdFR+;=ŵÃ! 
 
12. ¸Ƶ¼ƇɎƋ 
 HCT116ǚǯ+ƸƫvQ_BfYrIQW24šɊī+ǚǯBîß
!ǚǯB PBS'ƎƑīLysismbrD+ĻƞȡɛƌÂƬ 1ǈ10îB
5[bfȀ$&ǃǂ!ƅ' 20ÄɊɘǤī+ 4	 13,000 rpm' 20ÄȺĲÄ
ɔƗBîß!< 3 µlB¥Ʈ& BCA protein assay kit (Pierse)B
Ʈ
&_nQȟƟĤBƚč!,(Ⱦ+ 5SDS UtRmbr
DBÑ&ƚč+>Gtbf(!WCE 300 µg+Ĕ&ANTI-FLAG 
M2 Affinity Gel (Sigma)Tf(&IgG Sepharose 6 Fast Flow (GE 
Healthcare Bioscience) B 10 µl%Ñ4	 ' 3šɊȤ¯ƕì!TNEmbr
D' 3 îƎƑīƝÃmbrD (TNE mbrD+ 0.5 mg/ml +*>;+
FLAGwtag (Sigma) BÑ!9,) B 10 µlÑƅ' 10ÄɊɘǤ!,#
2,000 rpm' 30ǈȺĲÄɔƝÃƔBĭ!,ő¤B 3Ĥǣ=Ȭ!ɒ8!
ƝÃƔ+ 5UtRmbrDBÑ98	 ' 5ÄɊƣƈ!_nQȟ-
HJY_sbdFR+;=ŵÃ! 
 
13. in vivo pOaWEb[G 
 HCT116 ǚǯ+ƸƫvQ_BfYrIQW24 šɊī+ 10 µM ,
MG132BƖÑ3šɊ÷ɤ&ǚǯBîß!< 2Ȳ=,ŚƋ+Ĭ$&
Eb[GBȀ$!1 %Ƽ,ĿƋ(&ǚǯB PBS 'ƎƑīRIPA mbrD
ɨTris-HCl pH 7.6150 mM NaCl1 mM EDTA10%R[1% 
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TritonX-100 0.5% eLOWTɀhfH}0.1% SDS20 mM N-Ja{
G|gPI mixɩ+Ɲ!,#+¸Ƶ¼ƇɎƋ(æŸ,Ŀɝ' ANTI-FLAGŁ
£BƮ
&¸ƵƇɎBȀ$!2 %Ƽ,ĿƋ(&ǚǯB SDS lysis mbrD
ɨTris-HCl pH 7.6150 mM NaCl1 mM EDTA10%R[1% SDS
20 mM N-Ja{G|gPI mixɩ+Ļƞ 98	 ' 10 ÄɊÑƤ!,ī
DilutionmbrDɨTris-HCl pH 7.6150 mM NaCl1 mM EDTA10%R[
1% TritonX-10020 mM N-Ja{G|gPI mixɩ' 10®ĜɁ!
	(+ANTI-FLAG Ł£BƮ
&¸ƵŁ£BȀ$!FLAG-p53 +Ǟå!p
OaɄBHJY_sbf+;=čɄ! 
 
14. ¸ƵŰǷ 
 HCT116ǚǯB PBS'ɪîƎƑīfix solution (PBS4% nx}Eeog
20 mM MgCl25 mM EGTA)' 10 ÄɊñč!,ī PBS 'ƎƑ0.5% 
TritonX-100' 10ÄɊǴȱȸÂƬBś!Blocking One Histo (hMG)BƮ
& 15
ÄɊsbORÂƬBȀ
äƦƳƺŁ£B 37	 ' 1šɊÞĴ!<+ PBS
'ƎƑī+ Alexa Fluor 488Źț?!Ł{HY;/ŁHUP IgGŁ£B 37	 '
1šɊÞĴFluoro-KEEPER Antifade Reagent with DAPI (hMG)'ĕºī¼
ơƠVɡİɇBƮ
&Ȋē! 
 
15. ƭǚǯŲþȨȮƚč 
 HeLaǚǯ+pTRE3G-p53-Dronpa;/pEF1α-TET3GBfYrIQW
30 ng/ml,gOWUGQBÑ!,#24šɊ÷ɤ!,ī 5 µg/µl,W
QuOW|g( 10 µM,MG132ĳȆ+Ĵ& 10 nM,tf{GW B( 10 
µM , Nutlin-3a BƖÑ!p53-Dronpa ,ǽ·-¼ơƠVɡİɇ, 60 ®
ZBƮ
&Ȋē!6Ç8+ 488 nm ,VB 5 ǈħƢĖ>('
Dronpa,ǽ·BƓăŽ+ 405 nm,VBŲ¾ɟö+,7 10|ǈƢ
Ė>('Ų¾, p53-DronpaB¿ÓȠ!,Ƨĺ<İĦ* 488 nm,
V+;$&ǚǯȟ1(ƐÃ> Dronpa,WRhBƚč!kGZɏÛ-
MetaMorph]rfHIE(Molecular Devices, Co)+;$&Ȁ
ŲþȨȮɄ-,
ȍǔ+;=ǔÃ!ɰ 
  10 
Export = (Ct/C0) × (T0/Tt) 
Ct-¿ÓȠ< tǈī,ǚǯȟ,ğôWRhħĤBC0-¿ÓȠƽī,ǚǯȟ,ğ
ôWRhħĤBǅ6! Tt- t ǈī,»£,ğôWRhħĤBT0-¿Ó
Ƞƽī,»£,ğôWRhħĤBǅT0/Tt ƃ-šɊǝȸ+> Dronpa,ǽ·
,ȭ·Bȃſ>!8,©ŕ(&¥Ʈ!Ę*(9 10ǚǯBƮ
&ŲþȨȮ
ɄBȍǔ,ğô°BRrÖ! 
 
16. ǻÌĹáĵȋŮ 
 Cǚǯű+> TLPMDM2CDKN2Ap53 ,ƸƫɄ-ArrayExpress 
(https://www.ebi.ac.uk/arrayexpress/accession number: E-MTAB-783);=ºĿ!ǻ
ÌĹáĵ,ǊĤBǅ°(&ØǶƀɄɨIC50ɩBȍǔ+Ʈ
!6!ÖĉƷƋǻ
Ì(&Garnett<,șŖ[28]+ȏȧ?&
>Ȳ=sL{GWMtfd
WWYtaW_pg[_O[gO]pWJfzWgS
}W_p~ffO[f{Gf{GW CnQ_O[psYa
pkpBȼł?<, IC50°B¥Ʈ!{GQEG,ƭe_
<,ƸƫɄ,ńÃ- R ]rfHIE(mX 3.1.2)BƮ
& MAS5 (Microarray 
Analysis Suite 5 method)+;=Ȁ
»&,°BĝƮĔŕ+ýō!9,Bȍǔ+Ʈ

!  
 
17. ǟȍȋŮ 
 R]rfHIEBƮ
&tŵčÄŔÄŮdO, HSDŵčµȿǤÄ
ŔÄŮqE],ƾɋŵčBȻĎĳȆ+Ĵ&Ȁ$! 
  
 
 
 
 
 
 
 
  11 
Ǟů
1. TLP- p53,ċčĵBüĀp53,ȤÀƏĵÖǰBɦ8>  
 6Ç8+ p53,Żǰ+Ĕ> TLP,ĪÏBȘ2>!8+TLPBkbQ`H
!ɑ, p53,ƸƫBȘ2!ofĀǳCưŭ,ǚǯű'	> HCT116ǚǯBƮ

& TLPBȸƺ;/ċčƺ+ŀÉ!(@p53,_nQȟɄ,ƙĘ
7<?!ɨFig. 1ABɩÑ&ƸƫvQ_BƮ
& TLP BĽƸƫ>(
p53,_nQȟɄ,ş7<?!ɨFig. 1Aɩ,(<TLP- p53,Ƹ
ƫɄBýÖ&
>(Ǫ<?!6!TLP BkbQ`H!ɑ
HCT116ǚǯHeLaǚǯ,
?+
&9ɡǺ*ǚǯüƂ,ȶ7<?!ɨFig. 
1CɩŽ+ TLP- p53B_nQȟv'ÉĮ&
>)BŠ<+>
!8+_nQȟ,åļɍĒÌ'	>WQuOW|gBƮ
& p53 ,ÄȋȳĤ
BŵȎ!,ǞůTLPBȸÎƸƫ>( p53,_nQȟċčĵ-üÑ
Ś' TLPBkbQ`H>( p53,_nQȟċčĵ-ƙĘ>(Š<
+*$!ɨFig. 1DEɩp53,ŹƺȽć'	> p21:MDM2+
&9TLP
,kbQ`H+ p53 ,_nQȟ,ƙĘ+$!_nQɄ,ƙĘ7<?
!ɨFig. 1Eɩ?-mRNAv'9Ȋē>('TLPBkbQ`H
!ɑp53+;$&ƏĵÖ6!-ŀÉ?>Ƚć-? ?ƙĘüÑ>(
A$!ɨFig. 1Fɩ,Ś'p53ǵ£,mRNA-ƙĘ7<?ɨFig. 1Fɩ
_nQȟ,ÄȋɍĒÌ'	> MG132BÂƬ!ɑ+- TLP,kbQ`H+;
>ĩɜ7<?*$!ɨFig. 1Gɩ<+ƸƫvQ_+;> p53 ,ȸÎƸƫ
+
&9 TLP,kbQ`H+;$& p53,_nQȟ,ƙĘ7<?!(
<ɨFig. 1HɩTLP- p53B_nQȟv'ċčÖ&
>(ǅ?! 
 
2. TLP- UV²ĒĴǓ+> p53,ɈŦƏĵÖ+ĳȆ'	> 
 ǚǯ²Ē+> TLP, p531,ĩɜBŠ<+>!8+UVBƢĖ!
ɑ, TLP ,ŻǰBȋŮ!TLP ,ƸƫBċčƺ+ŀÉ> HCT116 ǚǯűBƮ

&1050 J/m2, UVBƢĖ 36šɊī, p21MDM2,ƸƫɄB RT-qPCR
'ƚč!,Ǟů50 J/m2, UV ƢĖ+
& TLP ŀÉ?&
>ǚǯ
'-Tf,ǚǯ(ƃȦ& p21MDM2 Ƚć,ƏĵÖ9¢>(
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ǅ?!ɨFig. 2Aɩ,ǚǯBƮ
& UVƢĖ< 4šɊ(, p53,_n
Qȟ(ŹƺȽć,ýÕBȘ2!p53( p53,ƏĵÖ{Q'	> p53, 382Ʋ
Ƽ,X,E[aÖ-(9+ 4šɊ¾+ş7<?UVƢĖĴǓ,īŦ'
	> 32šɊ4)'ƙĘ>(Š<+*$!ɨFig. 2BɩTLP,Ƹƫ- 32š
ɊƼɎ'Ƹƫş>(Ȋē?TLP BkbQ`H!Ƨĺ+
&
-?<, p53,_nQȟ,ƙĘ;=ɡǺ+*>(ǅ?!ɨFig. 2BɩÑ
&p21_nQȟ+
&9 TLPkbQ`H+;=ƏĵÖ¢*>(
ǅ?!ɨFig. 2Bɩ 
 Ž+ TLP kbQ`Hǚǯ+> UV ƢĖī, p53 ,ŹƺȽć,ƸƫB
RT-qPCR+;$&ŵȎ!ǚǯêŦ±ž+ɋA>Ƚć'	> p2114-3-3:
EzfWYBªȶ>Ƚć'	>PUMA:Fas*), p53+;$&ſ+Șǖ
?&
>Ƚć-UV ƢĖĴǓ,īŦɨ32-48 šɊɩ+
& TLP kbQ`H
+;=ɡǺ*ƸƫɄ,¢7<?!ɨFig. 2CɩŚ'ǚǯêŦBȶȀ>Ƚ
ć'	> CDC20 : FOXM1 *), p53 +;$&Ȟ+ÉĮ?&
>Ƚć+

&-?<,šɊ+
& TLPkbQ`Hǚǯ'ƸƫɄş>(
Ǟ
ů+*$!ɨFig. 2Cɩ6!TLP,ȤÀɄ-ťĸ+ş*$!(<TLP
- p53+;$&ÉĮ?&
*
(9Š<+*$!ɨFig. 2CɩŤī+ UVƢĖ
ī,ǚǯȷëBȘ2!(@TLP kbQ`Hǚǯ+
&-ƭĈƪTf
ǚǯ(ƃȦ&®ɦ
(ɨFig. 2DEɩǚǯǩÖ+Ĕ>ŃŁĵBǅ
(Š<+*$!ɨFig. 2Fɩ,Ǟů<TLP- UV²Ēš+ p53,
ɈŦƏĵÖBĥȠEzfWY:ǚǯǩÖ*)BſȖė>(Ǫ
<?! 
 
3. TLP- p53,ȤÀƏĵÖg~G+Ǟå> 
  TLP ( p53 -Ǟå>(Š<+?&
>(<Ž+ p53 , TLP Ǟ
åg~GBȋŮ!p53 ,»ö+A!$&ûøǤōýƳBėºɨFig. 3Aɩ
TLP( p53,ÙȘƏĵÖǰBWrI\Eb[G+;=ƚč!,Ǟů
p53,ȤÀƏĵÖg~G¾+¡Ǥ> 2223ƲƼ,GWftfrDB
R_|[+Ǥō! p53ýƳ£+
&p53( TLPB¼ȸÎƸƫ
!ɑ,ÙȘƺ*ȤÀƏĵ¢
(Š<+*$!ɨFig. 3Bɩ6! 2-lGsb
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gEb[GGSTt`H¸ƵƇɎ,Ǟů,ýƳ£- TLP(,Ǟåǰ¢
&
>(ǅ?!ɨFig. 3CDEɩ,Ǟů<TLP- p53, NŨ
Ǐ¾,ȤÀƏĵÖg~G+Ǟå>(Š<+*$! 
 
4. TLP- p53-MDM2,ǞåBɍĒ>(' p53,ÄȋBĄ> 
 TLP+;> p53ċčÖ,Ȕǚ*ŻŷBȘ2>!8+p53-MDM2ƾ¤Ʈ+
> TLP,ŻǰBȋŮ!TLPBȸÎƸƫ>( p53-ċčÖMDM2BȸÎ
Ƹƫ>( p53,_nQȟɄ,ƙĘ7<?>ŚTLPMDM2B¼ȸÎƸƫ
>(?<,ƙĘ7<?**$!ɨFig. 4Aɩ<+MDM2+Ǟå*

 p53ýƳ£ LW22/23QSBȸÎƸƫ>(æš+ TLPBkbQ`H!(
@,ýƳ£,_nQȟɄ-ƙĘ*
(Š<+*$!ɨFig. 4BɩŽ+
TLPBȸÎƸƫ!ɑ, p53,pOaÖɄBƚč!(@TLP,ƸƫɄ
ü>+!$& p53+Ǟå!pOa,ƙĘȊē?!ɨFig. 4Cɩ,
Ǟů-MDM2BȸÎƸƫ>('<+ɡǺ+*=ɨFig. 4DɩTLP(MDM2
-¼+ p53, TAD+Ǟå>(<Ǫ&TLP- p53-MDM2,ǞåBɍĒ
&
>(Ǫ<?! 
 ,ȗſ
)Bŵȑ>!8+ȓɥǕ¾ǚǯ¾+>Ǟåǐå
ďɥBȀ$!ĀǳǸ;=_nQȟBǗȄɨFig. 4EɩGST t`HBȀ$
!ǞůɃƭõ, MDM2 +
&- MDM2-p53 ,ǞåüÑ>+$&
TLP-p53 ,Ǟå,ƙĘ7<?!ɨFig. 4Fɩ,Ś'p53 ǞåǰB9!*

MDM2G58A ýƳ£BƮ
&æŸ,ďɥBȀ$!(@  [29],ýƳ£-
TLP-p53,Ǟå+ĩɜBÝ5*
(Š<+*$!ɨFig. 4Fɩ, TLP
MDM2+;>p53+Ĕ>Ǟåǐå-ǚǯ¾'9Ȋē?TLP,ƸƫɄş
TLP-p53ǞåüÑ>+$&MDM2-p53ǞåƙĘ>(ǅ?!ɨFig. 
4Gɩ?<,Ǟů<TLP - p53-MDM2 ,Ǟå+ĞƘMDM2 +;> p53
,pOaÖBɍĒ>(' p53BċčÖ&
>(Ǫ<?!ɨFig. 4Hɩ 
 
5. TLP-MDM2+;> p53,ŲþȨȮBŀÉ> 
 MDM2-p53 ÉĮŻŷ+> TLP ,ĪÏB<+Š<+>!8+TLP +
;> p53,ęòýÖBŵȎ!HCT116ǚǯ+
& p53( TLP-4(C)Ų¾
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+ęò7<?>ɨFig. 5AɩTLPBkbQ`H>(' p53,ǚǯȟ1,
ęò,üÑȕ8<?!ɨFig. 5Bɩp53,ŲþǉȀ-MDM2+;$&ÉĮ?&

>!8âȰƺ+Ƹ·BÉĮ>(,'>ǽ·_nQȟ'	> DronpaBƮ

& [30]TLP/MDM2+;> p53,ŲþǉȀBƭǚǯ'ŵȎ!ɨFig. 5Cɩ¼ơ
ƠVɡİɇ'ŵÃâǰ*Ť¢Ʉ,DronpaB TET-onWYd}BƮ
&HeLa
ǚǯ+Ƹƫ!ɨFig. 5DEɩ*,úå+
&9 TLP BkbQ`H
>(+;= p53 ,ǚǯȟęòÖǄȕ?!ɨFig. 5FɩWQuOW|g(
MG132BƮ
&_nQȟåļ(ÄȋBɍĒ!ī488 nm,VBǚǯ»
£+ƢĖ>(+;= p53-Dronpa ,ǽ·BƓă!Ž+Ų¾ɟö+,7
405 nm,İĦ*VBƢĖ&,ɟö,7į·!,#Ų<ƐÃ
> p53-Dronpa,ɄBƚč!ɨFig. 5GHɩ ,ǞůȲĝ'- 10%+ƛ!*

Ʉ, p53-Dronpa 720ǈ'ǚǯȟ1(ǉȀ>,+Ĕ&TLPBkbQ`H
!ǚǯ+
&- 30-40%, p53-Dronpaǚǯȟ1ǉȀ>(Š<+*
$!ɨFig. 5HFig. 5Iěɩ,ƫȝ-ŲþȨȮ,ɍĒÌ'	>tf{GW B
:ɨFig. 5IĂɩp53-MDM2ǞåBMDM2+¤Ʈ&ɍĒ> Nutlin-3a [31]
BƮ
!(+7<?*$!ɨFig. 5Iãɩ,Ǟů;=TLP-MDM2
×> p53,ŲþȨȮBŀÉ&
>(Ǫ<?! 
 
6. TLP-ǲƶ,üƂBŀÉ> 
 ?6'7<?!ƫȝ+> p53+Ĕ> TLP,ƭƬĉƺĸǧBŵȎ>!8
+C,Ƹȹ;/CƉƷ+> TLP,-!<BȋŮ!TLPkbQ
`H HCT116ǚǯBjg{HY+ǉŴ25ŝɊɣǭ!,#+Ĩļ?!ǲ
ƶ,ɂBƚč!ǞůĔƢǦ(ƃ2&ťĸ+ɂ
(ǅ?!ɨFig. 6AɩTLP
,ĂȾÄ80-115ƲƼ,E|kɀɟö p53,Ǟåɟö'	>!8of,ćđ
ɠC<Ƹȇ?! TLPýƳ£ D99H[32, 33] BƮ
&,ŻǰBȘ2!ɨFig. 
6BɩGST t`H,Ǟů,ýƳ£'- p53 (,Ǟå¢ɨFig. 6Cɩ6
!p53 §Ĉƺ*ǚǯüƂ,ŀÉǰɃƭõ(ƃȦ&¢
(Š<+*$!
ɨFig. 6DEɩ?<,Ǟů<TLP-p53Ǟå-C,ŀÉ+ĳȆ'	>(
Ǫ<?! 
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7. TLP-ÖĉƷƋǻÌ+Ĕ>ĹáĵB> 
 Ťī+Garnett <Ȁ$!Cǚǯű+>Ǣǥƺ*ȽćƸƫ;/ǻÌǫ
ĵǰȋŮ,e_[28]BƮ
&TLP,ƸƫɄŁCÌ,Ĺáĵ+ĩɜBÝ5
)BŵȎ!6CǚǯűB p53,ƧĺɨɃƭõ6!-ýƳõɩ'Äɢ
?<Cǚǯ¾, TLP,Ƹƫv(ÖĉƷƋǻÌ,Ĺáĵ,ŇŹ'	>ØǶƀ
ɄɨIC50ɩ(,ƾɋBǔÃ!,Ǟůp53Ƀƭõ,Cǚǯ+
&-TLP
,ƸƫɄ(ǻÌ,Ĺáĵ(Ȟ,ƾɋýƳõ(ƃȦ&ɦ
(ǅ?!ɨFig. 
7Aɩ(=AJfzWg+Ĕ> TLP ,ƸƫɄ,ƾɋ-ɦp53 Ƀƭõ'	
>(( TLP,ƸƫɄ-ƾƺ+¤Ʈǚǯ,ǻÌĹáĵBş>(Š
<+*$!ɨFig. 7BɩÑ&Ƀƭõ, p53 Bņ%C'ȇ<?>Ʀı'	>
MDM2ƸƫɄ,üÑ: CDKN2AƸƫɄ,¢(æŸ+TLP-Ƀƭõ p53,C
+
&Ƹƫťĸ+¢&
>(Š<+*$!ɨFig. 7Cɩ,Ǟů
<TLP- p53§Ĉƺ+ǚǯ+ÖĉƷƋǻÌ+Ĕ>ĹáĵB>(Š<
+*$!  
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Ǫē
 ?6',ǁǌ<p53;/,ŹƺȽć,ƏĵÖɄ(ƏĵÖņǠšɊǚ
ǯêŦ,±ž:EzfWYǚǯǩÖ(
$!66*ǚǯȷë,Ȇ*ƆčȆ
ï'	>(Š<+?&! [34, 35]ũǁǌ+;=TLP- p53_nQ
ȟ,ċčĵBüÑ>(' p53 +;>ȤÀŻǰBɦ8>(Š<+?
,Ǟů(&EzfWY:ǚǯǩÖBªȶ>(ǅ?!UV ²Ēī
TLP - p53 ,ƏĵÖBņǠ>(Š<+?,ƫȝ- TLP  p53 ,
ȤÀƏĵÖg~G+Ǟåp53-MDM2 ǞåBɍĒ>('ĥȠ?>
(ǅ?!6!, TLP +;> p53-MDM2 Ǟå,ɍĒ-p53 ,ŲþȨȮ
BŀÉp53 BŲ+«ņ>,+ĳȆ*Żŷ'	>(Ǫ<?!Ñ&TLP
C,üƂBŀÉ&
>(ÖĉƷƋǻÌ+Ĕ&ĹáĵB>(9Š<
+?!?<,Ǟů-TLP p53-MDM2ǝȣ+>MDM2ɍĒïć'
	=p53+;>ȻÅ*ǚǯȷëƆčBȃÒ>³B9%(Bǅ&
>ɨFig. 
8ɩ 
 TBP- RNAz~\ II+;$&ȤÀ?>Ƚć,t_+Ĉò
> TATA ybQY+ǞåȤÀɉąȅå£,ĨļBȖė>_nQȟ'	> 
[36]TLP-,ɢ ïć(&æč?y]}Ƚć,åļ*)66*
ƭƬĉƺ*t[Y+ɋA$&
> [19-22]6!TLP -øũȤÀïć'	>
TFIIA (Ǟå>('TBP-TFIIA ,ǞåBɍĒ> [37]TLP (Ǟå!
TFIIA-_Yn\ 1+;>ÅŘB¸?>('Ǟů(& TBP+;>ȤÀ-ŀ
É?> [37],(<9TLP,Żǰ, 1%(&_nQȟ-_nQȟ
ƾ¤Ʈ+Ĕ>ĞƘ¤ƮǪ<?> 
 p53(,ȤÀïć(,ɋA=-əĝ+ȅɓ'	>(=Ap53+;>ȤÀƏ
ĵÖŻŷ+>øũȤÀïć,ĪÏ-ŧ"+4(C)Š<+?&
*

TFIIH -øũȤÀȅå£Bŷļ> 1 %,_nQȟ'	=p53 ,ȤÀƏĵÖB
ªȶ>(' DNA ¬į*)+ɋ>(:[38]TBP - p53 +;>ȤÀƏĵ
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Ref, ÜǪŖƨ 
Gene Forward (5'-) Reverse (5'-) Size (bp) Ref 
14-3-3σ ACTACGAGATCGCCAACAGC CAGTGTCAGGTTGTCTCGCA 149   
CDC20 GCAAGGAGAACCAGCCTGAA ACCGTTCAGGTTCAAAGCCC 80   
Cyclin B1 CGCCTGAGCCTATTTTGGTTG CAGAGAAAGCCTGACACAGGT 96   
Fas CTTCCCATCCTCCTGACCAC TCGTAAACCGCTTCCCTCAC 113   
FoxM1 TGCCCAGATGTGCGCTATTA TCAATGCCAGTCTCCCTGGTA 69 46 
GADD45A ACGATCACTGTCGGGGTGTA CCACATCTCTGTCGTCGTCC 106   
MDM2 CAGCAGGAATCATCGGACTCA AGGTCCTTTTGATCACTCCCAC 80   
NOXA CTGGAAGTCGAGTGTGCTAC GTTCCTGAGCAGAAGAGTTTGG 101   
p21 CTGGGGATGTCCGTCAGAAC CATTAGCGCATCACAGTCGC 101   
p53 GTTCCGAGAGCTGAATGAGG TTATGGCGGGAGGTAGACTG 123 47 
PIG3 AAATTCACCAAAGGTGCTGGAGT TCCGCCTATGCAGTCTAGAATAAGA 51 48 
PTEN GACAGCCATCATCAAAGAGATCG TCTGCAGGAAATCCCATAGCAA 117   
PUMA CTCGGTGCTCCTTCACTCTG AGGCTAGTGGTCACGTTTGG 108   
TLP  TGCAGACAGTGATGTTGCAT GCTCCTTCCAAAGCAATCTTCC 102   
















Interaction between Transactivation Domain of p53 and
Middle Part of TBP-Like Protein (TLP) Is Involved in TLP-
Stimulated and p53-Activated Transcription from the
p21 Upstream Promoter
Ryo Maeda, Hidefumi Suzuki, Yuta Tanaka, Taka-aki Tamura*
Department of Biology, Graduate School of Science, Chiba University, Chiba, Japan
Abstract
TBP-like protein (TLP) is involved in transcriptional activation of an upstream promoter of the human p21 gene. TLP binds to
p53 and facilitates p53-activated transcription from the upstream promoter. In this study, we clarified that in vitro affinity
between TLP and p53 is about one-third of that between TBP and p53. Extensive mutation analyses revealed that the TLP-
stimulated function resides in transcription activating domain 1 (TAD1) in the N-terminus of p53. Among the mutants,
#22.23, which has two amino acid substitutions in TAD1, exhibited a typical mutant phenotype. Moreover, #22.23
exhibited the strongest mutant phenotype for TLP-binding ability. It is thus thought that TLP-stimulated and p53-
dependent transcriptional activation is involved in TAD1 binding of TLP. #22.23 had a decreased transcriptional activation
function, especially for the upstream promoter of the endogenous p21 gene, compared with wild-type p53. This mutant did
not facilitate p53-dependent growth repression and etoposide-mediated cell-death as wild-type p53 does. Moreover,
mutation analysis revealed that middle part of TLP, which is requited for p53 binding, is involved in TLP-stimulated and p53-
dependent promoter activation and cell growth repression. These results suggest that activation of the p21 upstream
promoter is mediated by interaction between specific regions of TLP and p53.
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Introduction
p53 is one of the most typical tumor suppressors that works as a
transcriptional regulator for many genes related to apoptosis
induction, DNA repair and cell-cycle repression [1–3]. p53 is
destabilized by association with MDM2 ubiquitin ligase, which
brings p53 to a proteasome-directed proteolytic pathway. When a
genotoxin signal enters a cell, intracellular kinase cascades
involving ATM/ATR and Chk1/Chk2 functions to phosphorylate
p53, which results in release of MDM2 from p53 [4–6], and the
phosphorylated p53 proteins form a homotetramer and bind to its
target sequence of a responding gene [1,7,8]. p53 forms a gene
family together with TAp63 and p73, all of which have the same
consensus sequence [9–12].
p21 (p21Waf1/Cip1) is a representative p53-responsive gene and
antagonizes a Cdk that functions as a cell-cycle engine [13,14].
p21 mainly works in a G1-to-S transition period and triggers G1
arrest followed by apoptosis. Hence, p21 is regarded as a potent
checkpoint factor and tumor suppressor. Expression of the human
p21 gene is regulated by multiple regulatory factors such as p53,
Sp1 and MyoD [15,16]. The human p21 gene has two major
promoters: a TATA-box-containing downstream promoter and a
TATA-less upstream promoter [17,18]. Since both promoters
have p53-binding sites, they are stimulated by genotoxic stresses.
We have identified TLP (TBP-like protein) as a novel regulatory
factor for the upstream promoter [19]. TBP (TATA-binding
protein) is one of the general transcription factors that binds to a
TATA-box promoter element of RNA polymerase II-driven genes
[20]. Transcription factor IID (TFIID), which consists of TBP and
multiple TBP-associated factors, is recruited to a TATA-contain-
ing promoter and triggers transcription initiation [21,22]. TBP
comprises a gene family that includes (TBP-related factor 1)
TRF1, TLP/TRF2, TRF3, and TRF4 in addition to TBP [23–
28]. TLP has 38% identity to the C-terminal conserved region of
TBP and binds to transcription factor IIA (TFIIA) more strongly
than TBP does [29,30]. Previously, we demonstrated that TLP
inhibits cell growth and induces apoptosis of chicken [31] and
mammalian cells [19]. Although TLP has no obvious sequence-
specific DNA-binding activity, accumulating evidence indicates
that TLP has transcription activation capacity [32,33]. TLP
regulates many genes including cyclin G2, TAp63, wee1, PCNA, and
NF1 in addition to p21 [31,34–37], all of which are categorized as
genes involved in cell-cycle regulation, apoptosis induction, tumor
suppression and DNA repair. Previously, we clarified that TLP
participates in genotoxin-induced and TAp63-mediated apoptosis,
and we presented a novel mechanism of p21 gene regulation
involving TLP and p53 [19,34]. These findings imply that TLP
works generally for cell integrity and growth control.
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We have demonstrated that TLP activates several TATA-less
promoters but not TATA-containing promoters [19]. Other
research groups have reported the same phenomenon [37]. We
showed that activity of the p21 upstream promoter is preferentially
enhanced by TLP. Moreover, this activation absolutely depends
on p53 function, since TLP does not work in promoters carrying
mutated p53-responsive elements or in p53-deficient cells.
Genotoxin treatment induced nuclear localization of TLP as well
as p53, and both factors are co-recruited to the upstream
promoter. Furthermore, we obtained evidence of an interaction
of TLP with p53 and genotoxin-facilitated recruitment of p53 to
the upstream promoter [19].
However, it has not been determined whether TLP-binding
ability of p53 is responsible for p53-dependent and TLP-
stimulated transcriptional activation of the upstream promoter.
In this study, we addressed this issue through mutagenesis of p53,
and obtained mutants that retain fundamental transcription-
activating function but decreased TLP-stimulated ability. Finally,
we found that transcription activation domain 1 (TAD1) residing
at the N-terminal region of p53 interacts with the middle part of
TLP and works for TLP-mediated transcriptional activation.
Materials and Methods
Cell culture, drug treatment, DNA transfection and cell
counting
Human HCT116, wild type and p532/2 cells, were maintained
in Dulbecco’s modified MEM with high glucose content (DMEM-
high, Sigma-Aldrich) at 37uC in the presence of 10% fetal calf
serum and 5% CO2. Etoposide dissolved in dimethyl sulfoxide
(DMSO) was added to the medium for some experiments.
Transfection of nucleic acids was performed by using Lipofecta-
mine and Plus reagent (Invitrogen) according to the manufactur-
er’s recommendation. Numbers of viable cells were counted by a
conventional dye-exclusion method using trypan blue.
Plasmids
Plasmids used in mammalian cells and
mutagenesis. FH-TLP, which is the same as pCIneo-FH-
TLP described in a previous report [30], is a mouse TLP
expression plasmid harboring FLAG and oligohistidine (FH) tags
at the N-terminus of TLP. Mouse and human TLPs have identical
amino acid sequences. A p53 expression plasmid, pcDNA-FLAG-
p53, supplied by Addgene (Cambridge, MA) was modified to
pcDNA-HA-p53 (referred to as HA-p53 in this study), which
contains an HA tag at the N-terminus. Mutant p53-expressing
plasmids were constructed by substitution of one or two amino
acid (AA) residues of p53 in pcDNA-FLAG-p53 and pcDNA-HA-
p53 plasmids using a PrimeSTAR Mutagenesis Basal Kit (Takara).
Expression plasmids for mutant TLPs (R86S, F100E and F114E)
were also constructed.
Reporter plasmids for luciferase assay. Basically,
pGL4.10 vector (Promega) for the luciferase reporter assay was
used for plasmid construction. A reporter plasmid (p21up/GL4)
containing an upstream region of the human p21 gene encom-
passing from 22266 to 21875 was described previously [19].
Effector and reporter plasmids for mammalian two-
hybrid assay. pBIND vector (Promega) as a bait that includes
the GAL4 DNA-binding domain and pACT vector (Promega) as a
prey that includes the VP16 activation domain were used for
plasmid construction. Open reading frames of TLP/mutant and
p53/mutant were linked just downstream from the GAL4 DNA-
binding domain of pBIND and VP16 activation domain of pACT
vector, respectively. pG5-luc vector (Promega) was used as a
reporter plasmid with the luciferase reporter gene.
Bacterial expression plasmids. pET-3a vector (Novagen)
containing an open reading frame of human p53 for production of
FH-p53 and pGEX4T-1 (GE Healthcare) containing an open
reading frame of human TBP and mouse TLP for production of
glutathione S-transferase (GST)-tagged proteins were described
previously [19].
Short interfering RNA (siRNA)
siRNAs were prepared by using a Silencer siRNA Construction
kit (Ambion) as described previously [38]. Sequences of siRNA for
human TLP were 59-UAACAGGGCCCAAUGUAAATT (sense)
and 59-UUUACAUUGGGCCCUAUUATT (antisense). A
scrambled sequence of a part of human TFIIAab containing 59-
UGGCUGACGACUACUGCGCTT (sense) and 59-GCGCA-
GUAGUCGUCAGCCATT (antisense) was used as a control
siRNA.
Luciferase assay
HCT116 p532/2 cells were inoculated into a 24-well plate
(16105 cells/well). Twenty-four hours later, cells were transfected
with a reporter plasmid and an effector plasmid and cultured for
24 hr. If necessary, the total amount of transfected DNA was
adjusted using pRL-TK (Promega). Cells were harvested and
disrupted with Passive Lysis Buffer (Promega). Luciferase activity
in lysates was determined using a Dual-Luciferase Reporter Assay
System (Promega).
Bacterially expressed recombinant proteins
The pET series of expression plasmids and pGEX series of
expression plasmids were transformed into BL21 and DH5a
strains of E. coli, respectively. The recombinant proteins were
induced by isopropyl 1-thio-b-D-galactoside and purified as
described previously [19].
GST pull-down assay
Purified FH-tagged proteins and glutathione-Sepharose 4B
beads (GE Healthcare)-bound GST-tagged proteins were sus-
pended in a binding buffer (50 mM Tris-HCl (pH 7.9), 150 mM
NaCl, 1 mM EDTA, 10% glycerol, 0.1% NP-40, and protease
inhibitor mixture [30]) and incubated at 4uC for 3 hr. Bound
proteins were eluted with SDS sample buffer and detected by
immunoblotting as described previously [39].
Immunoprecipitation of intracellular proteins
HCT116 p532/2 cells transfected with pcDNA-HA-p53/
mutants and pCI-neo-FH-TLP were suspended in IP buffer
(20 mM Hepes-KOH (pH 7.8), 150 mM NaCl, 1 mM EDTA,
10% glycerol, 0.1% NP-40, and protease inhibitor mixture),
disrupted by sonication, and centrifuged at 13,000 rpm for
20 min. The supernatant fractions were collected as whole cell
extracts. Protein concentration was determined using a BCA
Protein Assay kit (Pierce). Three hundred micrograms of the
extract was mixed with anti-FLAG M2 Affinity Gel (Sigma-
Aldrich) at 4uC for 3 hr. IgG-Sepharose 6 Fast Flow (GE
Healthcare) was used as a control antibody. Bound proteins were
eluted with FLAG peptides, boiled for 5 min in SDS sample
buffer, and analyzed by immunoblotting.
Immunoblotting
Proteins were separated by 12.5% SDS-polyacrylamide gel
electrophoresis, transferred to an Immobilon-P PVDF membrane
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(Millipore), and detected by ECL system (GE Healthcare) as
described previously [39] by using specific antibodies and
appropriate horseradish peroxidase-conjugated secondary anti-
bodies including anti (a)-rabbit IgG and a-mouse IgG. The
primary antibodies used included a-p53 antibody (Santa Cruz
Biotechnology), a-GST antibody (Ambion), a-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody (Ambion), and
antigen-purified a-TLP antibody as described previously [30].
RT-PCR
Total cellular RNA was prepared by using an RNeasy kit
(Qiagen), and reverse transcription-PCR (RT-PCR) was per-
formed as described previously [19]. Briefly, cDNA synthesized
from 500 ng of total RNA using Prime Script II (Takara) or avian
myeloblastosis virus Reverse Transcriptase XL (Takara) was
amplified by PCR using Paq5000 DNA polymerase (Stratagene)
and appropriate primer sets. Amplified products were analyzed by
2% agarose gel electrophoresis.
Statistical analysis
Quantitative data were examined with R Console (ver 3.0.1).
Tukey’s honestly significant differences test was used to analyze
significance of differences between sample means obtained from at
least three independent experiments.
Results
Affinity of p53 to TLP
In a previous study, we found that TLP binds to p53 as does
TBP even though the AA identity between TLP and TBP is not so
high [19,23]. In this study, we compared the p53-binding
capacities of these two proteins by GST pull-down assay. A
positive control experiment with a GST-TBP showed strong
binding to p53 (Fig. 1A, lane 1). GST alone did not yield any p53
signals (data not shown). The pull-down assay indicated that GST-
TLP also binds to p53, though recovered p53 was less than that
binding to TBP (Fig. 1A, lane 3). We performed a competition
pull-down assay using FH-TBP and FH-TLP as competitors.
When FH-TLP was added to the binding reaction of GST-TBP vs.
FH-p53, recovered p53 was decreased by 50% of that of the
control experiment (Fig. 1A-a and b: lane 2). On the other hand,
when TBP was added to the GST-TLP:FH-p53 binding reaction,
recovered p53 remained at only 6% of that of the control
experiment (Fig. 1A-a and b: lane 4). Hence, it was demonstrated
that affinity of TLP to p53 is lower than that of TBP. We
compared the p53-binding degrees of the two proteins using
increasing amounts of p53. In a control experiment with GST-
TBP, the ratio of bound p53 to input fraction reached a plateau at
0.5 (Fig. 1B-a and c), whereas the ratio reached a plateau at 0.2 for
GST-TLP (Fig. 1B-b and c). When we focused on data with
limited amounts of input p53 substrate (0.05 and 0.1 pmole),
degree of the slope of a curve for TLP was about 0.3 to that of
Figure 1. TLP binds to p53 in solution. (A) Detection of p53-biding ability of TLP. TLP and TBP were examined for p53 binding by a GST pull-
down assay, and affinities of both proteins against p53 were roughly determined by a competitive pull-down assay. (a) FH-p53 was challenged to
GTS-tagged TBP (lane 1) or TLP (lane 3) as indicated and a simple pull-down assay was performed. TBP/TLP and FH-p53 were detected by a-GST
antibody and a-53 antibody, respectively. No signal was detected when only GST tag was used (data not shown). FH-TLP (lane 2) and FH-TBP (lane 4)
were co-applied to the GST-fused protein-adsorbed beads together with FH-p53, respectively, as competitors for GST proteins. (b) Relative band
intensities of lane 2 (TBP+TLP), lane 3 (TLP) and lane 4 (TLP+TBP) to that of lane 1 (TBP) of panel (a) are displayed. (B) Comparison of p53-binding
affinities of TLP and TBP. GST pull-down assays of lane 1 and lane 2 of panel A-a were performed with increasing amounts of GST-TBP (a) and GST-TLP
(b), respectively. input: input protein corresponding to experimental (pull-down) materials. (c) Relative band intensity for p53 protein of panel (a).
Results of 0.05 and 0.1 pmole of GST proteins of panel (a) are shown again in the magnified graph.
doi:10.1371/journal.pone.0090190.g001
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TBP (Fig. 1B-d). From these results, TLP-p53 affinity was
estimated to be one-third.
Construction of p53 mutants and their functions in
transcription
It has been found that an upstream promoter of the human p21
gene is potentiated by TLP as is p53 and that TLP stimulates p53-
enhanced transcription [19]. We prepared various kinds of mutant
p53 and performed a luciferase reporter assay to identify the
region required for TLP-stimulated function (i.e., function of TLP
that potentiates the ability of p53). Native p53 activated the
promoter function by about 10 fold and TLP stimulated p53-
enhanced transcription further by 1.9 fold (Fig. 2B, WT). It is well
known that the function of p53 strongly depends on its DNA-
binding domain (DBD) (Fig. 2A). Although some mutants of DBD
were almost inert for basal activation function and we could not
determine the TLP-stimulated degree, three mutants,#152,#189
and #231, exhibited significant transcription activation activity.
These mutants showed the original degree of TLP-stimulated
function (1.6 fold to 1.9 fold), even though a severe mutant, #152,
still exhibited a high stimulation index (1.9 fold). These facts
suggest that DBD is not responsible for TLP-stimulated function.
Results of analysis of the C-terminal TD (tetramerization domain)
region (e.g., #320 and #350) also led to the same conclusion.
In the case of a region around the N-terminal trans-activation
domain (TAD), single AA substitution mutants including #22,
Figure 2. Function of p53 mutants in TLP-stimulated transcriptional activation. (A) Schematic representation of the structure of human
p53. (a) Positions of TAD (transactivation domain), DBD (DNA-binding domain) and TD (tetramerization domain) are indicated with AA positions.
Positions of mutation in the examined mutants are shown by vertical triangles. (b) AA residues of TAD1 in the TAD region. 22L and 23W have been
reported to be critical for transactivation (TA), and 18T and 20S are phosphorylated (PH) amino acids (6). (B) Analysis of TLP-stimulated function for
individual p53 mutants by an overexpression experiment. Cells were co-transfected with p21 upstream promoter-carrying reporter plasmid and
expression plasmid for p53/mutant alone or p53/mutant+TLP. Results are shown as relative luciferase activities (RLA). Ratio represents RLA of p53/
mutant expression to RLA of p53/mutant+TLP expression. Some data were examined by statistical analysis. Since the control experiment (ctr) was
performed with a vacant effector plasmid, ratios could not be obtained because measured faint luciferase activities are meaningless. (C) Analysis of
TLP-stimulated function of representative p53 mutants by a knockdown experiment. TLP siRNA and scrambled (control) siRNA were used as depicted
in the figure, and promoter activity was determined as described in panel B.
doi:10.1371/journal.pone.0090190.g002
Table 1. Summary of the mutation analysis.
degree of function*
name of
mutants details of mutation BTA TLP-SF TLP-BA
p53 wild type +++ +++ ++
#22 L22R ++ ++ +
#22.23 L22Q,W23S + 6 6
#22.57 L22R,D57A ++ + +
#22.324 L22R,D324Y ++ ++ +
#46 S46P +++ +++ ++
#98 P98L +++ +++ NT
#152 P152L + +++ ++
#189 A189V +++ +++ NT
#231 T231I +++ ++ NT
#320 K320N +++ ++ ++
#350 L350P +++ +++ ++
* Activation of the mutants are displayed in multiple degrees such as +++ (very
strong) , 6 (weak).
BTA: basal transactivation function.
TLP-SF: TLP-stimulated function examined by over-expression assay.
TLP-BA: TLP-binding activity.
NT: not tested.
doi:10.1371/journal.pone.0090190.t001
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Figure 3. TLP-binding ability of p53 mutants. (A) In vitro binding of various p53 mutants. A GST pull-down assay was performed as described in
the legend of Fig. 1 by using several representative p53 mutants. (B) Binding between TLP and p53 or its mutants in cells was examined by a
mammalian two-hybrid assay. Binding was monitored by luciferase reporter assay. Plasmids for TLP-containing bait (BIND) and p53/mutant-
containing prey (ACT) were introduced into cells as indicated. Since TLP is a transcriptional activator with poor DNA-binding capacity, experiments
with bait alone brought significant luciferase activity. (C) Immunoprecipitation to detect in vivo binding of TLP and p53. FH-TLP and HA-tagged p53
or its mutant (#22.23) were overexpressed in cells and immunoprecipitataied with M2 beads. Immunoprecipitates were analyzed for TLP-associating
p53, TLP and GAPDH.
doi:10.1371/journal.pone.0090190.g003
Figure 4. Effect of #22.23 mutation on gene expression from endogenous p21 promoters. (A) Two kinds of major p21 transcripts
produced from the human p21 gene. Position of exons of p21 alt-a and p21 variant-1 transcripts and genomic DNA around the two p21 promoters are
schematically illustrated. Open and solid boxes represent non-coding and coding exons, respectively. Two primer sets indicated by thick arrows were
used for RT-PCR to detect variant-1 and alt-a, respectively. (B) p532/2 cells were transfected with expression vectors for wild-type and mutant
(#22.23) p53, and two species of p21 transcripts were determined by RT-PCR. Vector: vacant vector. RNAs of endogenous b-actin, p53 and TLP were
also analyzed. (C) Assays for TLP-stimulated function of wild-type p53 and #22.23. (a) Experiments were performed as described in panel B. Cells
were transfected with a TLP expression plasmid in addition to a p53 expression plasmid as indicated. ctr and vec: corresponding vacant vectors. (b)
Amounts of intracellular p53 and #22.23 proteins were also detected by immunoblotting in addition to GAPDH and endogenous and exogenous
TLPs. (c) Degree of increase in alt-a transcripts stimulated by exogenous TLP in p53-expressing cells. Ratios of band intensities of alt-a of panel (a) in
vacant vector-introduced cells to that in TLP overexpressed cells were calculated for three kinds of cells.
doi:10.1371/journal.pone.0090190.g004
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#46 and #22.324 exhibited no apparent mutant phenotype for
the TLP-stimulated function (Fig. 2B). However, two double-
mutants for this region, #22.23 and 22.57, showed relatively low
TLP-stimulated functions of 1.3 fold and 1.4 fold, respectively
(Fig. 2B). The double-mutant #22.23, in which substituted AA
resides in the TAD1 region in the TAD, was the most severe
mutant examined. Results are summarized in Table 1. In order to
confirm the above results, we conducted a knockdown assay for
TLP by using siRNA and representative p53 mutants. As seen in
Fig. 2C, TLP siRNA weakened the TLP-stimulated function of
native p53 and #152 considerably (30% and 38%, respectively)
and that of#22 moderately (48%). We found that#22.23 exhibits
the lowest siRNA sensitivity (58%) among the mutants examined,
indicating that conclusions obtained from both over-expression
and knock-down experiments are consistent. Although differences
in the stimulation degrees were not so great in our assays, the
results are considered to be highly reproducible and significant
from statistical analyses. Consequently, #22.23 was found to be a
typical mutant for TLP-stimulated function in p53-directed
transcriptional activation.
TLP-binding ability of mutant p53 proteins
We further investigated in vitro TLP-binding ability of several
mutants. A GST pull-down assay revealed that #22 and #22.324
had a weakened but still substantial TLP-binding ability (Fig. 3A).
On the other hand, TLP-binding abilities of #22.23 and #22.57
were further decreased compared with those of #22 and 322.324
(Fig. 3A). Next, we conducted a mammalian two-hybrid assay to
examine an intracellular binding of TLP and p53 mutants. As can
be seen in Fig. 3B, #22 and #22.324 showed weaker interaction
than wild-type p53, whereas #22.57 and #22.23 showed much
weaker interaction. In conclusion, #22.23 is the most typical
mutant in both binding assays (Fig. 3A and B). An immunopre-
cipitation experiment revealed that #22.23 forms fewer intracel-
lular complexes with TLP, suggesting that #22.23 has a weaker
TLP-binding affinity than the wilt type in a physiological
condition. Since orders of TLP-stimulated function and TLP-
binding ability roughly coincided for those mutants, it is thought
that the TLP-stimulated property of p53 depends on its TLP-
binding ability participating with the TAD1 region.
Effect of TLP-binding ability of p53 on promoter strength
of endogenous p21 gene
In a previous study, we found that the p21 upstream promoter is
greatly dependent on TLP compared with the downstream
promoter [19]. The upstream and downstream promoters mainly
produce alt-a and variant-1 transcripts, respectively. We exoge-
nously expressed native p53 or #22.23 and detected endogenous
p21 transcripts by RT-PCR (Fig. 4A). Compared with wild-type
p53-expressing cells, the amount of alt-a was significantly small in
#22.23-expressing cells, whereas that of variant-1 decreased only
slightly (Fig. 4B). These results indicate that the upstream
promoter is more sensitive to the #22.23 mutation than is the
downstream promoter even though both promoters need p53
function for substantial levels of transcription. Next, we investi-
gated effects of exogenously expressed TLP on p53-enhanced
Figure 5. Effect of #22.23 mutation on cell growth and etoposide-induced cell death. (A) Five-hundred thousand p532/2 cells in a dish
were cultured for 24 hr. Cells were transfected with an expression plasmid for p53 (WT) or#22.23 (mut) together with a TLP expression plasmid. After
24 hr, 86104 cells were replated and maintained. Cell numbers were counted every 24 hr (panels a–c). ctr: vacant plasmid. (d) Cell numbers at each
time shown in panels a–c are displayed as ratios to the initial cell number. (B) Experiments were performed as described above, but replated cells
were maintained in a medium containing 30 mM etoposide to examine the effect of TLP on apoptotic cell death (a–c). Numbers of remaining viable
cells were counted. (d) Data are summarized as described above.
doi:10.1371/journal.pone.0090190.g005
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transcription for the two kinds of transcripts. TLP increased
production of alt-a but not that of variant-1 when wild-type p53
was co-expressed. In contrast, the #22.23 mutant did not bring a
stimulation effect on alt-a expression (Fig. 4C-a and c). Taken
together, the results indicated that TLP-binding function of p53 is
specifically exhibited in the upstream promoter.
TLP-binding ability of p53 and TLP-mediated cell death
Cells expressing a substantial level of p21 proteins undergo
growth arrest and occasional cell death. First, p532/2 cells were
transfected with various kinds of expression plasmids and cell
numbers were scored every 24 hr. Compared with vacant
plasmid-introduced cells (Fig. 5A-a, ctr), TLP overexpression
exhibited considerable growth inhibitory effect in exogenously
p53-expressing cells (b: WT), whereas this effect was not
prominent in #22.23-expressing cells (c: mut). Results are
summarized in panel d (Fig. 5A). Next, we investigated effect of
TLP on apoptosis. Cells were treated with etoposide to induce cell
death. In the case of vacant plasmid-introduced cells, cells died
gradually (Fig. 5B-a, ctr), whereas cells died slightly faster with a
cell death-facilitating rate (CDFR) of 0.7–0.85 when TLP was
over-expressed (Fig. 5B-a, ctr+TLP). CDFR of TLP (0.45–53) was
much greater than that in the control experiment in wild-type p53-
expressing cells (Fig. 5B-b). On the other hand, CDFR of TLP in
#22.23-expressing cells (0.73–0.77) was almost the same as that in
the control experiment (Fig. 5B-c). Results are summarized in
panel d (Fig. 5B). The results of these experiments suggest that
obtained phenomena are exhibited via interaction of TLP and p53
and might be involved in facilitated expression of p21 gene.
Examination using mutant TLPs
We further confirmed the p53-TLP interaction on p53-
mediated transcriptional activation by using mutant TLPs that
have impaired p53-binding ability. We prepared three kinds of
mutant TLPs; R86S, F100E, and F114E. Positions of these
mutated AAs are located in a region of TLP, whose corresponding
AAs are critical for transcriptional activation function of TBP and
the binding to TFIIA (i.e., another general transcription factor),
and are included in a putative p53-binding region of TBP (Fig. 6A)
[30,40,45]. Through a function assay, we found that R86S and
F100E exhibit weak and strong mutant phenotypes in transcrip-
tion activation function, respectively, in a p53-dependent manner
(Fig. 6B). Moreover, F100E was found to lose its p53-binding
ability (Fig. 6C). These results suggest that TLP binds to p53 via its
middle region. Overexpressing experiments demonstrated that
100th Phe (F100) of TLP is required for stimulation of alt-a but not
variant-1 p21 transcripts (Fig. 7A-a). This stimulation occurred in a
p53-dependent manner, because amounts of alt-a were similar in
WT- and F100E-transfected p532/2 cells (Fig. 7A-b). Further-
more, growth repression of wild-type cells was observed for WT-
transfected cells but not for F100E-transfected cells (Fig. 7B-a), and
this repression disappeared when p53-negative cells were used (7B-
b). Finally, we concluded that substantial transactivating function
of p53 to the p21 upstream promoter and subsequent growth
repression needs the binding of TAD1 domain of p53 to the
middle region of TLP.
Discussion
p53 is one of the most popular cellular regulators in vertebrates.
Upon genotoxic stresses, p53 is phosphorylated and dissociated
Figure 6. Examination of mutant TLPs on transcriptional activation and p53 binding. (A) Structural relationship between TBP and TLP.
Amino acid numbers are indicated from N-termini. TLP covers the evolutionally conserved region of TBP. A putative p53-binding region in TBP
deduced from deletion analyses [44] and its TLP counterpart (from 63 to 115) are depicted as a gray area. Positions of AAs of the TLP mutants used in
this study (R86S, F100E, and F114E) are indicated with vertical arrowheads. (B) Transcription activation function of wild-type (WT) and mutant TLPs
were assayed in native (a) and p532/2 (b) cells. (C) Binding of TLP and p53. Wild-type and F100E TLPs were analyzed for the p53-bidnding ability by
two-hybrid assay.
doi:10.1371/journal.pone.0090190.g006
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from MDM2 ubiquitin ligase, which destabilizes p53 [5,6].
Stabilized and nucleus-translocating p53 binds to a specific DNA
sequence as a homotetramer and regulates expression of genes
related to growth repression, apoptosis induction, stress response,
checkpoint and DNA repair [2,3]. Since p53 is such a wide-range
cellular regulator, various proteins can bind to p53 to modify its
function, dynamics and stability [41]. Some transcription-relating
factors such as general transcription factors (e.g., TFIID, TBP and
TFIIH) and transcriptional co-activators (e.g., p300, P/CAF) bind
to p53 [42–46]. Previously, we demonstrated that TLP is a novel
p53-binding protein [19]. In this study, we examined the TLP-
binding property of p53 in detail. From competitive and semi-
kinetic GST pull-down assays, we estimated that the binding
strength of p53 to TLP is about one-third of that to TBP. This
estimation seems plausible since TLP is only 38% identical to a C-
terminal conserved region that serves as a protein-binding surface
of TBP.
Through an extensive mutant analysis, we found a TLP-binding
region of p53. The #22.23 mutation, in which AA substitutions
reside in TAD1, exhibited the greatest defect in TLP-binding
ability among the mutants examined. Since #22.23 exhibited a
considerable defect in both in vitro and in vivo binding assays, L22
and W23 are thought to be critical for the binding. We concluded
that TLP binds to the N-terminal TAD1 region of p53. In two
mutated AAs in #22.23, W23 may be much critical, since #22
and #22.324 are not obvious mutants for TLP binding.
Alternatively, L22R may be a partial mutation and W23S may
strengthen the mutation phenotype.
p53 contains multiple functional domains including N-terminal
TAD, central DBD and C-terminal TD, all of which contribute to
transcriptional activation function in each way [47]. In order to
identify the region of p53 responsible for the TLP-stimulated
function in p53-activated transcription from the p21 upstream
promoter, we performed promoter assays through overexpression
of various types of p53 mutants together with TLP. #320 and
#152, which have AA substitutions in TD and DBD respectively,
exhibited lower transcription activation ability. However, these
mutants still showed a native TLP-stimulated function. On the
other hand, all mutants that have AA substitutions in TAD1
exhibited decreased function compared with that of the wild type.
Among the mutants, #22.23 was the most severe and exhibited
the lowest TLP-binding capacity. Moreover, orders of the mutant
phenotypes in the function assay and binding assay were basically
consistent. Consequently, we concluded that TLP-stimulated
function of p53 depends on its TLP-binding ability participating
with the TAD1 region. Since T18 and S20 are phospholylated
upon genotoxic stress (Fig. 2A-b), we constructed T18K and S20P
mutants and examined their functions. However, since they
exhibited native functions (data not shown), phospholyration of
TAD1 may not be needed for TLP binding.
Through mutation analyses, we identified a p53-bindiong
region of TLP (Fig. 6B and C). This is the first report to specify
Figure 7. Effect of F100E mutation of TLP on the expression of endogenous p21 gene and cell growth. (A) Wild-type (a) and p532/2 cells
(b) were transfected with expression vectors of wild-type and mutant (F100E) TLPs, and two species of p21 transcripts were determined by RT-PCR as
described in a legend of Fig. 4. (B) Wild-type and mutant TLP-transfected native (a) and p532/2 (b) cells were cultured for 24 hr. Cells (16105) were
replated and cell numbers were counted every 24 hr. ctr: vacant plasmid.
doi:10.1371/journal.pone.0090190.g007
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p53-binding AA residues for the TBP-family proteins. Like p53
mutants for TLP binding, the typical mutant TLP (F100E)
exhibited lower functions for p53-dependent transcriptional
activation from the p21 upstream promoter and cell growth
repression in addition to p53-binding. Consequently, we were able
to conclude that TLP-mediated p53 function needs direct
interaction of specific regions of these two proteins (i.e., the
TAD1 of p53 and a middle region of TLP around the 100th AA
residue). TBP has been shown as one of the typical p53-interactive
transcription factors [42–44]. Since locations of AAs needed for
p53 binding are analogous between TBP and TLP (Fig. 6A), p53-
binding fashion may be similar for both proteins.
Unlike TLP, TBP binds to p53 via the C-terminal TD in
addition to the TAD [45]. It is notable that our immunoprecip-
itation assay could detect intracellular TLP-p53 complex (Fig. 3C)
but not TBP-p53 (data not shown), even though binding strength
between TBP-p53 in solution is greater than that between TLP-
p53 (Fig. 1). Moreover, evidence relating to in vivo binding of TBP-
p53 and p53-dependent transcription activation function of TBP
has not yet been obtained. Hence, TBP may not functionally
interact with p53, and TLP might be unique among TBP family
proteins for functional p53 binding. We assume that TBP-
associated factors, but not TBP, in TFIID form a functional
complex in cells. Actually, it has been reported that TFIID
interacts with the TATA-containing downstream promoter of the
p21 gene, which also contains a p53-binding site.
The significance of TLP-p53 binding is not clear at the present
time. TLP may stabilize p53 or facilitate formation of a p53
homotetramer. However, we also assume that TLP directly works
in a transcriptional regulation process. We have demonstrated that
the TATA-less upstream promoter of the p21 gene is preferentially
stimulated by TLP [19]. It is speculated that the upstream
promoter-bound p53 is regulated by unknown factors in addition
to TLP. Suzuki et al. clarified that the upstream promoter is further
stimulated by TFIIA (manuscript in preparation). It is generally
known that TLP binds to TFIIA more strongly than does TBP
[29,30]. Taken together, our results suggest that the weak p53-
binding activity of TLP is augmented by TLP-associating TFIIA in
the upstream promoter. This may be a reason why TLP can
exhibit its function in the upstream promoter even though its p53-
binding affinity is low. Generally, a transcriptional activation
domain serves as a binding surface to basal transcription
machinery. Hence, TLP might bind to TAD1 and mediate a
transcriptional activation signal of p53 to the basal machinery. In
other words, TLP might work as a co-activator of p53 in the p21
upstream promoter.
Reason of the existence of dual promoters of p21 gene is not
elucidated so far. This promoter structure may have an advantage
to express p21 gene in various cellular situations. For example, in
contrast to the upstream promoter, p21 downstream promoter is
mainly governed by rather constitutive factor including TBP and
TBP-associated factors in addition to p53 [46]. Hence, the
downstream promoter may function preferentially in a usual
cellular condition. On the other hand, the upstream promoter may
be more important in unusual and/or inducible conditions such as
stress response, apoptosis induction, and development & differen-
tiation, since function of TLP is needed in such situations
[19,24,31,34].
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Abstract 
  Stress-induced activation of p53 is an 
essential cellular response to prevent aberrant 
cell proliferation and cancer development. 
The ubiquitin ligase MDM2 promotes p53 
degradation and limits the duration of p53 
activation. It remains unclear, however, how 
p53 persistently escapes MDM2-mediated 
negative control for making appropriate cell 
fate decisions. Here we report that TBP-like 
protein (TLP), a member of the TBP family, is 
a new regulatory factor for the p53-MDM2 
interplay and thus for p53 activation. We 
found that TLP acts to stabilize p53 protein to 
ensure long-lasting p53 activation, leading to 
potentiation of p53-induced apoptosis and 
senescence after genotoxic stress. 
Mechanistically, TLP interferes with MDM2 
binding and ubiquitination of p53. Moreover, 
single cell imaging analysis shows that TLP 
depletion accelerates MDM2-mediated 
nuclear export of p53. We further show that a 
cervical cancer-derived TLP mutant has less 
p53-binding ability and lacks a 
proliferation-repressive function. Our 
findings uncover a role of TLP as a 
competitive MDM2 blocker, proposing a 
novel mechanism by which p53 escapes the 
p53-MDM2 negative feedback loop to 
modulate cell fate decisions. 
 
Introduction 
 The tumor suppressor p53 is a potent 
transcription factor that promotes cell cycle 
arrest, senescence, and apoptosis in response to 
various types of stress (1). While p53 
orchestrates more than a hundred target genes, it 
is usually retained in an “Off” state because of 
its rapid turnover (2). This negative regulation is 
achieved mainly through recruitment of MDM2 
to the transactivation domain (TAD) in the 
N-terminus of p53 and the E3 ubiquitin ligase 
activity of MDM2 (3-5). MDM2 mediates both 
the monoubiquitination and polyubiquitination of 
p53 and promotes its degradation (6). 
Monoubiquitination at the DNA-binding domain 
and the C-terminal domain of p53 acts as not 
only a scaffold of polyubiquitination but also a 
signal for p53 nuclear export (7-9). In the 
cytoplasm, other E3 ligases and E4 enzymes 
such as CBP/p300 can lead polyubiquitination of 
p53 and 26S proteasomal degradation (10). 
Additionally, given that p53 principally works as 
a transcriptional factor in the nucleus, the nuclear 
export of p53 is a major step which limits p53 
function.  
  The p53-MDM2 interplay forms the basis of 
p53 dynamics, and several transcription-related 
factors regulate p53 activity (11). Upon 
genotoxic stresses, p53 is phosphorylated at Thr 
18 and Ser 20, both of which are critical for 
MDM2 binding, leading to the dissociation of 
the p53-MDM2 interaction (12, 13). p300/CBP 
then binds to the p53 TAD and acetylates 
multiple lysine residues in the C-terminal 
domain of p53 (14), and p53 escapes from 
degradation and becomes active as a 
transcription factor (15). Activated p53 in turn 
induces the expression of MDM2. High levels of 
MDM2 associate with HDAC1 and deacetylate 
p53 to promote its degradation (16). In the late 
phase of the stress response, TBP-associated 
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factor 1 (TAF1), the largest subunit of the basal 
transcription factor TFIID, phosphorylates p53 at 
Thr 55 and dissociates p53 from the p21 
promoter by elevating MDM2-binding affinity of 
p53 (17, 18). In addition, some unknown 
transcription-related factors may also be 
involved in p53 regulation, and identification of 
a novel regulator of the p53-MDM2 interplay is 
critical for understanding the mechanisms 
underlying p53 dynamics.  
  TLP is a member of the TBP family and is 
also named TBP-related factor 2 (TRF2), and 
TBP-like 1 (TBPL1) (19, 20). TLP has 38% 
identity to the C-terminal conserved region of 
TBP and mimics the function of a basal 
transcription factor in the regulation of various 
biological processes (21). TLP, but not TBP, is 
associated with a number of TATA-less 
promoters and mediates RNA polymerase 
II-driven transcription from those promoters 
including ribosomal protein genes (22). Upon 
genotoxic stress, TLP represses cell growth via 
regulation of cell cycle-associated genes such as 
wee1, Cdkn1a (p21), and Trp63 (23, 24). We 
have also found that TLP binds to the TAD of 
p53, as does TBP, and enhances p21 expression 
in a p53-dependent manner (25-27). However, 
little is known about the most fundamental 
question of how TLP regulates p53 target genes 
or p53 itself. 
 Here we aimed to investigate the role of TLP 
in p53 regulation and present evidence that TLP 
is a new regulatory factor of the p53-MDM2 
interplay. In the genotoxic stress response, TLP 
promotes p53-driven apoptosis and senescence 
by mediating persistent p53 activation. TLP 
binds to the p53 TAD and inhibits MDM2 
recruitment to p53, which results in suppression 
of p53 ubiquitination. We also aimed to real time 
chasing of p53 nuclear export and show that TLP 
is essential for suppressing MDM2-driven 
nuclear export of p53. Moreover, a cervical 
cancer-derived TLP mutant has little 
p53-binding ability and does not suppress cell 
growth. Taken together, our findings indicate 
that TLP disrupts the p53-MDM2 interaction and 
mediates long-lasting p53 activation in response 
to genotoxic stress. 
 
Results 
TLP stabilizes p53 protein and enhances its 
transcriptional activity. 
 To explore the role of TLP in p53 function, we 
first investigated the effects of TLP knockdown 
on the expression of p53 protein. Both transient 
and stable knockdown of TLP caused a decrease 
in p53 protein (Fig. 1A and B). This decrease 
was recovered in the siRNA-resistant TLP 
(TLPesc)-added HCT116 cells (Fig. 1A). The 
effect of TLP knockdown was evident based on 
accelerated cell growth in both TLP 
siRNA-transfected HCT and HeLa cells (Fig 1C). 
To investigate whether TLP regulates p53 at the 
protein level, we then chased the breakdown of 
p53 protein using cycloheximide (CHX). 
Overexpression of TLP increased the stability of 
p53 in both HCT116 and HeLa cells (Fig. 1D), 
whereas knockdown of TLP decreased the 
stability (Fig. 1E). Consistently, TLP-depleted 
cells contained decreased amounts of p53 targets 
such as MDM2 and p21 at the protein level (Fig. 
1E). The same phenomenon was also observed at 
the mRNA level, and p53-upregulated genes and 
p53-downregulated genes were decreased and 
elevated, respectively (Fig. 1F). In contrast, 
although TLP depletion decreased p53 protein 
levels, its transcripts were not decreased (Fig. 
1F). Additionally, CHX treatment decreased the 
levels of p53 protein, whereas treatment with the 
proteasome inhibitor MG132 increased it (Fig. 
1G). Overexpressed p53 was also decreased 
through TLP knockdown in p53-null HCT116 
cells (Fig. 1H). Moreover, TLP knockdown in 
p53-null HCT116 cells did not change the levels 
of p21 transcript, and the effect of TLP 
knockdown shown in wild-type HCT116 cells is 
also observed in the case of p53 overexpression 
(Fig. 1I). These results suggest that TLP 
upregulates p53 at the protein level, which 
results in inhibition of cell growth through 
control of p53 target genes. 
 
TLP is essential for persistent activation of 
p53 in response to UV irradiation. 
 Next, to investigate whether TLP enhances 
p53 function in response to genotoxic stress, we 
examined TLP function under UV irradiation. 
When TLP shRNA-expressing HCT116 cells 
were exposed to various doses of UV light and 
incubated for 36 h, the levels of transcripts of 
p53 target genes including p21 and MDM2 (Fig. 
2A) were less induced compared with control 
cells. To assess the interplay between p53 and 
TLP in response to UV irradiation, we chased 
the expression dynamics of p53 and its target 
proteins after a high dose (50 J/m2) of UV 
irradiation.  
  The protein levels of both total p53 and 
K382-acetylated p53, which is an activation 
marker for p53 transcriptional activity, were 
elevated within 4 h and decreased around 32-36 
h after UV irradiation (Fig. 2B). Notably, TLP 
was significantly elevated around 32-36 h, and 
depletion of TLP accelerated the decrease of 
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both total p53 and K382-acetylated p53 during 
these time points (Fig. 2B-bottom). Consistent 
with these results, the levels of p21 protein were 
not elevated in TLP-depleted cells (Fig. 
2B-bottom). 
 We then examined the expression of 
p53-upregulated target genes related to cell cycle 
arrest (p21, 14-3-3σ) and apoptosis (PUMA, 
Fas) and the expression of p53-downregulated 
targets participating in cell proliferation (CDC20, 
FOXM1) after UV irradiation (Fig. 2C). 
TLP-depleted cells clearly showed the reduction 
of p53 transcriptional activity in the late phase 
(at 32-48 h) of the UV response (Fig. 2C). In 
contrast, TLP mRNA was not significantly 
elevated (Fig. 2C; p = 0.14, Analysis of 
variance) though its protein was upregulated in 
the late phase of the UV response (Fig. 
2B-bottom). This finding suggests that TLP is 
regulated at the protein level and is not a p53 
target.  
  We also investigated whether p53 and TLP are 
recruited to the promoters of representative p53 
target genes. After UV irradiation, p53 was 
detected on the p21, PUMA, MDM2 promoters 
(Fig. 2D). As expected, the recruitment of p53 to 
these promoters was considerably reduced in the 
late phase of UV response of TLP-depleted cells 
(Fig. 2D). These results indicate that the levels of 
p53 protein reflect its occupation at these 
promoters. On the other hand, however, the 
recruitment of TLP to those promoters was not 
obvious (Fig. 2E), suggesting that TLP promotes 
p53 protein stability but not p53 recruitment to 
those promoters.  
  Finally, we investigated the viability and 
senescent state of the cells after UV irradiation. 
In this condition, the viability of TLP 
knockdown cells was more than three-times 
higher than that of control cells (Fig. 3A and B). 
Furthermore, TLP-depleted cells exhibited 
resistance to senescence after UV irradiation (Fig. 
3C). Taken together, these results indicate that 
TLP elongates the duration of p53 activation to 
promote apoptosis and senescence in response to 
the genotoxic stress. 
 
TLP prevents p53 degradation through 
disrupting the p53-MDM2 interaction. 
 To elucidate the detailed mechanisms by 
which TLP potentiates p53 activity, we 
investigated the involvement of MDM2 in the 
p53-TLP interplay. Overexpression of TLP and 
MDM2 increased and decreased the levels of 
p53, respectively (Fig. 4A). In addition, 
overexpression of both proteins canceled each 
effect (Fig. 4A). Furthermore, a p53 mutant 
L22Q/S23S (QS), which is defective in 
MDM2-binding, did not decrease when TLP was 
knocked down (Fig. 4B). An in vivo p53 
ubiquitination assay showed that the amount of 
ubiquitinated p53 decreased depending on the 
TLP expression level (Fig. 4C). This 
phenomenon became more evident when MDM2 
was coexpressed (Fig. 4D). TLP has been shown 
to binds to the p53 TAD (27); hence, we 
hypothesized that TLP prevents p53-binding of 
MDM2. 
 To evaluate the above hypothesis, we 
performed a competitive pull-down assay using a 
p53-binding ability-defective MDM2 mutant 
protein, G58A (Fig. 4E) (28). When wild-type 
MDM2 was added to the reaction mixture of the 
GST pull-down assay, the amount of p53-bound 
TLP was decreased, whereas the G58A mutant 
interfered with the TLP binding of p53 only 
slightly (Fig. 4F). We then performed an 
immunoprecipitation assay for p53 and found 
that p53-bound MDM2 decreased with increases 
in p53-bound TLP (Fig. 4G). This suggests that 
TLP and MDM2 competitively bind to p53 in 
cells. TLP and MDM2 did not form a complex 
with p53 simultaneously because TLP and 
MDM2 were not co-immunoprecipitated (Fig. 
4H). These results indicate that TLP stabilizes 
p53 protein by interfering with MDM2-mediated 
p53 ubiquitination (Fig. 4I).   
 
TLP suppresses MDM2-mediated nuclear 
export of p53. 
 Next, to scrutinize the involvement of TLP in 
MDM2 function in cells, we examined the 
localization of endogenous p53. Most of the p53 
and exogenous TLP were localized in the 
nucleus of HCT116 cells (Fig. 5A). In contrast, 
TLP knockdown cells showed increased 
cytoplasmic localization of p53 (Fig. 5B). These 
results suggest that TLP retains p53 in the 
nucleus. 
  To clarify whether TLP blocks 
MDM2-mediated nuclear export of p53, we 
performed a real-time nuclear export assay using 
the photoswitchable protein, Dronpa (Fig. 5C) 
(29). Low levels of p53-Dronpa were 
successfully induced in HeLa cells (Fig. 5D and 
E). We confirmed that cytoplasmic localization 
of p53-Dronpa was emphasized in TLP 
knockdown cells (Fig. 5F). After treatment with 
CHX and MG132, fluorescence of p53-Dronpa 
in a whole cell was erased at 488 nm. 
Fluorescence in the nucleus was then reactivated 
through excitation at 405 nm (Fig. 5G). The flux 
of the florescence of Dronpa was monitored as 
an indicator of nuclear export. As for control 
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shRNA-expressing cells, less than 10% of 
p53-Dronpa was exported to the cytoplasm 
within 720 sec following photoactivation (Fig. 
5H and I-left). In contrast, nuclear export of 
p53-Dronpa in TLP shRNA-expressing cells was 
greatly accelerated. We also performed the same 
experiment with the nuclear export inhibitor 
leptomycin B and MDM2 antagonist Nutlin-3a 
to disrupt the p53-MDM2 interaction (7, 30). 
Leptomycin B-treated cells showed that 
p53-Dronpa was retained in the nucleus 
regardless of TLP depletion (Fig. 5I-middle). 
Similarly, Nutlin-3a blocked the nuclear export 
of p53-Dronpa in TLP knockdown cells (Fig. 
5I-right), indicating that p53 nuclear export 
observed in TLP knockdown cells is dependent 
on MDM2. Taken together, these results suggest 
that TLP retains p53 in the nucleus by 
suppressing MDM2-driven nuclear export of 
p53. 
 
TLP suppresses tumor growth. 
 To explore the physiological significance of 
our findings, we assessed the role of TLP in 
cancer. We first investigated the involvement of 
TLP in the growth of xenograft tumors. 
Twenty-five days after injection, the weight of 
TLP-depleted HCT116-derived tumors was 
significantly higher than that of control 
HCT116-derived tumors (Fig. 6A), indicating 
that depletion of intracellular TLP accelerates 
tumor growth. We then prepared a human 
cancer-derived TLP mutant, D99H (31, 32). This 
mutant is found in cervical cancer that expresses 
wild-type p53, and the mutation is located in the 
p53-binding region (Fig. 6B) (27). As expected, 
the p53-binding ability of D99H was 
considerably lower than that of wild-type TLP 
(Fig. 6C). Wild-type TLP-transfected HCT116 
cells decreased cell growth in a p53-dependent 
manner (Fig. 6D). In contrast, overexpression of 
D99H did not influence cell growth (Fig. 6E). 
These results suggest that TLP-p53 binding is 
required for TLP-mediated cell growth 
repression. 
 
Discussion 
 Recent studies have proposed that the 
concentration and duration of activated p53 and 
its target genes determine the cell fate decision 
such as cell cycle arrest, apoptosis, and 
senescence (33, 34). In the present study, we 
showed that TLP stabilizes the p53 protein, 
thereby enhancing its function. We demonstrated 
that the TLP function is evident in the late phase 
of high-dose of UV exposure and is important to 
mediate the induction of apoptosis and 
senescence. This indicates that TLP is required 
for persistent p53 activation and direction of the 
cell fate decision. We further showed that TLP 
disrupts the p53-MDM2 interaction and 
demonstrated that TLP prevented p53 
degradation by interfering with MDM2-mediated 
ubiquitination and nuclear export of p53. 
Moreover, we found that the expression of TLP 
is increased at the protein level in the late phase 
of UV irradiation, suggesting that elevated TLP 
binds to p53 and releases p53 from the 
MDM2-mediated negative control. In contrast, 
the MDM2 function toward p53 becomes 
stronger when the levels of TLP in cells are low. 
Notably, MDM2 is one of the targets of p53 and 
thus downregulated by TLP knockdown. Though 
this result seems to cause p53 stabilization, TLP 
depletion decreased p53 levels. This situation is 
because the turnover of p53 became faster in 
TLP-depleted cells. These phenomena suggest 
that TLP maintains the protein levels of p53 and 
MDM2 in cells. Our findings indicate that TLP 
acts as an MDM2 blocker in the p53-MDM2 
negative feedback loop and establishes a novel 
mechanism for long-lasting p53 activation to 
direct appropriate cell fate decision (Fig. 7).  
 TBP recognizes the TATA element in 
promoters of many RNA polymerase II-driven 
genes, enabling it to constitute the basic 
transcriptional machinery on those promoters 
(35). TLP has been identified as a TBP family 
protein and is considered to be involved in 
various biological processes (21, 22). TLP binds 
to some general transcription factors, such as 
TFIIA, and interferes with the TBP-TFIIA 
interaction. The TLP-bound TFIIA precursor is 
protected from Taspase1-mediated cleavage, 
which leads to inhibition of TBP-mediated 
transcription (36). Perhaps, one role of TLP may 
be as a blocker of protein-protein interactions. 
We note that TLP depletion in HeLa cells 
increases p53 mRNA levels although p53 protein 
levels were downregulated in such a condition. 
This phenomenon seems to be governed by 
p53-independent TLP function, suggesting that 
TLP has multiple roles in both p53-dependent 
and independent manners.  
 The interplay between p53 and 
transcription-related factors in stress response is 
highly complicated. It is basically unknown 
whether basal transcription factors exert their 
positive or negative effects on p53 function. 
TFIIH, a multi-protein complex involved in both 
transcription and DNA repair, and TBP both 
activate p53-driven transcription (37, 38). In 
contrast, TAF1 phosphorylates p53 at Thr 55 and 
mediates degradation of p53 (17, 18). 
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TAF1-mediated phosphorylation of p53 
increases p53-MDM2 interaction and releases 
p53 from the p21 promoter in the late phase of 
UV irradiation. In this study, we confirmed that 
p53 is actually recruited to the promoters of its 
target genes. However, TLP is not significantly 
recruited to promoters of representative p53 
target genes. These results suggest that TLP 
affects p53 activity through a mechanism distinct 
from association of transcription machineries on 
a promoter. Hence, our findings may help to 
resolve the mechanisms underlying p53 
dynamics and linking basal transcription factors 
to p53 activation. 
  The nuclear export of p53 has also been 
widely discussed because a number of cancers 
show cytoplasmic localization of p53 (39, 40). It 
has been speculated that MDM2 induces a 
conformational change of p53 to expose the 
nuclear export signal at the C-terminal domain of 
p53. MDM2 then mediates p53 
monoubiquitination and promotes its nuclear 
export (6-8). We established a method for 
chasing real-time nuclear export of p53 using 
Dronpa and showed that TLP depletion increases 
the nuclear export of p53. However, TLP 
depletion does not fully export p53 to the 
cytoplasm, and the remaining p53 still activates 
transcription. These results suggest that TLP 
depletion is not sufficient for abolishing p53 
activity. Because many factors cooperatively 
and rapidly regulate the p53 level in normal cells 
(9), and real-time analysis using Dronpa may 
help to clarify such a complicated process.  
 About half of all human cancers have 
mutations in the p53 gene, whereas the reason 
why some cancer cells still retain wild-type p53 
has not been fully elucidated (41). In these 
cancer cells, several altered cellular processes 
are likely to suppress p53 function. In this study, 
we used HCT116 and HeLa cells. Interestingly, 
TLP-elevated p53 stability was clearly observed 
in HeLa cells. Human papillomavirus E6 protein 
in HeLa cell leads p53 to degradation (42), and 
because of these vulnerable conditions, TLP 
function for p53 may be strengthened. 
Furthermore, we found that multiple TLP 
mutations in human cancers were mapped in the 
p53-binding region of TLP. We used a TLP 
mutant, D99H, which is found in wild-type 
p53-expressing cervical cancer. This mutant had 
a weak p53-binding ability and exhibited a 
defect in suppression of cell growth. These 
findings are consistent with the notion that 
wild-type p53-expressing cancer cells have some 
p53 suppressive factors. Consequently, TLP is a 
novel regulator of the p53-MDM2 interplay that 
provides cells with sensitivity to genotoxic stress 
by mediating long-lasting p53 activation. 
 
Experimental procedures 
Cell culture, transfection and cell counting 
 Human HCT116 cells and HeLa cells were 
maintained in Dulbecco’s modified MEM 
(Sigma-Aldrich) with 10% fetal bovine serum. 
Transfection of expression plasmids and siRNAs 
was performed by using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s 
recommendation. Viable cells were counted 
using trypan blue.  
 
Expression plasmids, short interfering RNAs 
(siRNAs) and short hairpin RNAs (shRNAs) 
 pCI-neo-FH-mTLP and pCI-neo-HA-mTLP 
were prepared as described previously (27). The 
siRNA-resistant TLP mutant that has nucleotide 
substitutions but retaining the native amino acid 
sequence were constructed by PCR mutagenesis 
strategy. A p53 expression plasmid supplied by 
Addgene (Cambridge) was modified to 
pCI-neo-FH-p53, which contains a Flag-His 
(FH) tag at the N-terminus. A Dronpa open 
reading frame (ORF) was subcloned into 
pCI-neo-FH-p53 in frame with the p53 ORF. In 
addition, to induce the expression levels of p53 
by Tet-On system, p53-Dronpa was subcloned 
into a Tet promoter-containing vector, pTRE3G 
(Clontech). pEF1α-TET3G vector, which 
expresses Tet-On 3G transactivator and activates 
expression from TRE promoters in the presence 
of doxycycline (Dox), was transfected with 
pTRE3G-p53-Dronpa. Sequences of siRNA for 
human TLP were 
5'-UAACAGGGCCCAAUGUAAATT (sense) 
and 5'-UUUACAUUGGGCCCUAUUATT 
(antisense). To construct TLP shRNA-expressing 
vectors, human TLP sequence #1 
(5'-GTAACAGGGCCCAATGTAA) and human 
TLP sequence #2 
(5'-GGAGCAAATGTAATTTATA) containing 
shRNA sequences were cloned into pSilencer 
5.1-U6 retro (AM5782).  
 
Antibodies 
  Antigen-purified-TLP antibody was used as 
described previously (19). To detect total p53 
protein, anti-p53 monoclonal antibody (DO-1, 
Santa Cruz Biotechnology) was used in the most 
of the experiments. Only in experiments of 
Figure 4B, anti-p53 polyclonal antibody (FL-393, 
Santa Cruz Biotechnology) was used because the 
DO-1 antibody does not recognize p53 QS 
mutant. Antibodies against p53 Ac-382 (Cell 
Signaling Technology), MDM2 (4B11, 
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Calbiochem), GAPDH  (FL-335, Santa Cruz 
Biotechnology), p21 (M-19, Santa Cruz 
Biotechnology), HA (16B12, BioLegend), and 
FLAG (2H8, TransGenic Inc.) were used as 
primary antibodies. 
 
Establishement of stable cell lines 
 TLP shRNA-expressing HCT116, HCT116 
p53-/- and HeLa cell lines were established 
through transient transfection of TLP 
shRNA-containing pSilencer 5.1-U6 Retro 
(Thermo) followed by puromycin selection. 
Briefly, cells were transfected with these vectors 
and re-seeded 24 h after transfection. After 24 h, 
the cells were treated with 4 µg/ml of puromycin 
and incubated for 1 week. Then 
puromycin-resistant colonies were selected and 
expanded to culture scale. Cells in which TLP 
expression was greatly inhibited were selected 
by RT-PCR and Western blotting.  
 
Preparation of cell lysate and Western 
blotting 
 To prepare cell lysates, cells were suspended 
in a lysis buffer (Tris-HCl pH 7.6, 150 mM NaCl, 
1 mM EDTA, 10% glycerol, 0.1% NP-40, and 
protease inhibitor (PI) mixture) and underwent 
three cycles of freeze-and-thaw. After 
centrifugation at 13,000 rpm for 20 min, the 
supernatant fraction was collected as a whole 
cell extract. Proteins were separated by 12.5% 
SDS-polyacrylamide gel electrophoresis and 
transferred to an Immobilon-P PVDF membrane 
(Millipore). Proteins on the membrane were 
detected by ImmunoStar Zeta (Wako).  
 
RT-qPCR 
 Total cellular RNAs were prepared using an 
RNase Mini Kit (Qiagen), and reverse 
transcription-PCR (RT-PCR) was performed. 
Briefly, cDNA was synthesized from 500 ng of 
total RNA using Prime Script II (Takara). 
Quantitative determination of the PCR products 
(qPCR) was performed using a Thunderbird 
qPCR Mix (Toyobo) and CFX384 Touch 
Real-Time PCR Detection System (Bio-Rad). 
All reactions were performed in triplicate. 
Primer sets to detect transcripts are described in 
Table 1. 
 
ChIP assay 
  ChIP assay was performed as described 
previously with a few modifications (26). 
Sonicated chromatin of HCT116 cells was 
incubated with a specific antibody. The sample 
was then immunoprecipitated with protein 
G-Sepharose (GE Healthcare Bioscience), and 
the presence of target DNA sequences in the 
precipitates was analyzed by qPCR. Primer sets 
used are described previously (p21 and PUMA, 
43; MDM2, 44). 
 
Colony formation assay 
 HCT116 cells were exposed to 50 J/m2 of UV 
light. Then the cells were trypsinized and 
re-plated into a 6-well plate. Seven days after 
re-plating, the cells were fixed and stained by a 
staining solution (PBS, crystal violet, 1% 
formaldehyde, and 1% methanol). Numbers of 
colonies with >100 cells were counted.   
 
Senescence-associated β-galactosidase 
staining   
 Senescence states of UV light-irradiated 
HCT116 cells were detected using Cellular 
Senescence Assay Kits (Chemicon). 
β-galactosidase-positive cells was counted using 
ImageJ. 
 
Immunoprecipitation  
 Cells transfected with a Flag-tagged protein 
were suspended in IP buffer (20 mM 
Hepes-KOH pH 7.8, 150 mM KCl, 1 mM EDTA, 
10% glycerol, 0.1% NP-40, and PI mixture), 
disrupted by sonication and centrifuged at 
13,000 rpm for 20 min. The supernatant fraction 
was then collected. FH-proteins in the extracts 
were precipitated by anti-Flag M2 Affinity Gel 
(Sigma-Aldrich) at 4℃ for 2 h. IgG-Sepharose 6 
Fast Flow (GE Healthcare Bioscience) was used 
as a control antibody. Bound proteins were 
eluted with Flag peptides (0.5 mg/ml) at 4℃ for 
30 min, boiled for 5 min in SDS sample buffer, 
and analyzed by Western blotting. 
 
In vivo ubiquitination assay 
 To detect in vivo ubiquitination of p53, 
HCT116 cells were transfected with various 
combinations of plasmids as described in the 
figure legend. Twenty-four hours after 
transfection, the cells were treated with 10 µM 
MG132 for 3 h, and an in vivo ubiquitination 
assay was performed in two ways. One method 
for the assay, for which results are shown in 
Figure 4C, was performed as below. Cells were 
lysed with 500 µl of RIPA buffer (50 mM 
Tris-HCl pH 7.6, 150 mM NaCl, 1 mM EDTA, 
10% glycerol, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, 20 mM 
N-ethylmaleimide (NEM), and PI mixture) and 
subsequently immunoprecipitated as described 
above. As for another method, for which results 
are shown in Figure 4D, cells were lysed with 
200 µl of SDS lysis buffer (50 mM Tris-HCl pH 
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7.6, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 
1% SDS, 20 mM NEM, and PI mixture) and then 
boiled for 10 min. The lysate was homogenized 
and subsequently diluted with 1.8 ml of dilution 
buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 
1 mM EDTA, 10% glycerol, 1% Triton X-100, 
20 mM NEM, and PI mixture). Flag-tagged p53 
in the lysate was immunoprecipitated. 
 
Immunofluorescence 
 Cells were washed with PBS, fixed with fix 
solution (PBS, 4% paraformaldehyde, 20 mM 
MgCl2, and 5 mM EGTA) for 10 min, washed 
again with PBS, and permeabilized with 0.5% 
Triton X-100 for 10 min. The cells were then 
incubated with Blocking One Histo (Nacalai 
Tesque Inc.) at room temperature for 15 min and 
subsequently incubated with anti-p53 or FLAG 
antibody at 37℃ for 1 h. After washing with 
PBS, the cells were incubated with Alexa Fluor 
488-conjugated anti-mouse IgG antibody and 
Alexa Fluor 555-conjugated wheat germ 
agglutinin (WGA) at 37℃  for 1 h. After 
washing again, the cells were mounted with 
Fluoro-KEEPER Antifade Reagent with DAPI 
(Nacalai Tesque Inc.) on a slide glass. 
 
Real-time nuclear export assay 
 Nucleocytoplasmic shuttling of p53-Dronpa 
was analyzed as described previously (29). HeLa 
cells were transfected with pTRE3G-p53-Dronpa 
and pEF1α-TET3G and then treated with 30 
ng/ml of Dox for an experiment at 24 h post 
transfection. Fifty micrograms per microliter of 
cycloheximide, 10 µM MG132, 10 nm 
leptomycin B, and 5 µM Nutlin-3a were added if 
necessary. p53-Dronpa-expressing cells were 
observed under a FV1200 confocal microscope 
(Olympus) equipped with a 60x objective lens 
and two scanning units. Fluorescence of Dronpa 
was erased at 488 nm for 5 sec, followed by its 
photoactivation at the predetermined region by 
excitation at 405 nm for 10 msec. The flux of the 
fluorescence of Dronpa was monitored through 
weak excitation. Background noise subtraction 
and measurement of fluorescence signal 
intensities were executed using MetaMorph 
software (Molecular Devices, Co). The nuclear 
export rate was calculated using the following 
equation: 
Export = (Ct/C0) × (T0/Tt). 
where Ct is the average signal intensity in the 
cytoplasm at time t after photoactivation. To 
calculate the nuclear export of p53-Dronpa, the 
average signal intensity of reactivating states in 
the cytoplasm was determined as C0. Tt is the 
average signal intensity of the entire cell at time t, 
and T0 is the average signal intensity of the entire 
cell after reactivation during the measurement of 
nuclear export. The ratio of T0/Tt serves as a 
correction factor to control and eliminate loss of 
fluorescence signal during the image acquisition 
phase (45). All values were derived from at least 
10 cells. 
 
Tumor xenograft assay  
 Five-week-old BALB/c nu/nu male athymic 
nude mice (Japan SLC) were used. All animal 
experiments described adhered to policies and 
practices approved by Chiba University. 
TLP-depleted HCT116 cells (1106 cells in 20 
µl) were injected subcutaneously into nude mice. 
Tumor weight was measured 25 days after the 
injection. 
 
Statistical analysis  
 Welch’s t-test, Tukey’s honestly significant 
difference test, and two-way repeated measures 
ANOVA (analysis of variance) with replicate 
data sets were performed using R software.  
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 Table 1. Primers for RT-qPCR. 
                                                           
                                                                Ref, Reference 
        
 
 
 
  
Gene Forward (5'-) Reverse (5'-) Size (bp) Ref 
14-3-3σ ACTACGAGATCGCCAACAGC CAGTGTCAGGTTGTCTCGCA 149   
CDC20 GCAAGGAGAACCAGCCTGAA ACCGTTCAGGTTCAAAGCCC 80   
Cyclin B1 CGCCTGAGCCTATTTTGGTTG CAGAGAAAGCCTGACACAGGT 96   
Fas CTTCCCATCCTCCTGACCAC TCGTAAACCGCTTCCCTCAC 113   
FoxM1 TGCCCAGATGTGCGCTATTA TCAATGCCAGTCTCCCTGGTA 69 46 
GADD45A ACGATCACTGTCGGGGTGTA CCACATCTCTGTCGTCGTCC 106   
MDM2 CAGCAGGAATCATCGGACTCA AGGTCCTTTTGATCACTCCCAC 80   
NOXA CTGGAAGTCGAGTGTGCTAC GTTCCTGAGCAGAAGAGTTTGG 101   
p21 CTGGGGATGTCCGTCAGAAC CATTAGCGCATCACAGTCGC 101   
p53 GTTCCGAGAGCTGAATGAGG TTATGGCGGGAGGTAGACTG 123 47 
PIG3 AAATTCACCAAAGGTGCTGGAGT TCCGCCTATGCAGTCTAGAATAAGA 51 48 
PTEN GACAGCCATCATCAAAGAGATCG TCTGCAGGAAATCCCATAGCAA 117   
PUMA CTCGGTGCTCCTTCACTCTG AGGCTAGTGGTCACGTTTGG 108   
TLP  TGCAGACAGTGATGTTGCAT GCTCCTTCCAAAGCAATCTTCC 102   
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Figure Legends 
Fig. 1. TLP stabilizes p53 and increases transcription of p53 target genes. 
 (A) HCT116 cells were transfected with TLP siRNA (siTLP) together with a Flag-His-tagged (FH-) 
and siRNA-resistant TLP expression plasmid (TLPesc). p53, TLP, and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) levels in whole cell lysate were analyzed by Western blot. siCtrl, control 
siRNA; empty, empty vector. (B) Proteins in whole cell extracts of two distinct TLP shRNA 
(shTLP#1 and shTLP#2)-expressing HCT116 clones were analyzed. shCtrl, control shRNA. Because 
the knock-down effect of the two TLP shRNAs was similar, shTLP#1 and shTLP#2 are described as 
shTLP in the following figures when either of the TLP shRNAs was used. (C) (Left) HCT116 cells 
were transfected with the siTLP together with the TLPesc expression vector. Forty-eight hours after 
transfection, the cells were stained with crystal violet. Scale bar, 200 µm. (Middle) Viable cells were 
counted at 48 h after transfection. Results are presented as cell number relative to that at the 
transfection time. Each value is the mean ± standard deviation (SD) of at least three independent 
experiments (mean ± SD). *p < 0.05; **p < 0.01 (Tukey’s honestly significant difference test). (Right) 
A repeat experiment as shown in the middle panel of C was performed using HeLa cells. (D) HCT116 
(Left) and HeLa cells (Right) were transfected with a FH-TLP expression vector. Twenty-four hours 
after transfection, the cells were treated with 50 µg/ml of cycloheximide (CHX) and harvested at 
indicated times. (E) HCT116 (Left) and HeLa (Right) cells were transfected with siTLP. Forty-eight 
hours after transfection, the cells were treated with CHX and harvested at the indicated times. (F) 
HCT116 cells (Left) and HeLa cells (Right) expressing shTLP were analyzed for transcripts of 
p53-upregulated and p53-downregulated genes by quantitative reverse transcription PCR (RT-qPCR; 
mean ± SD). Results are shown as relative amounts of mRNA to that of TBP. (G) HCT116 cells were 
transfected with siTLP. Forty-eight hours after transfection, the cells were treated with 10 µM of 
MG132 (M) or/and CHX (C) for 1 h. Cells were harvested and indicated proteins in the whole cell 
lysate were determined. NT: non-treatment. (H) Two shTLP-expressing p53-null HCT116 clones were 
transfected with p53 expression vector. Twenty-four hours after transfection, the cell lysates were 
analyzed for indicated proteins. (I) p53-null HCT116 cells (HCT116 p53-/-) expressing shTLP were 
transfected with empty or p53 expression vector and incubated for 24h. Amounts of indicated 
transcripts were determined for each gene by RT-qPCR (mean ± SD).  
 
Fig. 2. TLP prolongs the duration of p53 activation upon UV irradiation. 
 (A) shTLP-expressing HCT116 cells were exposed to the indicated doses of UV light and incubated 
for 36 h. Amounts of indicated transcripts were determined for each gene by RT-qPCR (mean ± SD). 
(B) (Left) HCT116 cells expressing shTLP were exposed to 50 J/m2 of UV light and harvested every 4 
h. p53, Lys382-acetylated p53 (Ac-382), MDM2, and p21 in whole cell lysates were detected. (Right) 
p53, p21, and TLP proteins shown in the upper figures of panel B were quantified (mean ± standard 
error (SE)). **p < 0.01 (p53 and p21, Welch’s t-test; TLP, Tukey’s honestly significant difference 
test). (C) shTLP-expressing HCT116 cells were exposed to UV light and harvested every 8 h. 
Transcripts were determined by RT-qPCR (mean ± SE). (D) TLP-depleted HCT116 cells were 
exposed to UV light and harvested every 16 h. Then chromatin-bound p53 was immunoprecipitated 
with anti-p53 antibody, and the sequences of the p21, PUMA, and MDM2 promoters were determined 
by qPCR (mean ± SE). (E) HCT116 cells were transfected with the FH-TLP expression vector and 
exposed to UV light for 36 h. Chromatin-bound TLP was immunoprecipitated with anti-FLAG 
antibody, and the sequences of the p21, PUMA, and MDM2 promoters were determined by qPCR 
(mean ± SE). 
 
Fig. 3. TLP promotes UV-mediated cell death and senescence 
(A) shTLP-expressing HCT116 cells were exposed to UV light, and viable cells were counted at the 
indicated times. (B) shTLP-expressing HCT116 cells were exposed to UV light, and the cells were 
re-plated in a 6-well plate. After 7 days, colonies were stained with crystal violet. NT: no treatment. 
(C) (Top) shTLP-expressing HCT116 cells were exposed to UV light and cultured for 5 days, and then 
senescence-associated β-galactosidase (SA-β-gal) activity was measured using a SA-β-gal staining 
method. A single cell is enclosed by a dotted line. Scale bar, 100 µm. (Bottom) The SA-β-gal-positive 
cells were quantified and results are shown as ratios (mean ± SD). **p < 0.01 (Welch’s t-test).  
 
Fig. 4. TLP suppresses p53 ubiquitination and interferes with the p53-MDM2 interaction. 
 (A) HCT116 cells were transfected with MDM2 and TLP expression vectors. (Left) Twenty-four 
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hours after transfection, amounts of indicated proteins were determined. (Right) Relative band 
intensities of p53 are displayed (mean ± SD, n = 4). *p < 0.05; **p < 0.01 (Tukey’s honestly 
significant difference test). (B) HCT116 p53-null cells were transfected with wild-type p53 (p53 WT) 
or MDM2 binding ability-defective mutant p53 (p53 QS) together with siTLP. p53 protein was 
detected with polyclonal p53 antibody. (C) HCT116 cells were transfected with expression vectors for 
FH-p53, HA-ubiquitin (Ub), and increased amount of TLP. Twenty-four hours after transfection, the 
cells were treated with MG132 for 3 h. The whole cell lysate was immunoprecipitated (IP) with 
anti-Flag Sepharose beads. p53-bound HA-tagged ubiquitin (HA-Ub) was detected by Western blot 
(WB) using anti-HA antibody. (D) HCT116 cells were transfected with expression vectors for FH-p53, 
HA-Ub, MDM2, and increased amount of TLP. Twenty-four hours after transfection, the cells were 
treated with MG132 for 3 h. Then FH-p53 in whole cell lysate was immunoprecipitated with anti-Flag 
Sepharose beads, and p53-bound ubiquitin was detected. (E) E. coli-expressed GST-p53, FH-MDM2 
(WT) and FH-MDM2 mutant (G58A) were purified from cell extracts using tag affinity resins. 
Proteins were stained with CBB. (F) Increased amounts of FH-MDM2 or FH-G58A were added to 
constant amounts of glutathione Sepharose-bound GST-p53 and FH-TLP. Pull-downed proteins were 
detected by Western blot with corresponding antibodies. (G) Expression vectors for FH-p53 and 
increased amount of HA-TLP were introduced into HCT116 cells. FH-p53 in cell lysates was 
immunoprecipitated with anti-Flag-Sepharose beads and eluted with a Flag-peptide. p53, p53-bound 
MDM2, and p53-bound TLP were then detected. (H) HCT116 cells were transfected with expression 
vectors for FH-MDM2 or FH-TLP together with HA-p53. Twenty-four hours after transfection, the 
cells were treated with MG132 for 2 h. FH-MDM2 (upper) and TLP (lower) in whole cell lysate was 
immunoprecipitated with anti-Flag Sepharose beads.  (I) Schematic model of the interplay between 
p53, MDM2, and TLP. Low levels of TLP resulted in a situation whereby MDM2 promotes p53 
ubiquitination and degradation. When TLP levels are elevated (e.g., in response to genotoxic stress), 
TLP binds to and stabilizes p53 by releasing p53 from MDM2-mediated negative control.   
 
Fig. 5. TLP suppresses nuclear export of p53. 
 (A) HCT116 cells were transfected with FH-TLP, and cells were subjected to immunofluorescence 
staining with anti-p53 (p53) and anti-FLAG (TLP) antibodies. Scale bar: 10 µm. Nuclei were stained 
with DAPI. (B) TLP-depleted HCT116 cells were treated with 5 µM MG132 for 30 min and subjected 
to immunofluorescence staining with anti-p53 antibody. Cell membranes were detected with Alexa 
Fluor 555-conjugated wheat germ agglutinin (WGA). (Left) Fluorescence was observed using a 
confocal microscope. (Right) Histogram of p53 intensity in the cytoplasm/that in the nucleus of each 
cell (n = 55). **p < 0.01 (Welch’s t-test). (C) Schematic representations of the property of Dronpa. 
Intense irradiation at 488 nm changes Dronpa to a dark form, and weak irradiation at 405 nm restores 
it to a bright form. (D) HeLa cells were transfected with pEF1α-TET3G and pTRE3G-p53-Dronpa, 
and the expression of p53-Dronpa under control of the Tet-On system was induced using the indicated 
amount of doxycycline (DOX). The p53-Dronpa signal in each cell was scanned using a confocal 
microscope. Three independent HeLa cell batches (cell #1-3) were analyzed. (E) shTLP-expressing 
HeLa cells were transfected with pEF1α-TET3G and pTRE3G-p53-Dronpa, and the expression of 
p53-Dronpa was induced using 30 ng/ml of Dox. Cells were treated with CHX and MG132, and 
p53-Dronpa was detected by Western blot. (F) shTLP-expressing HeLa cells were transfected with 
pEF1α-TET3G and pTRE3G-p53-Dronpa, and p53-Dronpa was induced by treatment with Dox. 
(Left) Twenty-four hours after transfection, the p53-Dronpa signal in each cell was scanned using a 
confocal microscope. (Right) Histogram of p53 intensity in the cytoplasm/ in the nucleus of each cell 
(n = 60). Scale bar, 20 µm. *p = 0.013 (Welch’s t-test). (G) Schematic representation of p53-Dronpa 
detection method for its nuclear export. (H) shTLP-expressing HeLa cells were transfected with 
pEF1α-TET3G and pTRE3G-p53-Dronpa, and p53-Dronpa was induced by treatment with Dox. Cells 
were treated with CHX and MG132, and the p53-Dronpa signal in each cell was observed using a 
confocal microscope. Scale bar: 20 µm. (I) (Left) Time courses of the nuclear efflux of p53-Dronpa in 
TLP-depleted HeLa cells. In negative control experiments, leptomycin B (Middle) and Nutlin-3a 
(Right) were added to cells in addition to CHX and MG132. The closest time point after the 
reactivation was defined as “time 0”, and increment of the intensity of cytoplasmic p53-Dronpa from 
time 0 was calculated (mean ± SE) and displayed as the relative intensity. At least eight cells were 
measured per experiment. **p < 0.01; NS, not significant (two-way repeated measures ANOVA).  
 
Fig. 6. TLP suppresses tumor growth. 
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 (A) (Left) A representative photograph of xenograft tumor-bearing mice at 25 days after injection of 
shCtrl and shTLP-expressing HCT116 cells. (Right) Weight of each tumor was plotted. **p < 0.01 
(Welch’s t-test). (B) Point mutation map of human cancers obtained from The cBio Cancer Genomics 
Portal (http://cbioportal.org). TLP contains two TBP-homology domains (TBP). Mutations at 99th Glu 
are scored as D99E and D99H, and the D99H mutant was used in this study. The binding region of 
p53 (p53-binding: amino acid residue between 64th and 115th) is depicted as orange solid line. (C) 
Glutathione Sepharose-bound GST-p53 and FH-TLP (WT) or D99H were mixed, and p53-bound TLP 
was detected. (D) WT and p53-null HCT116 cells were transfected with a mouse TLP expression 
vector. Forty-eight hours after transfection, cell numbers were counted. Results are presented as cell 
numbers relative to control cells (mean ± SD). **p < 0.01; NS: not significant (Welch’s t-test). (E) 
HCT116 cells were transfected with wild-type TLP or D99H. Twenty-four hours after transfection, the 
numbers of viable cells were counted at the indicated culture times (mean ± SD). Statistical analysis 
was performed between the values of wild-type TLP and that of D99H. *p < 0.05; **p < 0.01 
(Welch’s t-test) 
 
Fig. 7. Model of the action of TLP on p53-MDM2 interplay.  
 (A) Regulation of the p53-MDM2 negative feedback loop by TLP. TLP interrupts MDM2-mediated 
negative regulation toward p53. (B) TLP promotes p53 function by disrupting p53-binding of MDM2. 
TLP binding to p53 interferes with the p53-MDM2 interaction and retains p53 in the nucleus. As a 
consequence, TLP promotes p53 functions such as growth inhibition and senescence induction. 
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TATA-binding protein-like protein (TLP) binds to transcription factor IIA
(TFIIA) with high affinity, although the significance of this binding is
poorly understood. In this study, we investigated the role of TFIIA in tran-
scriptional regulation of the p21Waf1/Cip1 (p21) gene. It has been shown that
TLP is indispensable for p53-activated transcription from an upstream
TATA-less promoter of the p21 gene. We found that mutant TLPs having
decreased TFIIA-binding ability exhibited weakened transcriptional activa-
tion function for the upstream promoter. Activity of the upstream pro-
moter was enhanced considerably by an increased amount of TFIIA in a
p53-dependent manner, whereas activity of the TATA-containing down-
stream promoter was enhanced only slightly. TFIIA potentiated the
upstream promoter additively with TLP. Although TFIIA is recruited to
both promoters, activity of the upstream promoter was much more depen-
dent on TFIIA. Recruitment of TFIIA and TLP to the upstream promoter
was augmented in etoposide-treated cells, in which the amount of TFIIA–
TLP complex is increased, and TFIIA-reactive TLP was required for the
recruitment of both factors. It was confirmed that etoposide-stimulated
transcription depends on TLP. We also found that TFIIA-reactive TLP
acts to decrease cell growth rate, which can be explained by interaction of
the p21 promoter with the transcription factors that we examined. The
results of the present study suggest that the upstream TATA-less promoter
of p21 needs TFIIA and TFIIA-reactive TLP for p53-dependent transcrip-
tional enhancement.
Structured digital abstract
! TLP physically interacts with TFIIA beta and TFIIA alpha by anti tag coimmunoprecipitation (View
interaction)
! TFIIA alpha/beta physically interacts with TLP by anti bait coip (View interaction)
Introduction
Transcriptional regulation of an RNA polymerase II
driven gene is governed by a particular set of gene-
specific DNA-reactive transcription regulatory factors
and their associating transcriptional cofactors. More-
over, general transcription factors such as TFIID
(transcription factor IID) and TFIIA are assembled
at a promoter region to conduct transcriptional initia-
tion [1–3], which is enhanced by gene-specific tran-
scription regulatory factors through functional
interaction.
Abbreviations
ChIP, chromatin immunoprecipitation; qPCR, quantitative PCR; siRNA, short interfering RNA; TBP, TATA-binding protein; TFIIA, transcription
factor IIA; TLP, TBP-like protein.
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TATA-binding protein (TBP) is an essential compo-
nent in TFIID that binds to the TATA-box promoter
element [2,4–6]. TBP-like protein (TLP, also called
TRF2) has been identified as one of the TBP family
proteins [7–9] and has been shown to enhance expres-
sion of TATA-less genes such as NF-1, Cyclin-G2,
TAp63 and Wee1 [10–12]. TLP is unable to bind to
the TATA-box, and a consensus TLP-binding
sequence has not been determined so far. In the Dro-
sophila PCNA gene, TLP is engaged in transcriptional
activation as a cofactor for a transcription regulatory
factor called DREF [13]. Although TLP is usually con-
centrated in the cytoplasm, it translocates to the
nucleus in a particular cell-cycle period or when acti-
vated by a genotoxin such as etoposide [12]. Hence,
TLP is thought to be involved in gene regulation
related to growth control and DNA damage response.
Recently, we have identified p21 (p21Waf1/Cip1) as one
of the TLP-target genes [14].
p21 is a CDK inhibitor and causes cell-cycle arrest
at G1 or G2 phase [15,16]. Since p21 also participates
in apoptosis, DNA repair and tumor suppression in
some cases [17], p21 is regarded as a major gene for
cell growth regulation. The amount of intracellular
p21 is regulated at the transcription level, and its
expression level is enhanced by multiple transcription
factors [18,19]. The promoter-enhancer region of p21
contains several binding sites for p53, which enhances
the promoter activity. p53, which works for genome
homeostasis, is a typical tumor suppressor and major
regulator of the p21 gene [20–22]. The human p21 gene
has two major promoters: a TATA-containing down-
stream promoter and an upstream TATA-less pro-
moter [23,24]. TFIID is recruited to the TATA-box of
the downstream promoter together with p53 upon UV
irradiation, but it does not participate in regulation of
the upstream promoter [24]. We have found that activ-
ity of the upstream promoter absolutely depends on
TLP and p53 [14], and these two factors form a com-
plex in cells [14,25].
The most attractive property of TLP is its potent
TFIIA-binding ability. TFIIA is another member of
the family of general transcription factors [3].
Although TFIIA binds to TBP to some extent in order
to potentiate TFIID-dependent promoters, it is also
used for TATA-less promoters [3,26,27]. In higher
eukaryotes, TFIIA consists of three subunits including
TFIIA a, b and c [3]. TFIIAab is encoded by a single
gene and is cleaved into individual a and b subunits
[3,28]. We have found that TLP binds more strongly
to TFIIA than to TBP [29]. Although TLP is mainly
localized in the cytoplasm, mutant TLPs with impaired
TFIIA-binding ability display a diffuse localization
pattern [29]. However, the significance of the TFIIA-
binding ability of TLP in transcriptional regulation
has remained to be clarified.
In this study, we investigated the contribution of
TLP–TFIIA interaction to p21 gene regulation, and
we found that mutant TLPs with weakened TFIIA-
binding ability exhibit decreased transcription stimula-
tion activity. Moreover, etoposide, which stimulates
p21 gene expression, facilitated binding of the
upstream promoter to TFIIA and TFIIA-reactive
TLP. One reason why TLP possesses a strong TFIIA-
binding ability may be elucidated through this study.
Results
Transcriptional activation function of mutant
TLPs for the p21 promoter
We previously constructed various kinds of mutant
TLPs [29]. Among them, N37E and R52E have weak-
ened binding ability to TFIIA, and N37E is a more
severe mutant than R52E for TFIIA binding, whereas
R55E binds to TFIIA as strongly as does wild-type
TLP. In this study, we first investigated in detail the
intracellular TFIIA-binding strength of these mutants
by co-immunoprecipitation assays. It was confirmed
that wild-type TLP and R55E exhibited significant
binding to TFIIA, whereas N37E did not bind to
TFIIA (Fig. 1). We further investigated processed and
unprocessed forms of TFIIAa/b and found that R52E
binds to the a and b subunits of TFIIA but does not
bind to uncleaved TFIIAab (Fig. 1, lane 12).
The human p21 gene produces mainly alt-a and var-
iant-1 transcripts from the upstream and downstream
promoters, respectively (Fig. 2A) [14,23]. Knockdown
Fig. 1. TFIIA-binding ability of TLP. Co-immunoprecipitation to
detect the interaction between TLP and TFIIA. Extracts of HCT116
cells into which FH-TLP (TLP) and its mutants (R55E, R52E and
N37E) had been introduced were immunoprecipitated with M2
beads (M2) and examined for indicated proteins by western blotting
using specific antibodies. Inp, input.
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of endogenous TLP resulted in decreased production
of whole p21 transcripts, mainly due to the decreased
level of alt-a transcripts (Fig. 2B). An overexpression
experiment confirmed that alt-a is specifically depen-
dent on intracellular TLP level. Next, we investigated
the transcriptional activation function of the above-
mentioned TLP mutants. R55E, which has a native
TFIIA-binding ability, considerably enhanced alt-a
production (Fig. 2C–a, lane 3), whereas R52E and
N37E exhibited almost no effect (lanes 5 and 6). R52E
and N37E showed decreased transcription stimulation
activity for the upstream promoter compared with that
of wild-type TLP and R55E (Fig. 2C). To obtain
direct evidence that TFIIA-reactive TLP potentiates
the upstream promoter, we performed a luciferase
reporter assay in mutant TLP-overexpressed cells. It
was demonstrated that R55E enhanced promoter
activity as much as wild-type TLP did, whereas R52E
and N37E had less effect on promoter activity than
did wild-type TLP (Fig. 2D). These results suggest that
TFIIA-binding ability is required for the transcription
stimulation function of TLP.
A B
C D
(a)
(a)
(b)
(b)
Fig. 2. Activation of the endogenous p21 upstream promoter by TFIIA-reactive TLP. (A) Schematic representation of the promoter region of
the human p21 gene. Transcription start sites for the upstream and downstream promoters, which produce alt-a and variant-1 transcripts,
respectively, are shown by arrows. Dotted lines (I and II) represent promoter regions included in luciferase reporter plasmids. (B) Effect of
TLP knockdown on p21 gene expression. Amounts of whole p21 transcripts (p21) and alt-a (alt-a, p21 alt-a) in HeLa cells were determined
by semi-quantitative RT-PCR (a) and RT-qPCR (b). Control siRNA is depicted as – or scr. Each mRNA level for scr (open column) is assigned
as 1.0, and relative mRNA level for siTLP (solid columns) is shown. Arrow, position of the specific signal. (C) Effects of overexpressed TLP
and its mutants on mRNA transcribed from upstream (alt-a) and downstream (variant-1) promoters. HCT116 cells into which TLP or its
mutants had been introduced were assayed for p21 transcripts by RT-PCR (a) and RT-qPCR (b) using specific primer sets. The relative
mRNA levels for TLP and N37E are displayed as ratios to the mRNA level for vec (lane 1). vec, empty vector. (D) Transcriptional activation
of the upstream promoter by mutant TLPs. HCT116 cells transfected with indicated effector plasmids together with a reporter plasmid
(p21up/GL4) carrying p21 promoter-containing DNA from !2266 to !1875 were examined by luciferase assay for transcriptional activation
function of the native and mutant TLPs.
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TFIIA sensitivity of the upstream promoter
Since TFIIA-binding ability of TLP was found to
affect the transcriptional activation function of the
upstream promoter (Fig. 2C,D), we investigated how
TFIIA works for p21 promoters. Overexpression of
TFIIAab considerably stimulated the upstream pro-
moter (Fig. 3A-a, lane 3). Since TFIIAc exhibited lit-
tle effect (Fig. 3A-a, lane 4), the concentration of
TFIIAc in cells seemed to be sufficient for the
upstream promoter. We further investigated the coop-
erative effect directed by TLP and TFIIA in transcrip-
tional regulation through co-overexpression of
TFIIAab and TLP or N37E. Although the activation
degree of TLP for the upstream promoter was 2.6-
fold, co-overexpression of both TLP and TFIIAab
yielded 4.0-fold activation (Fig. 3A-b, lanes 1–3).
However, this additive effect was relatively small (1.8-
fold) when N37E and TFIIAab were used (Fig. 3A-b,
lanes 4 and 5). A dose-responsive effect of TFIIA on
TLP-dependent promoter activation was observed
(Fig. 3A-c), suggesting physical and functional interac-
tions between TLP and TFIIA. To exclude a possibil-
ity that overexpressed TFIIA increases the amount of
TLP protein, we examined the expression level of TLP
and TFIIA and confirmed that TFIIA does not exhi-
bit a significant effect on the expression of both
endogenous and exogenous TLP (Fig. 3A-d). The
downstream promoter was potentiated only slightly by
TFIIA (Fig. 3B). Therefore it is suggested that the
upstream promoter is much more sensitive to the
A
B C
(a)
(a)
(b)
(b)
(c) (d)
Fig. 3. Activation of p21 promoter by TFIIA. The promoter activity in a reporter plasmid was examined in response to TFIIA in normal
HCT116 cells. Cells were co-transfected with TFIIA expression plasmids for TFIIAab (IIAab, IIA) and TFIIAc (IIAc), and activities of the
upstream promoter in p21up/GL4 (A) and downstream promoter in p21down/GL4 (B) were determined. (A-b) Cells were transfected with
TLP and TFIIAab or N37E and TFIIAab to investigate the additive effect of the transcription factors. (A-c) Cells were transfected with a
constant amount of TLP and an increasing amount of TFIIAab. (A-d) Expression levels of TFIIA and TLP protein were determined by
western blotting. (C) Cells were co-transfected with TFIIAab siRNA (+) or control siRNA (!) and the indicated reporter plasmids. (C-a)
Luciferase activities were determined for the upstream (up) and downstream (down) promoters; core, core region of the downstream
promoter without a TATA-box in p21core/GL4 plasmid. (C-b) Effect of TFIIA knockdown was checked by western blotting.
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concentration of TFIIA and that TFIIA-binding activ-
ity of TLP is involved in this process. Knockdown
experiments revealed that the upstream promoter is
much more dependent on TFIIA than is the down-
stream promoter (Fig. 3C–a). The effect of downregu-
lation of TFIIA by short interfering RNA (siRNA)
was evaluated by western blotting (Fig. 3C–b). We
then investigated whether TFIIA-dependent activation
of the upstream promoter occurs in p53-deficient cells.
As shown in Fig. 4A, however, TFIIA did not activate
the upstream promoter in p53-deficient cells. More-
over, the upstream promoter harboring a mutant
p53RE did not respond to TFIIA in addition to TLP
(Fig. 4B).
Recruitment of TFIIA to the upstream promoter
of the endogenous p21 gene
It has been reported that TFIIA can be recruited to
some TATA-less promoters as well as TFIID-depen-
dent TATA-containing promoters [26,27,30,31]. In this
study, we demonstrated that TFIIAab activates the
upstream promoter additively with native TLP
(Fig. 3A-b,c). We investigated whether TFIIA is asso-
ciated with p21 promoters. Although we detected chro-
matin-bound TFIIA in the upstream promoter region
(p53RE) as well as the downstream promoter region
(TATA-box) (Fig. 5B), the amount of TFIIA was lar-
ger for the downstream promoter (Fig. 5B-c), possibly
due to TFIID-assisted recruitment. We performed
TFIIA knockdown experiments to examine TFIIA
function for p21 gene regulation, and we found that
the production of alt-a mRNA was dependent on the
amount of TFIIA (Fig. 5C). The amount of p21 vari-
ant-1 (Fig. 5C) and the total amount of p21 mRNA
(data not shown) were also decreased in TFIIA-
depressed cells.
Recruitment of TFIIA and TFIIA-reactive TLP to
the upstream promoter in etoposide-treated cells
Previously, we demonstrated that p53 and TLP are
recruited to the same region of the p21 gene in etopo-
side-treated cells [14]. In this study, we confirmed that
p53 (Fig. 6A) and TLP (Fig. 6D, lanes 1 and 2) were
substantially recruited to the upstream promoters in
cells treated with etoposide, which is one of the typical
genotoxins. Figure 6B shows that large amounts of
TFIIA bind to the upstream p53RE-containing region.
Furthermore, we found that exogenous TLP but not
N37E increased the amount of upstream promoter-
bound TFIIA (Fig. 6C). These results indicate that
TFIIA-binding ability of TLP is required for recruit-
ment of TFIIA to the upstream promoter. We next
determined how many mutant TLPs are recruited to
the promoter in etoposide-treated cells. Exogenously
expressed TLP and R55E clearly bound to the p53-
responsive element (Fig. 6D, lanes 2 and 3). On the
other hand, R52E and N37E showed decreased bind-
ing signals (lanes 4 and 5) although these proteins were
substantially present in cells. A further chromatin
immunoprecipitation (ChIP) assay demonstrated that
the amount of promoter-bound wild-type TLP was sig-
nificantly increased by etoposide, whereas that of
N37E did not change and was lower than TLP, even
though amounts of N37E were higher than those of
TLP in nuclei of control and etoposide-treated cells
(Fig. 6E). Consequently, R52 and N37E, whose chro-
matin-binding results were overestimated (Fig. 6D,E),
were demonstrated to have weakened promoter-bind-
ing abilities compared with wild-type TLP. We then
examined the effect of etoposide on TLP–TFIIA inter-
action. A co-immunoprecipitation experiment revealed
that TLP and TFIIA form an intracellular complex in
etoposide-treated cells upon DNA damage (Fig. 6F).
A B
Fig. 4. p53-dependent promoter activation
by TFIIA. Promoter activation function of
TFIIA was examined in a p53-deficient
condition. (A) Experiments similar to those
for which results were shown in Fig. 3A-b,
B were performed using p53!/! HCT116
cells, and activities of upstream and
downstream promoters were determined.
(B) Cells were transfected with expression
plasmids of TLP, N37E and TFIIAab and
the activity of the upstream promoter
carrying a mutated p53 response element
(p53RE) was determined.
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The same result was obtained when exogenously
expressed FH-TFIIA was examined (data not shown).
Lastly, we investigated whether activity of the
upstream promoter is modulated by TLP in etoposide-
treated cells. TLP knockdown resulted in a decrease in
upstream promoter-driven mRNA production
(Fig. 6G, left two columns). We found that the net
quantity of knockdown-directed decreased mRNA
production in etoposide-treated cells was twice as
much as that obtained in normal cells (Fig. 6G, right
two columns). We have confirmed that etoposide
enhances transcription from the endogenous p21
upstream promoter [14,23]. These situations suggest
that etoposide-augmented promoter-recruited TLP,
perhaps together with TFIIA, works for activated
transcription from the p21 upstream promoter.
Negative regulation of cell growth by TLP and
TFIIA
In the above-described figures, we showed that TLP
and TFIIA potentiate the upstream promoter of the
p21 gene and upregulate anti-mitotic p21 protein. We
then examined how TLP and TFIIA affect the growth
profile. Knockdown experiments demonstrated that
reduction of endogenous TLP resulted in elevated pro-
liferation for both normal (Fig. 7A-a) and p53-defi-
cient cells (Fig. 7A-b). However, the rate of
proliferation acceleration caused by depression of TLP
was much higher for wild-type cells than in p53-defi-
cient cells. Moreover, overexpression of N37E exhib-
ited a slight but significant growth-inhibitory effect
compared with wild-type TLP (Fig. 7B). Knockdown
of TFIIA also resulted in acceleration of the cell pro-
liferation rate (Fig. 7C). We next examined the effects
of TLP and TFIIA on the profile of etoposide-trig-
gered cell death by knockdown experiments (Fig. 7D),
and we found that both TLP (Fig. 7D–a) and TFIIA
(Fig. 7D–b) accelerated cell death rate in a DNA-dam-
aged condition. Since TLP and TFIIA play a negative
role in cell growth and since association of the two
factors is implicated from the results shown in Fig. 7B,
these factors might modify the expression of growth-
and apoptosis-related genes including p21.
Discussion
Previously, we demonstrated that TLP, which is one of
the TBP family proteins, is involved in regulation of
the upstream promoter [14]. The most attractive prop-
erty of TLP is its stronger TFIIA-binding ability than
that of TBP [29,30], although the functional signifi-
cance of this property has not been elucidated. Bryant
et al. [31] reported that mutant TBPs with decreased
TFIIA-binding ability showed decreased transcription
activation function in vitro. In this study, we demon-
strated that Asn37 and Arg52 of TLP, which corre-
spond to TFIIA-reactive Asn189 and Arg205 of TBP,
respectively [31], are required for TFIIA binding in
human cells (Fig. 1). N37E and R52E exhibited
decreased transcriptional activation functions for the
endogenous upstream promoter, while R55E, which
A
B
C
(a)
(a)
(b)
(b)
(c)
Fig. 5. Functional association of TFIIA
with the upstream promoter. (A)
Schematic illustration around the p21
upstream region. Three regions indicated
by horizontal lines (a, control region; b,
p53RE-containing upstream promoter; c,
TATA-box-containing downstream
promoter) were assayed by ChIP. (B)
Determination of chromatin-bound TFIIA
by ChIP assay with TFIIAab-specific
antibody. (C) Effect of TFIIA knockdown
on p21 gene expression. TFIIAab was
depressed by specific siRNA, and alt-a,
variant-1 and several control RNAs were
determined by RT-PCR (a) and RT-qPCR
(b). Each mRNA level for scr (open
column) is assigned as 1.0, and relative
mRNA levels for siIIA (solid columns) are
shown.
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has substantial TFIIA-binding capacity, exhibited
native function (Fig. 2C). These mutant TLPs also
exhibited decreased transcriptional activation function
for the upstream promoter in an exogenous reporter
plasmid (Fig. 2D). Consequently, TFIIA-binding abil-
ity of TLP is thought to be required for TLP-depen-
dent transcriptional activation. Although R52E had
binding ability to processed TFIIA (Fig. 1, lane 12), it
exhibited little transcriptional function. Because unpro-
cessed TFIIA has been reported to be transcriptionally
A
D E
F G
B C
(a) (b) (c)
Fig. 6. Recruitment of TFIIA and TLP to the p21 upstream promoter upon etoposide stress. Etoposide-induced recruitment of p53 (A) and
TFIIA (B) to the upstream promoter. Normal HCT116 cells treated with etoposide were subjected to ChIP assay using specific antibodies.
ChIP enrichment was determined by qPCR. (C) Amount of chromatin-bound endogenous TFIIA was determined by ChIP using a-TFIIAab
antibody. Cells transfected with an effector plasmid (TLP or N37E) and empty vector (vec) were treated with etoposide, and chromatin-
bound TFIIA was detected for three regions as shown in Fig. 5A. (D) Binding of mutant TLPs to the upstream promoter of the endogenous
p21 gene. Cells into which FH-tagged wild-type and mutant TLP had been introduced were subjected to ChIP assay using a-FLAG M2
beads after etoposide treatment. Results are shown in the left panel. p53RE, an experimental p53RE-containing upstream promoter region;
control, negative control region. Nuclear TBP and exogenous TLP proteins were determined by western blotting. We assigned the signal
intensity of TLP (lane 2) as 1.0, and relative intensities of experimental ChIP signals are displayed as ratios to that of each TLP (right panel).
(E) Amount of chromatin-bound TLP in etoposide-treated cells. Enrichment of chromatin-bound TLP or N37E at the upstream promoter
region was determined. Cells treated with etoposide (E) or a solvent (V) were subjected to ChIP (left panel). Nuclear TBP and exogenous
TLP proteins were determined by western blotting. Relative intensity of experimental ChIP signals (E/V for each TLP protein) is also shown
(right panel). (F) Association of TFIIA and TLP in etoposide-treated cells. Cells treated with etoposide or a solvent were harvested and a
co-immunoprecipitation assay was performed. Material immunoprecipitated with a-TFIIAab antibody was detected for TLP. IP(IIA),
immunoprecipitation with a-TFIIAab. (G) Requirement of TLP for etoposide-stimulated expression of the p21 gene. HeLa cells transfected
with TLP siRNA or control siRNA were exposed to etoposide. The level of alt-a was determined by RT-qPCR. We assigned the mRNA level
of lane 1 as 1.0, and the relative mRNA level of each sample is shown.
3132 FEBS Journal 281 (2014) 3126–3137 ª 2014 The Authors. FEBS Journal published by John Wiley & Sons Ltd on behalf of FEBS
TLP and TFIIA in p21 gene regulation H. Suzuki et al.
active [28], it is possible that binding to unprocessed
TFIIA is required for TLP function to activate p21
upstream promoter.
TFIIA activates RNA polymerase II promoters via
interaction with various transcription factors. As is gen-
erally known, TFIIA indirectly associates with the
TATA-box promoter element via TBP [1–3,6]. Li et al.
[24] showed that TFIID is recruited to the TATA-box
of the p21 downstream promoter and that p53 is associ-
ated indirectly with the TATA-box via TFIID. Indeed,
abundant chromatin-bound TFIIA was detected at the
downstream promoter (Fig. 5B). However, overexpres-
sed TFIIA enhanced the endogenous downstream pro-
moter only slightly (Fig. 3B). On the other hand, the
upstream promoter was significantly activated by
TFIIA (~3.0-fold) (Fig. 3A-a). Moreover, results shown
in Fig. 3C and maybe Fig. 5C suggest that the upstream
promoter requires a high concentration of intracellular
TFIIA for its maximal activity. It has remained a ques-
tion for a long time why TFIIA is an essential factor for
cell growth [32], despite the fact that it works just as a
cofactor. We speculate that some essential TATA-less
genes need TFIIA as well as TLP. Results shown in
Fig. 3A-b also demonstrate an additive effect between
TFIIA and TFIIA-interactive TLP but not mutant ones,
suggesting a functional interaction of these two factors
for the upstream promoter. As already stated, the
human p21 gene has two major promoters: a TATA-less
upstream promoter and a TATA-containing down-
stream promoter [23,24]. Although the mechanism by
which TFIIA exhibits different responses to the two
promoters of the p21 gene is not fully understood, the
TATA-box element seems to be one of the determi-
nants. Existence of multiple promoters of the p21 gene
might have an advantage to maximize the level of gene
expression, which is governed by different sets of tran-
scription factors, when cells are exposed to different
kinds of stimuli and stresses.
A (a)
(a)
(b)
(b)
B
C D
Fig. 7. Inhibitory effect of TLP and TFIIA on cell growth. HCT116 cells were treated with dimethylsulfoxide (A) or etoposide (D). (A) Normal
(a) and p53!/! cells (b) were transfected with TLP siRNA (siTLP) or control siRNA (scr). The cells were replated and cultured. Then cell
numbers were counted at the indicated times. (B) Growth profile of TLP-overexpressing cells. Cells transfected with an effector plasmid
expressing TLP or its mutants were replated and cell numbers were counted. (C) Growth profile of TFIIAab knockdown cells. Cells were
transfected with TFIIAab siRNA (siIIA) or control siRNA (scr), and the growth profile was analyzed. (D) Knockdown of TLP (a) or TFIIA (b) of
etoposide-treated cells. Cells transfected with siRNAs were cultured in an etoposide-containing medium and viable cells were counted at
the indicated times.
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It has been confirmed that the upstream promoter is
basically driven by p53 [23]. Activity of the upstream
promoter was almost inert in p53-deficient cells
(Fig. 4A). Moreover, TLP does not exhibit a transcrip-
tion activation function for the upstream promoter in
p53-null cells. We found that the upstream promoter is
upregulated by TFIIA and is dependent on TFIIA in
addition to p53 and TLP (Figs 3 and 4). The results
shown in Figs 5 and 6 demonstrate that these three
transcription factors are recruited to the upstream pro-
moter, and etoposide, which stimulates p21 gene
expression, increased this recruitment. Drosophila TLP
works as a cofactor for DREF transcription factor of
the PCNA gene [13]. Moreover, TFIIA can work as a
co-activator of several activators [33–36] and binds to
p53 [37]. We have observed intracellular binding of
TLP and TFIIA [29]. Furthermore, we showed interac-
tion between TLP and p53 [25]. We therefore speculate
that TLP can form a triple complex with TFIIA and
p53, and TLP and TFIIA coordinately function as a
binary co-activator complex for p53 on the p21
upstream promoter. The fact that the native, but not
N37E, TLP stimulates the upstream promoter addi-
tively with TFIIA (Fig. 3A-b) supports this hypothesis.
In addition to p21, TLP and p53 are widely
involved in growth repression and apoptosis of cells.
The present study revealed that TFIIA is also associ-
ated with the function of TLP. The results presented
in Fig. 7A show that TLP-mediated growth repression
is dependent on p53. Since TLP with decreased TFIIA
reactivity exhibited a weaker growth-inhibitory effect
(Fig. 7B), some parts of TLP-mediated growth repres-
sion can be governed by at least TLP- and TFIIA-
dependent transcription from the upstream promoter
of the anti-mitotic p21 gene. Furthermore, we observed
that TLP and TFIIA are also involved in etoposide-
mediated cell death (Fig. 7D). We believe that TLP
and TFIIA contribute to this phenomenon through
interaction with the p21 upstream promoter.
Materials and methods
Cell culture, drug treatment and DNA
transfection
Human HCT116 cells (wild-type and p53-deficient mutant
cells) [27] and HeLa cells were maintained in Dulbecco’s
modified MEM with high glucose and low glucose respec-
tively (Sigma-Aldrich, St. Louis, MO USA) at 37 °C in the
presence of 10% fetal bovine serum. Cell numbers were
counted by the trypan blue dye-exclusion method with a
hematocytometer. Etoposide dissolved in dimethylsulfoxide
was added to the medium to 30–50 lM. Transfection of
nucleic acids was performed by using Lipofectamine and
Plus Reagent (Invitrogen, Carlsbad CA, USA).
Expression plasmids for mammalian cells
pCIneo-FH-TLP, which is an expression plasmid of flag/oli-
gohistidine (FH) tagged mouse TLP, was described previ-
ously [14]. Mouse and human TLPs have an identical amino
acid sequence. Plasmids for mutant TLPs (R55E, R52E and
N37E) were described previously [29]. TFIIA expression
plasmids, pCIneo-FH-TFIIAab and pCIneo-FH-TFIIAc,
have an open reading frame of human TFIIAab and
TFIIAc with an FH-tag at their amino termini.
Reporter plasmids for luciferase assay
pGL4.10 vector (Promega, Madison WI, USA) was used
for construction of luciferase reporter plasmids. A reporter
plasmid (designated p21up/GL4) containing a human p21
promoter region encompassing from !2266 to !1875 was
described previously [14]. The +1 position represents the
transcription start site of the downstream promoter. In this
study, we constructed two new luciferase reporter plasmids,
p21down/GL4 and p21core/GL4, that contain a down-
stream promoter region from !168 to +66 and a short
DNA stretch from !5 to +66 of the p21 downstream pro-
moter, respectively. These constructs were generated by a
PCR-based strategy using a reporter plasmid encompassing
from !2677 to +66, which has been named p21luc1 as pre-
viously described [14]. Primer sets to amplify DNA frag-
ments from !168 to +66 and from !5 to +66 sequences
were as follows: !168 to +66 forward, 50-
CTCGAGGGCCTGCTGGAACTCGGCCAG; !5 to +66
forward, 50-CTCGAGGCGCCAGCTGAGGTGTGAGCA;
and common reverse, 50-AGATCTCGGCGAATCCGCGC
CCAGCT.
RNA interference
siRNAs were prepared by a Silencer siRNA Construction
Kit (Ambion, Carlsbad, CA, USA). Sequences for target
human TFIIAab were 50-GATGGGCAGGTGGAAGAAG
(sense) and 50-CTTCTTCCACCTGCCCATC (antisense).
The sequence for human TLP was described previously
[14]. A scrambled sequence of a part of TFIIAab was used
as a control siRNA. Cells were transfected with 50–100 nM
of siRNA and cultured for an appropriate period.
PCR
Total cellular RNAs were prepared using an RNeasy Mini
Kit (Qiagen, Chatsworth, CA, USA), and RT-PCR was
performed as described previously [38]. Amplified products
were analyzed by agarose gel electrophoresis. Quantitative
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determination of the PCR products (qPCR) was performed
using a Thunderbird qPCR Mix (Toyobo, Osaka, Japan)
and 7300 Real Time PCR System (Applied Biosystems,
Foster City, CA, USA). All reactions were performed in
triplicate. Primer sets to detect p21 transcripts were as
follows: total p21 forward, 50-GACACCACTGGAGGG
TGACT; reverse, 50-CCCTAGGCTGTGCTCACTTC; alt-
a forward, 50-GGTGGCTATTTTGTCCTTGG; reverse, 50-AC
AGGTCCACATGGTCTTCC; variant-1 forward, 50-CTGCC
GAAGTCAGTTCCTTG; reverse, common to alt-a reverse.
Luciferase assay
Cells were inoculated into a 24-well plate (8 9 104
cells!well"1). Twenty-four hours later, cells were transfected
with the indicated amount of a reporter plasmid and an
effector plasmid and cultured for 24 h. Total amounts of
transfected DNA were adjusted with pRL-TK (Promega).
Cells were disrupted with a Passive Lysis Buffer (Promega).
Luciferase activity in lysates was determined by a Dual
Luciferase Reporter Assay System (Promega).
Immunoprecipitation of intracellular proteins
Cell extracts were prepared as previously described [29]. Five
hundred micrograms of the extract was used for immunopre-
cipitation. Endogenous proteins in extracts were mixed with
a specific antibody and precipitated with protein G-Sepha-
rose 4 Fast Flow (GE Healthcare Bioscience, Piscataway,
NJ, USA). FH-proteins in extracts were precipitated by anti-
Flag M2 Affinity Gel (Sigma-Aldrich). Normal rabbit IgG
(Santa Cruz, Santa Cruz, CA, USA) and IgG-Sepharose 6
Fast Flow (GE Healthcare Bioscience) were used as control
antibodies. Bound proteins were eluted and analyzed by wes-
tern blotting as described before [29].
Western blotting
Proteins were separated by SDS/PAGE, transferred to an
Immobilon-P poly(vinylidene difluoride) membrane (Milli-
pore, Billerica, MA, USA) and detected by an ECL Prime
(GE Healthcare Bioscience) as previously described [29] by
using specific antibodies and appropriate horseradish-per-
oxidase-conjugated secondary antibodies including anti(a)-
rabbit IgG and a-mouse IgG. As primary antibodies, we
used a-p53 antibody (Santa Cruz), a-b-actin antibody
(Sigma-Aldrich) and antigen-purified a-TLP antibody and
TFIIAab antibody as described previously [29].
Chromatin immunoprecipitation (ChIP)
Cells transfected with plasmids were treated with 50 lM eto-
poside for an appropriate time. After fixation of cells, ChIP
assay was performed as described previously [14]. Endoge-
nous and exogenous FH-proteins were precipitated with a
specific antibody and Protein G-Sepharose 4 Fast Flow (GE
Healthcare Bioscience) and a-Flag M2 Affinity Gel (Sigma-
Aldrich), respectively. Immunoprecipitated DNAs and con-
trol input DNAs were analyzed by semi-quantitative PCR or
qPCR using p21 promoter-specific primer sets. Primer sets
for ChIP analysis were as follows: p53RE forward, 50-CAC
CTTTCACCATTCCCCTA; reverse, 50-GCAGCCCAAGG
ACAAAATAG; TATA-box forward, 50-TGCTGGAAC
TCGGCCAGGCTCAGCTG; reverse, 50-CCAGCTCCG
GCTCCACAAGGAACTG; control forward, 50-TGGTAG
GCCTCTCCAAGGTA; reverse, 50-ACACATGTGACTTG
GGGTGA.
Statistical analysis
Data in this study are shown as mean # standard error of
the mean obtained from at least three independent experi-
ments. Statistical significance of quantitative data was
determined using Bonferroni’s method with R CONSOLE (ver.
3.0.3). The number of experiments used for statistical
analysis was at least three (n = 3). P < 0.05 was considered
to be statistically significant. Statistical significance of dif-
ferences between samples is shown in the figures with aster-
isks: *P < 0.05; **P < 0.01; ***P < 0.001.
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ABSTRACT
TBP-TFIIA interaction is involved in the potentiation
of TATA box-driven promoters. TFIIA activates tran-
scription through stabilization of TATA box-bound
TBP. The precursor of TFIIA is subjected to Taspase1-
directed processing to generate ! and " subunits.
Although this processing has been assumed to be re-
quired for the promoter activation function of TFIIA,
little is known about how the processing is regu-
lated. In this study, we found that TBP-like protein
(TLP), which has the highest affinity to TFIIA among
known proteins, affects Taspase1-driven processing
of TFIIA. TLP interfered with TFIIA processing in vivo
and in vitro, and direct binding of TLP to TFIIA was
essential for inhibition of the processing. We also
showed that TATA box promoters are specifically po-
tentiated by processed TFIIA. Processed TFIIA, but
not unprocessed TFIIA, associated with the TATA
box. In a TLP-knocked-down condition, not only the
amounts of TATA box-bound TFIIA but also those of
chromatin-bound TBP were significantly increased,
resulting in the stimulation of TATA box-mediated
gene expression. Consequently, we suggest that TLP
works as a negative regulator of the TFIIA processing
and represses TFIIA-governed and TATA-dependent
gene expression through preventing TFIIA matura-
tion.
INTRODUCTION
The assembly of the transcription initiation complex on a
promoter region is a critical step in gene expression. The
TATA box is a promoter-proximal regulatory element that
is responsible for high transcription efficiency ofRNApoly-
merase II (polII)-dependent genes (1,2). It is known that
over 20% of polII-driven promoters have a TATA box (3).
Recruitment of general transcription factors (GTFs) de-
termines the activity of TATA box-containing promoters
(TATA promoters). TATA-binding protein (TBP), which is
amain component of transcription factor IID (TFIID), rec-
ognizes and directly binds to the TATA box, and it recruits
other GTFs to the promoter-proximal region (2,4–6). Tran-
scription factor IIA (TFIIA) is another GTF and is known
to be a binding partner of TBP (7–9). TFIIA enhances the
transcription activity of TATA promoters through stabi-
lization of binding of TBP to the TATA box. TFIIA di-
rectly binds to TBP and constitutes the core of the preiniti-
ation complex with TFIIB. In addition, TFIIA has been re-
ported to have an activator-like function (10,11), implying
that transcription is regulated by TFIIA via various mecha-
nisms. Otherwise, TFIIA is a biologically significant protein
since it is essential for cell growth (12). However, compared
with other GTFs, TFIIA has not been deeply investigated
from mechanistic point of view in gene expression.
TFIIA consists of !, " and # subunits (9). TFIIA! and
" are encoded by single gene called TFIIA-L, which is re-
ferred to as TOA1 in budding yeast. The TFIIA!" precur-
sor is processed by Taspase1 at the QVDG site (13), and
processed TFIIA! and " assemble into a holo-TFIIA com-
plex together with TFIIA# (!/" + # ). The holo-TFIIA
complex has been thought to be a transcriptionally func-
tional form of TFIIA. In the process of spermatogenesis,
the TFIIA!" precursor is processed by Taspase1 alongwith
development, and holo-TFIIA potentiates the expression of
spermatogenic genes (14). In cultured HeLa cells, most of
the TFIIA proteins exist as processed forms. On the other
hand, it has been reported that the unprocessed TFIIA!"
precursor itself also has a transcription activation function.
An abnormality in the development of a TFIIA-deficient
Xenopus embryo was rescued by the introduction of un-
cleavable TFIIA (13). It has also been reported that, unpro-
cessed TFIIA!" in P19 embryonic carcinoma cells forms
a complex with TBP and TFIIA# , which is referred to as
TAC (TBP-TFIIA-containing) complex (15,16). Those re-
ports suggest that processed and unprocessed TFIIAs each
have a specific role in cell growth and development. The
function of processed and unprocessed TFIIAs has there-
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fore been studied in specific biological conditions like em-
bryonic development. Moreover, the mechanistic investiga-
tion for each form of TFIIA has been performed just by
in vitro analyses. Eventually, the intrinsic and general sig-
nificance of the processing in transcriptional regulation is
remained to be elucidated. Therefore, studies in functional
differences between processed and unprocessed TFIIA and
the regulatory mechanism of TFIIA processing are to be
carried out by using commonly used cells such as HeLa
cells.
TBP-like protein (TLP) was identified as one of the
TFIIA-binding proteins with the highest affinity (17,18).
TLP, also known as TRF2, is a member of the TBP-family
proteins (19–22). Amino acids of TBP for binding to TFIIA
andTFIIB are conserved in TLP, even thoughTLPdoes not
bind stably to the TATA box sequence. It has been reported
that the affinity of TLP to TFIIA is one order higher than
that of TBP (18). We previously found that interaction be-
tween TLP and TFIIA is required for activation of TATA-
less promoters (23–25). TLP and TFIIA regulate cell prolif-
eration through activation of the upstream promoter of the
p21 gene in a p53-dependent manner. A recent study has
also shown that TLP is engaged in potentiation of several
types of TATA-less promoters of Drosophila (26,27). Fur-
thermore, in an in vitro assay system, TLP inhibits TATA
box-driven transcription by competing with TBP for TFIIA
association (28). However, the in vivo role of TLP in TATA
box promoters remains unclear.
In this study, we examined the effect of TLP-TFIIA inter-
action on TATA promoters and found that TLP represses
TATA box-driven gene expression in vivo. We propose as
a new mechanism that TLP represses promoter activity
by preventing Taspase1-mediated processing of TFIIA. We
also found that the TFIIA!" itself is not involved in TATA
box-mediated transcription activation and the processing of
the TFIIA!" precursor by Taspase1 is essential for full po-
tentiation of TATA box promoters in cultured human cells.
The role of TLP-TFIIA interaction is thought to be a criti-
cal determinant for expression of TATA box genes.
MATERIALS AND METHODS
Cell culture, transfection and drug treatment
Human HCT116 cells and HeLa cells were maintained
in Dulbecco’s modified MEM with high and low concen-
tration of glucose, respectively (Sigma-Aldrich) at 37◦C
in the presence of 10% fetal calf serum. Knockdown ex-
periments were performed as described previously (25).
Lipofectamin2000 reagent (Invitrogen) was used for trans-
fection of plasmids and siRNA. Cycloheximide (CHX)
and MG132 dissolved in dimethyl sulfoxide (DMSO) were
added to the media for some experiments.
Plasmids
Mammalian expression plasmids: expression plasmids
for flag/oligohistidine-tagged (FH)-TLP, FH-N37E, FH-
TFIIA-L, FH-TFIIA-S and FH-MyoD were described
previously (25,29). pCIneo-FH-TBP has an open read-
ing frame of human TBP with an FH-tag at each of its
amino termini. DGAA mutant of TFIIA-L was generated
by a polymerase chain reaction (PCR)-based mutagenesis
method from pCIneo-FH-TFIIA-L. Amino acids of the
274th aspartic acid and 275th glycinewere substituted by ala-
nine in the DGAA mutant.
Bacterial expression plasmids: open reading frames of
TBP, Taspase1, TFIIAαβ and TFIIAγ were subcloned into
a pET-3a vector (Novagen). An FH-tag was added to each
of the amino terminal ends of the open reading frames of
TBP and Taspase1, and oligohistidine (His)-tag was linked
to that of TFIIAγ .
Reporter plasmids for luciferase assay: a pGL4.10 vec-
tor was used for construction of reporter plasmids. Pro-
moter regions of human p21 were amplified from human
genomicDNAand cloned into a pGL4 vector by a standard
PCR-based method. p21-168/GL4, p21-65/GL4 and p21-
5/GL4 harbor distinct length of the p21 promoter as shown
in Figure 2A(a). In the figure, +1 represents the transcrip-
tion start site of a promoter gene. GAPDHWT/GL4, which
carryies a promoter region from −145 to +52 of the hu-
man GAPDH gene, was also generated as described above.
GAPDHmutTATA/GL4, which is a mutant construct of
GAPDHWT/GL4, has a disrupted TATA box sequence.
PCR
Preparation of total cellular RNAs and reverse tran-
scription PCR (RT-PCR) and quantitative PCR (qPCR)
were performed as previously described (25,30). Semi-
quantitative PCR was performed using Paq5000 DNA
polymerase, and amplified products were analyzed by 2%
agarose gel electrophoresis. All reactions were performed in
triplicate. Primer sets to detect transcripts were as follows:
"-actin forward, 5′-ACTGGGACGACATGGAGAAAA;
reverse, 5′-GATAGCACAGCCTGGATAGCAA;
GAPDH forward, 5′-GTCAAGGCTGAGAACGGGAA;
reverse, 5′-AAATGAGCCCCAGCCTTCTC; c-Myc
forward, 5′-CATCAGCACAACTACGCAGC; reverse,
5′-GCTGGTGCATTTTCGGTTGT; !-tubulin for-
ward, 5′-CTGGCTTCACCTCACTCCTG; reverse,
5′-GAAGGCACAGTCTGAGTGCT; BRCA1 for-
ward, 5′-GGTGGTACATGCACAGTTGC; reverse,
5′-ACTCTGGGGCTCTGTCTTCA; TLP forward,
5′-GGAAGATTGCTTTGGAAGGAGC; reverse,
5′-CCTGAGGACCAAATTGTAGCTG; INK4a for-
ward, 5′-GAATAGTTACGGTCGGAGGC; reverse,
5′-GTACCGTGCGACATCGCGAT; LMNA for-
ward, 5′-TCGCATCACCGAGTCTGAAG; reverse,
5′-ACTGAGTCAAGGGTCTTGCG; TBP forward,
5′-CTGGCCCATAGTGATCTTTGC; reverse, 5′-
TCAATTCCTTGGGTTATCTTCACA; TFIIA-S for-
ward, 5′-TTTGGGAAACAGTCTTCAGGA; reverse,
5′-CCATCACAGGCTACAATTTTCA; 14-3-3# for-
ward, 5′-AGAGCGAAACCTGCTCTCAG; reverse,
5′-CTCCTTGATGAGGTGGCTGT; GADD45 for-
ward, 5′-ACGAGGACGACGACAGAGAT; reverse,
5′-GCAGGATCCTTCCATTGAGA; p21alt-a for-
ward, 5′-CTGTTTTCAGGCGCCATGTC; reverse,
5′-GGTGGCTATTTTGTCCTTGG
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Figure 1. Negative function of TLP in endogenous gene expression. (A) Effect of TLP knockdown on endogenous gene expression of human cells. HeLa
cells were transfected with TLP siRNA (siTLP) and control siRNA (scr), and amounts of mRNAs were determined by qRT-PCR. Relative amount of
mRNA with siTLP (solid columns) to that with scr (open columns) for each of the genes is shown. Knockdown efficiency of TLP was checked by Western
blotting (left panel). (B) Effect of exogenous expression of TLP on endogenous gene expression. HeLa cells were transfected with TLP siRNA together with
a TLP expression plasmid. TLP mRNA was determined by semi-qRT-PCR (a). mRNAs of GAPDH, c-Myc and TFIIA-S were determined by qRT-PCR
(b–d). (C) Amounts of chromatin-bound TFIIA. TLP-knocked-down HeLa cells were subjected to a ChIP assay using a TFIIA!"-specific antibody. ChIP
enrichment was determined by qPCR. IgG and IIA: IgG- and TFIIA-specific immnoprecipitates, respectively. Myc-u and Myc-d indicate upstream and
downstream promoters of the c-Myc gene, respectively. p21FUR indicates the far-upstream region (-7018 to -6833) of the p21 promoter used as a negative
control.
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Figure 2. TLP-dependent repression of TATApromoters. (A) Luciferase reporter assay for TATA-containing human p21 promoters. HeLa cells transfected
with TLP siRNA together with the indicated p21 promoter reporter were examined for relative luciferase activity. (a) Schematic representation of the
promoter regions of the human p21 gene inserted in p21-168/GL4, p21-65/GL4 and p21-5/GL4. Open arrowheads show the TATA box sequence. (b)
Relative promoter activity was determined. (B) Luciferase reporter assay for TATA-containing human GAPDH promoter. Relative luciferase activity of
theGAPDH promoter in TLP-knocked-downHeLa cells and the ratios were determined as described above.WT: wild-type TATA box-harboringGAPDH
promoter. mutTATA: consensus TATA box sequence of the GAPDH promoter (TATAAAT) was mutated to gcggttg. (C) Effect of overexpressed TLP on
GAPDH promoter activity. Wild-type TLP and its mutants R55E, R52E and N37E were introduced into HeLa cells together with a GAPDH promoter-
containing reporter plasmid, and relative luciferase activity was determined. (D) Effect of co-expression of TLP and TFIIA on the p21 promoter. HCT116
cells were transfected with TFIIA expression plasmids together with TLP (b) and N37E (c) expression plasmids, and the ratios of luciferase activity of
p21-168/GL4 (vec = 1.0) are shown.
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Luciferase reporter assay
A luciferase assay was performed as previously described
(25). In a TLP-knocked-downed condition, siRNA for TLP
was introduced into cells 36 h before transfection of re-
porter and effector plasmids. Cells were transfected with
the indicated amounts of reporter plasmids and cultured
for 12–24 h. Then the cells were disrupted with a Passive
Lysis Buffer (Promega). Luciferase activity in lysates was
determined by a Dual Luciferase Reporter Assay System
(Promega). Amounts of transfected DNA were standard-
ized with a control thymidine kinase promoter (Promega).
In a single luciferase assay, luciferase activity was normal-
ized with protein concentration of lysates determined by the
BCA method.
Immunoprecipitation
Cell extracts were prepared as previously described (18).
Three hundred micrograms of the extract was used for im-
munoprecipitation. Extracts were mixed with a specific an-
tibody and precipitated with protein G-Sepharose 4 Fast
Flow (GE Healthcare Bioscience). Exogenous FH-tagged
proteins in extracts were precipitated with anti-Flag M2
Affinity Gel (Sigma-Aldrich). Normal rabbit IgG (Santa
Cruz) and IgG-Sepharose 6 Fast Flow (GEHealthcare Bio-
science) were used as control antibodies. Bound proteins
were eluted and detected by Western blotting as described
before (18).
Western blotting
Proteins were separated by SDS-PAGE, transferred to an
Immobilon-P PVDF membrane (Millipore), and detected
by an ImmnoStar Zeta (Wako) by using specific anti-
bodies and appropriate horseradish peroxidase-conjugated
secondary antibodies including anti (!)-rabbit IgG and
!-mouse IgG. The primary antibodies used included !-
p53 antibody (Santa Cruz), !-"-actin antibody (Sigma-
Aldrich), !-GAPDH antibody (Santa Cruz), !-!-tubulin
antibody (Santa Cruz), !-p21 antibody (Santa Cruz) and
!-FLAG M5 antibody (Sigma-Aldrich). Anti-TLP, !-
TFIIA!", !-TFIIA# , !-TBP and !-TFIIB antibodies were
used as antigen-purified antibodies.
Chromatin immunoprecipitation (ChIP)
ChIP was performed by a previously described method
(23). Briefly, cells were cross-linked with formaldehyde, fol-
lowed by cell lysis and DNA-fragmentation by micrococcal
nuclease. Endogenous proteins and exogenous FH-proteins
were precipitated with a specific antibody using Protein
G-Sepharose 4 Fast Flow (GE Healthcare Bioscience)
and !-Flag M2 Affinity Gel (Sigma-Aldrich), respectively.
Antigen-purified !-TFIIA!" antibody and commercial
!-TBP antibody (Santa Cruz) were used for ChIP analyses.
Immnoprecipitated DNAs were purified and analyzed
by qPCR. Primer sets for ChIP analysis were as follows:
"-actin forward, 5′-TCCTCAATCTCGCTCTCGCT; re-
verse, 5′-GCCGCTGGGTTTTATAGGGC; GAPDH
forward, 5′-CTCAAGACCTTGGGCTGGG; re-
verse, 5′-TCGAACAGGAGGAGCAGAGA; Myc-u
forward, 5′-GGCGTGGGGGAAAAGAAAAA; re-
verse, 5′- CGTCCAGACCCTCGCATTAT; Myc-d
forward, 5′-GAGGCTTGGCGGGAAAAAGA; re-
verse, CTCTGCCTCTCGCTGGAAT; IIA-S for-
ward, 5′- CTTCCCTGACAAGGCTTGAGT; re-
verse, 5′- CAGAACTGAGCTGACGACCC; TBP
forward, 5′-CTCAAGAGCTTCGCCCCTC; reverse,
5′-AATGTCACTTCCGCCAGTT.
Electrophoretic mobility shift assay (EMSA)
EMSA was conducted with purified recombinant proteins.
Double-stranded DNA carrying a GAPDH TATA box se-
quence (sense: CGGTTTCTATAAATTGAGCC) was la-
beled with 32P-# -ATP as previously described (23), and 80
000 cpm of the DNA probe was used for each EMSA re-
action. Fifty nanograms of TBP was mixed with 40 ng of
TFIIA# and 40 ng of processed or unprocessed TFIIA!" in
EMSA buffer (20 mMHepes-KOH [pH 7.9], 5 mMMgCl2,
100 mM KCl, 0.2 mM EDTA, 5 mM dithiothreitol, 10%
glycerol) and incubated at 37◦C for 30 min to form TBP-
TFIIA complex. Labeled probeDNAwas then added to the
mixture and incubated at 30◦C for 45 min to form protein-
DNA complex. Protein-DNA complexes were separated by
4% native PAGE and detected by autoradiography. If nec-
essary, unlabeled probe DNA was added to the binding re-
action as a competitor.
Purification of bacterially expressed proteins
FH-TBP, FH-Taspase1, TFIIA!" and His-TFIIA# were
transformed into BL21 (DE3) E. coli., and the recombinant
proteins were induced by isopropyl-1-thio-"-D-galactoside.
Cells were lysedwith lysis buffer (500mMNaCl, 10mM im-
idazole, 1% Triton X-100, 10% glycerol, protease inhibitor
mix [PImix]). Proteins were purified from lysates using anti-
Flag M2 Affinity Gel or Ni-NTA Agarose (QIAGEN). Al-
though TFIIA!" has no appending tags, it binds to Ni-
NTA due to an oligohistidine moiety in the central region
of the polypeptide. Affinity carriers were washed three times
with lysis buffer, andM2 andNi-NTA-bound proteins were
eluted with FLAG peptide and imidazole, respectively.
For preparation of processed TFIIA! and " subunits, 1
$g of the TFIIA!" precursor was mixed withM2 Agarose-
bound FH-Taspase1 in a reaction buffer (20 mM Hepes-
KOH [pH 7.9], 5mMMgCl2, 100mMKCl, 0.2mMEDTA,
5 mM dithiothreitol, 10% glycerol) and incubated at 37◦C
for 1 h. M2 Agarose-bound FH-Taspase1 was eliminated
from the TFIIA solution by centrifugation centrifuge. Pro-
cessing of the TFIIA!" precursor was checked by SDS-
PAGE and silver staining.
Cell fractionation
A method described by Xie et al. (31) was used for prepa-
ration of chromatin-free and chromatin-bound fractions.
Cells were lysed with NETN100 buffer (100 mM NaCl, 1
mM EDTA, 0.5% NP-40, 20mM Tris-HCl [pH 7.5]), and
the supernatant fraction was collected as the chromatin-
free fraction. Chromatin pellets were washed twice with
NETN100 buffer. The pellets were then suspended in
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NETN420 buffer (420 mM NaCl, 1 mM EDTA, 0.5% NP-
40, 20mM Tris-HCl [pH 7.5]) and the supernatant material
was collected as the chromatin-bound fraction.
Statistical analysis
Data obtained in this study are shown as means± standard
error of means from at least three independent experiments.
Statistical significance of quantitative data was determined
by Bonferroni’s method with R Console (ver.3.0.3). P <
0.05 was regarded as statistically significant. Statistical sig-
nificance of differences between samples is shown in figures
with asterisks such as *; P < 0.05, **; P < 0.01 and ***; P
< 0.001.
RESULTS
Repression of TATA box genes by TLP
A subset of TATA-less promoters including NF1, TAp63
and p21 is potentiated by TLP through its recruitment to
a promoter region (23–25,32,33). On the other hand, TLP
is reported to have neither affinity to TATA box DNA nor
a function for activation of TATA box-containing promot-
ers (TATA promoters) (22). Indeed, chromatin-bound TLP
was not detected in TATApromoters in our previous works.
Rather, TLPwas shown by in vitro analyses to repress TATA
promoters (28,32). In this study, to elucidate the in vivo func-
tion of TLP in a TATA box, we first performed knock-
down experiments to investigate effect of TLP on expression
of endogenous genes. Knockdown of endogenous TLP in-
creased mRNAs of TATA genes (β-actin, GAPDH, c-Myc,
α-tubulin and BRCA1) (Figure 1A). In contrast, expression
of TATA-less genes (INK4a, LMNA, TBP, TFIIA-S, 14-
3-3σ , GADD45 and p21alt-a) was not increased by TLP
knockdown (Figure 1A). Rather, expression of GADD45
and p21alt-a was decreased by TLP knockdown, suggest-
ing that TLP potentiates a subset of TATA-less promoters.
Additionally, expression of GAPDH and c-Myc was sup-
pressed when TLP expression was recovered by introduc-
tion of a TLP expression plasmid (Figure 1B). These re-
sults demonstrate that TLP affects the expression of TATA
genes.
We next examined the effect of TLP on the in vivo
promoter-associating capacity of TFIIA. ChIP results con-
firmed that TFIIA was enriched in TATA promoters (Fig-
ure 1C). We found that TLP knockdown increased the
amount of TATAbox-boundTFIIA (Figure 1C). Consider-
able amounts of promoter-associating TFIIA were detected
in TATA box-carrying GAPDH, β-actin and c-Myc pro-
moters under a TLP-knocked-down condition (Figure 1C,
lanes 1–8). The human c-Myc gene has two TATA promot-
ers (34), and the amount of promoter-bound TFIIA was in-
creased for both TATA elements (Figure 1C, lanes 5–8).
We further examined whether the TATA box sequence
is critical for TLP-mediated repression of promoters. We
performed a luciferase reporter assay using p21 (CDKN1A)
and GAPDH promoters. In a TLP-knocked-down con-
dition, the TATA box-harboring p21 promoter exhibited
higher activity than that of the control one (Figure 2A).
Similarly, the GAPDH promoter was significantly elevated
by TLP knockdown, while mutation of a canonical TATA
sequence to a non-TATA sequence abolished the TLP sen-
sitivity (Figure 2B), indicating that TLP affects promoter
activity via the TATA box sequence. Consistent with the re-
sults described above, TLP overexpression donwregulated
the activities of TATA-containingGAPDH (Figure 2C) and
p21 promoters (data not shown). Additionally, we exam-
ined three TLP mutants R55E, R52E and N37E. While
R55E has normal TFIIA binding ability, R52E and N37E
have been shown to be defective just in TFIIA binding abil-
ity (18). TFIIA-reactive R55E exhibited a repression effect
on TATA-promoters as the wild-type TLP did (Figure 2C,
lanes 2 and 3). Notably, R52E and N37E, which do not
interact with TFIIA, did not affect those promoter activ-
ities (Figure 2C, lanes 4 and 5), implying that TFIIA re-
activity of TLP is required for repression of the TATA pro-
moter by TLP.We then examined a synergistic effect of TLP
and TFIIA on the TATA promoter. Exogenously expressed
TFIIA potentiated the TATA promoter of p21 (Figure 2D,
panel a), and that promoter activation was suppressed by
TLP overexpression (panel b), while the repression was not
restored byN37E (panel c). These results suggested that, al-
though endogenous TLP does not associate with the TATA
promoter, it represses TATA-containing genes through in-
hibition of TFIIA activity needed for TATA promoters.
Inhibition of TFIIA maturation by TLP
We next focused on the mechanism of TLP-mediated re-
pression of TFIIA activity. Since the TFIIA!" precursor
is processed into mature ! and " subunits by Taspase1 (13),
the processing is a key step for intracellular TFIIA activ-
ity. To investigate the effects of TLP on TFIIA processing,
we performed overexpression and knockdown experiments.
The TFIIA!" precursor has been reported to be rapidly
processed into matured subunits in cells (35). Indeed, we
found that the half-life of intracellular TFIIA!" was less
than 30 min. However, the amount of TFIIA!" signifi-
cantly increased in a TLP-overexpressed condition, and the
half-life was prolonged to over 1 h (Figure 3A, lanes 5–8).
Stabilization of the TFIIA!" precursor was not observed
for the N37E mutant (lanes 13–16). In turn, TLP knock-
down resulted in destabilization of the TFIIA!" precursor
(Figure 3B). To demonstrate the inhibitory effect of TLP
on nascent TFIIA protein, we examined the processing effi-
ciency of TFIIA!" by using exogenously expressed TFIIA.
The exogenous TFIIA!" precursor was processed into each
subunit like the endogenous one (Figure 3C, lane 2). As ex-
pected, TLP, but not N37E, decreased the processing rate
for exogenous TFIIA!" (Figure 3C). Moreover, the pro-
tein level of DGAA mutant TFIIA, which is not processed
by Taspase1, was not affected by TLP overexpression (Fig-
ure 3D). The amount of TFIIA transcript was not affected
by TLP (Figure 3E). These results suggest that processing
of TFIIA!" precursor is inhibited by TLP.
We showed that the TFIIA!" precursor was not de-
graded by the ubiquitin-proteasome system (Figure 4A).
We further checked whether reduction of the precursor was
due to Taspase1 (Figure 4B). We examined the inhibitory
effect of TLP on in vivo processing of the TFIIA!" pre-
cursor using purified recombinant proteins. Although the
precursor of recombinant TFIIA!" was sufficiently pro-
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Figure 3. Inhibitory effect of TLP on the processing of TFIIA!". TFIIA!" protein was determined by Western blotting. (A) Effect of overexpressed
TLP on intracellular TFIIA!" protein. TLP- and N37E-introduced HCT116 cells were treated with CHX for the indicated time, and the amount of
endogenous TFIIA protein was determined. (B) Effect of TLP knockdown on TFIIA!" precursor. The amount of endogenous TFIIA!" precursor in
TLP-knocked-down HeLa cells was assayed as described above. (C) Effect of TLP on TFIIA!" processing. HeLa cells were transfected with expression
plasmids for FH-TLP and FH-N37E together with FH-TFIIA!", and the TFIIA!" precursor and generating ! subunit were detected. (D) Effect of TLP
on the uncleavable DGAA mutant. HeLa cells were transfected with expression plasmids of FH-TFIIA and FH-DGAA mutant together with TLP, and
the amount of the FH-TFIIA!" precursor was determined. FH-MyoD introduced into cells was used as an electrophoresis loading standard. (E) RT-PCR
for detection of TFIIA-L transcripts. TLP-overexpressed HCT116 cells were assayed for TFIIA-L transcripts by RT-PCR using specific primers.
cessed into ! and " subunits by recombinant Taspase1
(Figure 4C), supplementation of TLP protein clearly pre-
vented the processing of TFIIA!" in a TLP-dose depen-
dent manner, while the !IIA mutant of TLP, which has
no affinity to TFIIA, did not affect the processing ef-
ficiency (Figure 4D). Taken together, the results showed
that TLP inhibits Taspase1-driven processing of TFIIA!".
Since TFIIA-binding ability-deficient TLP mutants did not
affect the processing rate of the TFIIA!" precursor, direct
binding of TLP to TFIIA!" was suggested to be critical for
prevention of the processing.
TATA promoter activation by processed TFIIA!"
Since TLP repressed TATA-containing genes and inhibited
processing of the TFIIA!" precursor, we speculated that
TLP negatively regulates TATA genes through inhibiting
TFIIA!" processing. However, it has remained ambiguous
how the processing of the TFIIA!" precursor functions in
potentiation of TATA promoters.
To clarify the significance of TFIIA!" processing for
promoter regulation, we performed an EMSA to exam-
ine the TATA box-association potential of processed and
unprocessed forms of TFIIA!". First, we confirmed that
purified recombinant TFIIA!" was processed by Tas-
pase1, whereas the DGAA mutant was not affected (Fig-
ure 5A). Although TBP alone did not stably bind to the
TATA box, addition of TFIIA generated a higher protein
(TBP-TFIIA)-DNA complex (Figure 5B). Unprocessed
TFIIA!" and processed TFIIA!" generated two specific
complexes. The combination of TBP, TFIIA# and unpro-
cessed TFIIA!" or DGAA mutant generated a faster mi-
grating complex (lower complex) (Figure 5B(a), lanes 3, 5
and 6). On the other hand, processed TFIIA!" generated
a slower migrating complex (upper complex) together with
TBP and TFIIA# (Figure 5B(a), lane 4). Since combina-
tions of TBP and TFIIA!", or TBP and TFIIA# did not
generate stable protein-DNA complex (Figure 5B(b)), both
TFIIA!" and TFIIA# were suggested to be required for
formation of TBP-based protein-DNA complex. A compe-
tition assay revealed that these complexes were specific for
the TATA box sequence (Figure 5C). We further performed
a super-shift assay using specific antibodies to clarify the
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Figure 4. Inhibition of Taspae1-mediated processing of the TFIIA!" precursor by TLP. (A) Effect of MG132 on TFIIA proteins. HCT116 cells were
treated with MG132 and CHX for the indicated time, and the amount of TFIIA protein was determined. (B) Effect of overexpressed Taspase1 on the
endogenous TFIIA!" precursor. HCT116 cells were transfected with expression plasmids of FH-Taspase1, and the amount of the TFIIA!" precursor
was determined. (C) Taspase1-mediated processing of the TFIIA!" precursor in vitro. Five nanograms of purified recombinant TFIIA!" was mixed with
20 ng of purified recombinant FH-Taspase1 and incubated at 37◦C for 1.5 h, and proteins were detected by Western blotting. Effect of TLP on Taspase1-
mediated processing of the TFIIA!" precursor in vitro. Twelve nanograms of TFIIA!" and 6 ng of TFIIA# were incubated with 50 to 200 ng of TLP or
!IIA mutant protein at 37◦C for 1 h. Fifty nanograms of FH-Taspase1 was then added to the mixture and incubated for 1.5 h.
characteristic of these complexes. It was confirmed that
both complexes contain TBP because these shifted bands
reacted with a TBP-specific antibody (Figure 5D, lanes 2
and 5). However, these shifted bands exhibited different re-
action to a TFIIA-specific antibody (Figure 5D, lanes 3 and
6). Because the lower complex did not react to TFIIA anti-
body, it was suggested that TFIIA!" was not included in
the lower complex, whereas processed form of TFIIA!"
was included in the upper complex. These EMSA results
show that the processing step of TFIIA!" is required for
stable association of TFIIA with the TATA box.
We performed ChIP analyses to determine whether the
processing of TFIIA!" is critical for its in vivo association
with TATA promoters. Exogenously expressed TFIIA!"
was processed into the subunits (Figure 6A(a)). Processed
TFIIA proteins were detected at the TATA promoter of
the endogenous GAPDH gene, while the DGAA mutant
was not detected at the promoter (Figure 6A(b)). Analy-
sis of the promoter activation function of TFIIA showed
that unprocessed TFIIA!" is almost inert for the TATA-
containing promoter (Figure 6B). To investigate the mecha-
nism to achieve transcriptional activation by processed and
unprocessed TFIIA!", we examined the interaction of the
TFIIA!" precursor (DGAA) with TFIIA# . Although the
TFIIA!" precursor and processed TFIIA exhibited simi-
lar affinity to TLP, the TFIIA!" precursor exhibited lower
affinity to TFIIA# (Figure 6C). The function assay revealed
that TFIIA# is required for TFIIA!"-mediated potenti-
ation of the TATA promoter. A dose-responsive effect of
TFIIA# on TFIIA!"-mediated TATA promoter activation
was observed (Figure 6D). The TFIIA# subunit is thus
thought to be required for potentiation of TATApromoters.
Indeed, the EMSA showed that stable protein-DNA com-
plexes were not generated in the absence of TFIIA# (Figure
5B(b)). Consequently, it was clarified that processing of the
TFIIA!" precursor is required for its association with the
TATA box and TFIIA# -dependent potentiation of target
promoters. Therefore, inhibition of TFIIA!" processing by
TLP is responsible for depression of TATA genes.
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Figure 5. EMSA to detect the association of TFIIA with TATA the box. (A) in vitro processing of recombinant TFIIA!" precursor protein. Twenty
nanograms of purified recombinant TFIIA!" and DGAA expressed in E. coli were mixed with 70 ng of purified recombinant FH-Taspase1 and incubated
at 37◦C for 1 h. Proteins were separated by SDS-PAGE and detected by silver staining. (B–D) EMSA of TFIIA and TBP to detect TATA box binding of
the GAPDH promoter. Purified TFIIA!", His-TFIIA# and FH-TBP were used. Panel B: (a) processed TFIIA!" (indicated as Processing +, same with
!" of panel b) and unprocessed TFIIA!" (indicated as Processing -, same with !/" of panel b) were used for EMSA. Processing: purified recombinant
TFIIA!" and DGAA were incubated with FH-Taspase1, and TFIIA proteins were purified. (b) Indicated combinations of purified proteins were used for
EMSA. Panel C: cold probe DNA (WT) and its mutant (mut) were used as competitors in EMSA binding reactions. Sequences of wild-type and mutant
competitors were 5′-CGGTTTCTATAAATTGAGCC and 5′-CGGTTTCCAGTAACTGAGCC, respectively. Panel D: specific antibodies against TBP,
TFIIA!" and control IgG were included in the EMSA. !" and !/" indicate unprocessed and processed TFIIA!", respectively.
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Figure 6. In vivo function of mature TFIIA! and TFIIA". (A) Chromatin binding of TFIIA!". Wild-type FH-TFIIA!" (WT) and FH-DGAA (DGAA)
were introduced into HeLa cells. Processing of wild-type TFIIA!" was checked by Western blotting (a). Amounts of chromatin-bound exogenous FH-
TFIIA!" and FH-DGAAwere determined by ChIP usingM2Agarose beads. ChIP enrichment at the TATA box-containingGAPDH promoter (GAPDH
pro) and control DNA region (p21FUR) was determined by qPCR (b). Ctrl indicates control. (B) Activation of TATA promoter. Wild-type FH-TFIIA!"
and FH-DGAA were introduced into HeLa cells together with indicated p21 reporter constructs, and the luciferase activity was determined. (C) Affinity
of TFIIA!" to its interacting proteins. Exogenously expressed FH-TFIIA!" and FH-DGAA were immunoprecipitated with M2 Agarose beads, and co-
precipitated TLP and TFIIA# were detected. Inp: input. (D) A dose-responsive effect of TFIIA# on TATA promoter activation. Indicated combinations
of TFIIAs were introduced into HCT116 cells together with p21-65/GL4 reporter plasmid, and luciferase activity was determined. For dose-dependent
analysis, 100 ng (+) or 200 ng (++) of TFIIA# expression plasmid was used.
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Prevention of chromatin binding of TBP by TLP
TBP is essential for potentiation of TATA promoters, and
TFIIA supports TBP function through stabilization of the
TBP-DNA association (9). Since TLP repressed TFIIA ac-
tivity, it is speculated that TBP-DNA binding is affected by
TLP. To confirm this hypothesis, we examined the amount
of chromatin-bound TBP by cell fractionation and ChIP
techniques. As expected, the amount of chromatin-bound
TBP was markedly increased in a TLP-knocked-down con-
dition (Figure 7A). Moreover, ChIP results showed that
chromatin-bound TBP was specifically increased in the
core promoter region (Figure 7B). This TLP-knockdown-
dependent increase in TBP-chromatin binding was corre-
lated with the increase in expression levels of TATA genes
(Figure 1A). These results suggest that TLP works as a neg-
ative factor for TBP-driven transcription through inhibiting
TFIIA function.
DISCUSSION
Repression of TATA genes by TLP
Since TLP is one of the TBP-family proteins, the role of
TLP in transcription regulation has been studied (21,22).
The most attractive characteristic of TLP is the highest
affinity to TFIIA (17,18). In the transcription regulation
of TATA-less promoters, several direct regulatory mecha-
nisms of TLP have been shown over the past decade. We
previously demonstrated that TATA-less promoters includ-
ing cyclinG2, TAp63 and p21 need TLP-TFIIA interaction
for transcription activation (23–25,33,36). Other groups
demonstrated that several TATA-less promoters are also
governed by TLP (e.g. TCT- and DPE-driven promoters
and promoters of the histone gene cluster of Drosophila)
(26,27). On the other hand, the mechanism by which TATA
genes are affected by the TLP-TFIIA interaction in vivo has
remained unclear. In this study, we showed that the TLP-
TFIIA interaction has a negative effect on TATA genes
(Figures 1 and 2). We found a novel mechanism that TLP
inhibits TATA genes expression through preventing TFIIA
maturation (Figures 3 and 4). Since 24%of the core promot-
ers of human genes have a typical TATA box or TATA-like
element (3), TLP may widely affect the expression of TATA
genes as a global regulator.
TLP behaves as an inhibitor of TFIIA processing
Sequence-specific cleavage of proteins is critical for reg-
ulation of cellular functions such as cell death, home-
ostasis and cell-cycle progression (37–39). TFIIA!" has
been demonstrated to be subjected to Taspase1-mediated
proteolytic processing for production of mature TFIIA!
and TFIIA" (13). Although the processing of TFIIA!" is
known to be critical in spermatogenesis and head morpho-
genesis (14,40), the regulation mechanism of TFIIA!" pro-
cessing has remained unknown. We found that TLP func-
tions as an inhibitor of TFIIA!" processing (Figures 3 and
4). TLP has a specific and critical function for TFIIA!"
through its strong affinity to TFIIA. Results of this study
suggest that direct binding of TLP to TFIIA!" is required
for inhibition of TFIIA!" processing (Figures 3 and 4D).
Although the amino acid sequence of TBP is 40% similar
to that of TLP (19,28), TBP never inhibits the processing
in vivo (data not shown). Our previous works have further
shown that TLP has one-order higher affinity to TFIIA
than TBP does (18). The high degree of stability of the
TLP-TFIIA complex ensures the prevention of Tapsase1-
mediated processing of the TFIIA!" precursor. These ob-
servations suggest that TLP is not just a TBP alternative
with inadequate ability but is a unique factor with a func-
tion distinct from that of TBP.
TFIIA!" processing is required for activation of the TATA
promoter
Although the transcription activation function of TFIIA
has been studied in yeast, yeast TFIIA!" (TOA1) does not
undergo proteolytic processing (13). On the other hand,
the significance of Taspase1-mediated TFIIA!" process-
ing in human cells has not been elucidated. Although,
from results of previous in vitro analyses, the Taspase1-
mediated processing has been thought to be essential step
for the TATA promoter activation (9), several studies
demonstrated that the unprocessed TFIIA!" has transcrip-
tional activity (15,16,40). To demonstrate functional differ-
ences between each form of TFIIA clearly, we examined
TFIIA function in conventionally used cultured cells. Fi-
nally, we showed that the processing of TFIIA is required
for activation of TATA genes in human HeLa cells and
HCT116 cells (Figure 6), and the unprocessed TFIIA!" is
inactive in transcription activation, which is explained be-
low. We demonstrated that there are essential functional
differences between processed and unprocessed forms of
TFIIA!". Only processed TFIIA!" is associated with the
TATA box together with TBP and TFIIA# (Figures 5 and
6). Moreover, processed TFIIA!" has transcription acti-
vation function specifically for TATA promoters (Figure
6B). TFIIA# is required for holo-TFIIA function (41),
and the present study revealed that TFIIA# is needed for
both the TATA box associating ability and promoter ac-
tivation function of processed TFIIA!" (Figures 5B and
6D). In agreement with the promoter activation ability of
processed TFIIA!", processed TFIIA!" exhibited higher
affinity to TFIIA# than did its unprocessed form (Figure
6C). This considerable affinity is presumably needed for
the TATA box-activation function of processed TFIIA!".
Thus, the Taspase1-mediated processing of the TFIIA!"
precursor is required for acquiring both TATA box as-
sociation ability and promoter activation function. Since
processed TFIIA!" can associate with the TATA box in
the presence of TBP and TFIIA# (Figure 5B), processed
TFIIA!" is likely to function as a co-activator of TBP to-
gether with TFIIA# . Since the unprocessed TFIIA!" does
not exhibit such ability, this co-activator function is thought
to be one of the mature TFIIA!"-specific identities.
Unprocessed TFIIA!" can facilitate TBP-TATA box bind-
ing but is inactive in transcription activation
TBP alone does not exhibit high affinity to the TATA box
(3). This is probably because TBP is a sticky protein and
tends to form functionally inactive homo-dimers (42,43).
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Figure 7. Negative effect of TLP on chromatin binding of TBP. (A) Amounts of chromatin-bound TBP. Chromatin-unbound (Ch-free) and chromatin-
bound fractions (Ch-bound) were prepared from TLP-knocked-down HeLa cells, and the proteins were detected. Tubulin and histone H4 were used as
standard proteins for chromatin-unbound and chromatin-bound fractions, respectively. (B) Amounts of promoter-bound TBP. TLP-knocked-down HeLa
cells were subjected to a ChIP assay using a TBP-specific antibody. ChIP enrichment was determined by qPCR. IgG and TBP: IgG- and TBP-specific
immnoprecipitates, respectively.
Figure 8. TLP-dependent promoter selection model of TFIIA. TLP inhibits Taspase1-mediated maturation of TFIIA!" and represses TATA gene expres-
sion. TLP forms a complex with both the processed and unprocessed forms of TFIIA!" and potentiates TLP-mediated genes. Consequently, TLP governs
promoter selectivity of TFIIA and regulates gene expression.
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We previously found that TFIIA enhances the dissociation
of TBP dimers (18,44). Unprocessed TFIIA!" does not ex-
hibit a stable TATAbox-association function (Figures 5 and
6), but it facilitated the formation of a stable TBP-TATA
box complex in solution (Figure 5). Other groups also re-
ported that TBP-TATA box binding is stimulated by un-
processed TFIIA!" (8,41). Hence, even the unprocessed
TFIIA!" can dissociate TBP dimers and orientate a TBP
monomer to the TATA box. Because processed TFIIA!"
also facilitated TBP-TATA box association (Figure 5), the
TBP-TATA stabilizing function of TFIIA!" is restored af-
ter processing. So far, TATA box-association of TFIIA has
been assumed to be required for orientation of TBP to a
TATA box. Data obtained in this study, however, suggest
that even the TFIIA!" precursor, which does not exhibit
association ability with the TATA box, basically has TBP-
TATA box stabilization ability, and Taspase1-directed pro-
cessing enables TFIIA to associate with the TATA box for
full potentiation of TATA promoters as mentioned above.
Consequently, we hypothesize that there are two steps for
TFIIA-mediated potentiation of TATApromoters. The first
step is orientation of a TBP monomer to TATA box DNA
without association of TFIIA with the TATA box. The sec-
ond step is TATA box-binding of TFIIA itself for activa-
tion of an associating promoter. Moore et al. demonstrated
by in vitro analysis that TLP prevents TBP-TATA box com-
plex formation as the first step through competingwith TBP
for TFIIA binding (28). We clearly showed that TLP pre-
vents TBP-TATA box binding in vivo (Figure 7), probably
due to disruption of TBP-TFIIA interaction by TLP. On
the other hand, it might be possible that TLP disrupts TBP-
TATA box binding via other mechanisms such as alterna-
tion of chromatin structure (45). In any cases, the present
study demonstrated clearly that the Taspase1-mediated pro-
cessing is a novel step for TLP to inhibit TATA-containing
genes (Figure 8).
TLP participates in promoter selectivity of TFIIA
We demonstrated that unprocessed TFIIA!" is inactive
in TATA promoter activation. On the other hand, un-
processed TFIIA!" has much more capacity to activate
a subset of TLP-dependent TATA-less promoters (Figure
8). We found that unprocessed TFIIA!" activates the up-
stream promoter of the human p21Cip1 gene (our un-
published data), which is rather dependent on TLP. Actu-
ally, promoter recruitment of unprocessed TFIIA!" has
been reported. Takeda et al. demonstrated that unpro-
cessed TFIIA!" associates with TATA-less promoters of
p16Ink4a and p19Arf genes and enhances expression of
those genes during mouse craniofacial morphogenesis (40).
Thus, the TFIIA!" precursor is likely to activate TBP-
independent and TLP-governed TATA-less promoters. Be-
cause TLP also interacts with TFIIB, another GTF, TLP-
governed promoters can be regulated by a specific transcrip-
tion preinitiation complex containing TLP, unprocessed
TFIIA and TFIIB.
We propose a TLP-governed promoter selectionmodel of
TFIIA (Figure 8). TLP inhibits processing of the TFIIA!"
precursor and accumulates the precursor. Although inhibi-
tion of TFIIA!"maturation by TLP results in repression of
TATAgenes, TLP and accumulating unprocessed TFIIA!"
are cooperatively recruited to TATA-less promoters and po-
tentiate a subset of genes.
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a b s t r a c t
TBP-like protein (TLP) is one of the metazoan-restricted transcription factors participating in develop-
ment and differentiation, though the molecular mechanism by which TLP regulates these processes
remains unclear. In this study, we investigated the relationship between TLP and myogenesis of mouse
C2C12 myoblasts. We found that TLP gene expression decreases during myogenic differentiation. Over-
expression and knockdown of TLP revealed that the levels of muscle-speciﬁc myosin heavy chain and the
myogenic transcription factor myogenin are downregulated by TLP. TLP inhibits the progression of
morphological change from myoblasts to myotubes, thereby suppressing myogenesis. We further show
that TLP represses the promoter activity of myogenin. The proximal AT-rich sequence of the myogenin
promoter is responsible for TLP-mediated transcriptional repression. The results of this study suggest
that TLP inhibits myogenesis through downregulation of the myogenin gene.
© 2016 Elsevier Inc. All rights reserved.
1. Introduction
TBP is one of the general transcription factors for RNA poly-
merase II-driven promoters and activates transcription initiation
[1]. In 1999, we identiﬁed TLP (TBP-like protein), also called TBP-
related factor 2 (TRF2), as one of the ﬁve TBP family proteins [2].
Given that TLP has only 38% identity to the essential region of TBP
and does not have an obvious speciﬁc DNA-binding sequence, TLP
seems not to have a transcription regulatory function. However, TLP
is found restrictedly in multi-cellular animals, suggesting that TLP
has a common role in animal development and differentiation.
Several studies have carried out on TLP to elucidate its role in an-
imal development. For example, suppression of the TLP gene by
RNA interference in C. elegans [3], Xenopus [4], and zebra ﬁsh [5]
revealed that TLP is required for normal development of animals.
In addition, knockout of the TLP gene in mice causes a defect in
spermatogenesis [6]. However, the mechanisms by which TLP
regulates animal development were not fully addressed in those
studies.
In 2001, we demonstrated through mammalian one-hybrid as-
says that TLP has a potent transcription activating potential [7].
After that, we further showed that TLP exhibits its transcription
activating function even in a natural promoter context [8]. Different
from typical transcriptional regulators, TLP is thought to function as
a co-activator because it lacks obvious sequence-speciﬁc DNA-
binding ability. This co-activator function has been suggested to be
involved in functions of certain DNA-bound transcription factors
such as DNA replication-related element binding factor [9] and p53
[10]. We further demonstrated that TLP works as a positive tran-
scriptional regulator for TAp63 [11] and p21 genes [12]. Other
groups also reported that PCNA and NF-1 genes are enhanced by
TLP [9,13]. Moreover, transcription factor IIA (TFIIA), another gen-
eral transcription factor, stimulates TLP-governed transcriptional
activation [14]. In some cases, TLP represses transcription from the
wee1 promoter [15] and several TATA-containing promoters [13]. It
has thus been generally established that TLP has the ability to
regulate transcription.
Development of multi-cellular organisms is conducted by a
number of transcription factors that work for growth-related and
differentiation-related genes. Because TLP is required for the
proper developmental schedule of metazoans and is involved in
transcriptional regulation, we speculated that TLP plays a role in
animal differentiation through its transcription regulation func-
tion. In this study, we investigated the role of TLP in myogenesis
of C2C12 cells. We describe here that TLP gene expression is
Abbreviations: TBP, TATA-binding protein; TLP, TBP-like protein; TFIIA, tran-
scription factor IIA; MHC, myosin heavy chain; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; FH, FLAG and oligohistidine; CHX, cycloheximide.
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decreased during cell differentiation and that TLP actively in-
hibits the progression of myogenesis. Moreover, TLP represses
transcription of the myogenin gene. Myogenesis is governed by
several genes for transcription factors. Among them, myogenin is
the most critical gene for myotube development and myoﬁber
maturation. We will provide a new insight into the role of TLP in
animal development.
2. Materials and methods
2.1. Cell culture, differentiation procedure and transfection
Mouse C2C12 myoblasts were grown in a growth medium
containing Dulbecco's modiﬁed MEM with high glucose content
(DMEM-high, Sigma-Aldrich) with 20% fetal calf serum. To induce
myogenic differentiation, the growth medium was replaced with a
differentiation medium containing DMEM-high and 2% horse
serum as previously described [16,17]. HeLa cells grown in DMEM-
low (Sigma-Aldrich) were also used. Transfection of plasmid DNAs
and siRNAs was performed by using a Lipofectamine 2000
(Invitrogen).
2.2. Plasmids and luciferase assay
pCIneo-FH-TLP, which is a mammalian cell expression plasmid
of ﬂag/oligohistidine-tagged mouse TLP (FH-TLP), was
described previously [18]. Reporter plasmids with the luciferase
reporter gene were used to determine the myogenin promoter
activity. For the construction of a luciferase reporter plasmid of
the mouse myogenin promoter, a DNA fragment carrying the
promoter sequence of the mouse myogenin gene from !635
to þ23 relative to the transcription start site (i.e., assigned ac-
cording to the DataBase of Transcriptional Start Sites) was cloned
into the pGL4.10 vector (Promega) by PCR-based DNA ampliﬁ-
cation using mouse genomic DNA. Based on this wild-type re-
porter construct, we further prepared mutant promoter
constructs, mutant1 and mutant2, by using a Prime Star Muta-
genesis kit (TaKaRa), in which AT-rich motifs around !62
and !28, respectively, were changed as depicted in Fig. 4A. For
the luciferase assay, FH-TLP or an empty plasmid (100 ng)
was introduced into cells together with the reporter plasmid
(100 ng). Twenty-four hours after transfection, cell extracts were
prepared and luciferase activity was determined by a Dual-
Luciferase Reporter Assay System (Promega) as previously
described [14].
2.3. siRNA
Short interfering RNA (siRNA) for mouse TLP (siTLP) was a
commercial product of Japan Bioservice. siRNA with a scramble
sequence of a part of TFIIA [14] was used for control siRNA (siCtrl).
2.4. RT-PCR
Total RNA was prepared by using an RNeasy kit (Quiagen).
Reverse transcription PCR (RT-PCR) was performed as described
previously [20]. Brieﬂy, cDNA synthesized from total RNA using
Prime Script II (TaKaRa) or avian myeloblastosis virus Reverse
Transcriptase XL (TaKaRa) was ampliﬁed by PCR using Paq5000
DNA polymerase (Stratagene) and appropriate primer sets. Ampli-
ﬁed products were analyzed by 2% agarose gel electrophoresis.
Quantitative determination of the PCR products (qPCR) was per-
formed using a Thunderbird qPCR Mix (Toyobo) and CFX384 Touch
Real-Time PCR Detection System (Bio-Rad).
2.5. Antibodies, Western blotting and immunoﬂuorescence staining
Antibodies against myogenin (Pharmingen) and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) (Santa Cruz) were
commercial products. Antibodies against TBP [19], TLP [20] and
myosin heavy chain (MHC) [15] were described before. For
Western blotting, proteins separated by 12.5% SDS-PAGE and
transferred to an Immobilon-P PVDF membrane (Millipore) were
detected by Immuno Star Zeta (Wako) by using speciﬁc primary
antibodies and appropriate horseradish peroxidase-conjugated
secondary antibodies including anti-rabbit IgG and anti-mouse
IgG. Protein concentration was determined using a BCA Protein
Assay kit (Pierce). Immunoﬂuorescence staining was carried out
basically as described previously [16]. C2C12 cells on a coverslip
were ﬁxed with paraformaldehyde, permeabilized with Triton X-
100, incubated with an anti-MHC antibody, and then incubated
with Alexa488-conjugated mouse IgG. Nuclei were stained with
DAPI.
2.6. Statistical analysis
Welch's t-test and Tukey's honestly signiﬁcant difference test
were performed using R software (ver. 3.1.2).
3. Results
3.1. Expression of TLP gene in differentiating C2C12 cells
To investigate the relationship between cell differentiation and
TLP, we chose C2C12 myoblasts, which differentiate into myotubes
in culture. It was found that myogenin, a representative myogenic
transcription factor, appeared at 1 day after the start of the differ-
entiation protocol, while TLP was decreased signiﬁcantly (Fig. 1A
and B). Essentially the same results were obtained for a longer
period of cell differentiation (i.e., to differentiation day 5) (Fig. 1C).
Whenwe added cycloheximide (CHX), a protein synthesis inhibitor,
the myogenin signal did not appear, indicating that myogenin is
unstable in differentiating cells (Fig. 1C). This is because myogenin
is rapidly degraded by the ubiquitin-proteasome system [16].
Consistently, the myogenin signal was observed when MG132 was
added (Fig. 1C). On the other hand, the TLP signal did not weaken
evenwhen CHX was added. These results show that TLP is stable in
C2C12 cells and that the myogenesis-related decrease of TLP is not
due to increased sensitivity to the protein degradation mechanism.
Muscle-speciﬁc myosin heavy chain (MHC), a representative mus-
cle marker protein, appeared at differentiation day 2 (data not
shown). Next, we determined the gene expression of TLP in
differentiating C2C12 cells and found that TLP gene expression
decreased at 1 day after the start of the differentiation protocol
(Fig. 1D and E). It was therefore demonstrated that the decrease of
TLP protein in differentiating C2C12 cells is due to the decreased
gene expression.
3.2. Effects of TLP on muscle-speciﬁc proteins and their gene
expression in differentiating C2C12 cells
In experiments of Fig. 1, we clariﬁed that TLP in C2C12 cells
decreases in accordance with differentiation. To determine the role
of TLP in expression of endogenous muscle-speciﬁc genes in
differentiated C2C12 cells, we performed TLP overexpression ex-
periments. Cells were transfected with an expression vector for FH-
TLP, and the amounts of MHC were determined. In the case of
control vector-transfected cells, MHC protein appeared at differ-
entiation day 1, whereas it appeared at day 3 when FH-TLP was
overexpressed (Fig. 2A). To ascertain the negative function of TLP in
A. Nakazato et al. / Biochemical and Biophysical Research Communications 479 (2016) 814e819 815
Fig. 1. TLP in differentiating C2C12 cells. (A) Proteins in differentiating C2C12 cells. Cells were grown in a growth medium and the growth mediumwas exchanged to a differentiation
medium and the cells were maintained for 24 h. Proteins including TLP, MHC and TBP in whole cell extracts were detected by Western blotting at indicated times after the medium
change. (B) Relative band intensities of TLP in multiple experiments as shown in panel A are displayed. **p < 0.01 (Tukey's honestly signiﬁcant difference test). (C) Proteins shown in
panel A were determined for a longer period of the differentiating procedure. In lanes D, C, and M, cells were treated with DMSO (solvent for CHX), 50 mg/ml CHX (cycloheximide),
and CHX þ 10 mg/ml MG132 for 5 h before cell harvest, respectively. (D) Gene expression in differentiating C2C12 cells. Amounts of mRNAs of TLP, myogenin, and GAPDH were
determined by RT-PCR. (E) Relative amount of TLP mRNA in multiple experiments as shown in panel D was determined by quantitative RT-PCR (RT-qPCR).
Fig. 2. Effects of TLP on expression of muscle-speciﬁc MHC and myogenin. (A) Proteins in TLP-overexpressed cells. C2C12 cells were transfected with a TLP expression plasmid (FH-TLP)
or its empty vector (empty) and subjected to the differentiation protocol, and then MHC, TLP and GAPDH were determined at indicated times after the differentiation procedure.
TLP: endogenous TLP protein. (B) Proteins in TLP-knockdown cells. Cells were transfected with TLP siRNA (siTLP) or control siRNA (siCtrl) and subjected to the differentiation
protocol, and then proteins were determined. (C) Expression of endogenous genes including myogenin in TLP-overexpressed cells. Myogenin gene expression in cells prepared as
described in panel [A] was assayed by RT-PCR. (D) Relative amount of myogenin mRNA in multiple experiments as shown in panel C was determined by RT-qPCR. **p < 0.01 (Welch's
t-test). (E) mRNAs in siRNA-treated cells. Gene expression in cells prepared as indicated in panel B was determined. (F) Relative amount of myogenin mRNA in multiple experiments
as shown in panel E was determined by RT-qPCR. *p < 0.05 (Welch's t-test).
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the expression of myogenin protein, we further performed gene
knockdown experiments using siRNA of TLP (siTLP) (Fig. 2B). siTLP
advanced the timing of MHC appearance compared with that in the
experiment using control siRNA (siCtrl). Next, we examined myo-
genin gene expression in TLP-overexpressed cells. Fig. 2C and D
shows that the appearance of myogenin mRNA was delayed by 1
day compared with that in control cells. On the other hand, an
essentially opposite result was obtained when cells were trans-
fected with siTLP (Fig. 2E and F). Consequently, it was concluded
that TLP negatively affects the expression of muscle-speciﬁc genes
such as MHC and myogenin.
3.3. Inhibition of myogenesis by TLP
We next examined the morphological changes of C2C12 cells
frommononuclear myotubes to longer andmultinuclear myotubes.
We found that the proportion of myotubes decreased when cells
were transfected with the FH-TLP expression vector (Fig. 3A). On
the other hand, transfection of siTLP increased the proportion of
differentiating cells (Fig. 3B). We quantiﬁed the differentiating cells
and found that lengths of myotubes obtained from TLP over-
expression and siTLP transfection became shorter and longer,
respectively (Fig. 3C and D). It was also found that populations of
multinuclear cells and MHC-positive cells show a positive correla-
tion, and the proportions of differentiating cells are lower in FH-
TLP-overexpressed cells and higher in TLP-knocked-down cells
(data not shown). From the results shown in Figs. 2 and 3, we
concluded that TLP actively represses myogenesis.
3.4. Repression of the myogenin promoter by TLP
Myogenin is one of the most typical and potent transcription
factors for myogenesis, and it functions for differentiation of
myotubes and their maturation [21]. It is speculated that myo-
genin gene expression is affected by TLP because TLP has that
ability to modulate transcription. We performed a gene reporter
assay by using mouse myogenin promoter-containing reporter
plasmids (Fig. 4A). It was demonstrated that myogenin promoter
activity in C2C12 cells was decreased by co-transfection of FH-TLP
dose-dependently (Fig. 4B-a). We also used a mutant TLP, N37E,
that has a lower afﬁnity to TFIIA than does wild-type TLP [18].
TFIIA is a general transcription factor and is needed for TLP
function [8]. Because N37E did not efﬁciently inhibit themyogenin
promoter (Fig. 4B-a), we suggest that TFIIA is required for TLP-
mediated promoter repression. We performed a similar experi-
ment using HeLa cells, which are not related to myogenesis.
Fig. 4B-d shows that the myogenin promoter is repressed signiﬁ-
cantly by TLP even in HeLa cells, suggesting that a common
transcription factor is involved in the TLP-mediated repression. In
contrast, the promoter activity in siTLP-treated cells was signiﬁ-
cantly higher than that in control cells, conﬁrming a negative
function of TLP for themyogenin promoter (Fig. 4C). Consequently,
we concluded that myogenin promoter activity is downregulated
by TLP.
There are two TATA-box-like AT-rich sequences at !62
and !28 of the mouse myogenin promoter, and these motifs are
speculated to function as positive promoter elements. We
generated two mutant promoters, mutant1 and mutant2, having
mutations around the distal and proximal AT-rich sequences,
respectively (Fig. 4A). It was found that mutant1 behaves like the
wild-type promoter in response to FH-TLP overexpression
(Fig. 4B-b), meaning that the distal AT-rich sequence is not
related to the repressive function of TLP but responds to some
unknown positive transcription factors because net promoter
activity decreased considerably (24%). On the other hand,
mutant2 did not respond to TLP overexpression and exhibited
weaker promoter activity (12%) than that of mutant1 (Fig. 4B-c).
The results of this experiment suggest that the AT-rich sequence
at !28 works as a potent positive cis-acting element and behaves
as a functional target of TLP.
Fig. 3. TLP-mediated repression of myogenic differentiation. (A and B) C2C12 myoblasts were transfected with an FH-TLP expression vector (A) or siTLP (B). One day after transfection,
cells were subjected to the differentiation protocol and maintained for 3 days, and then intracellular MHC was detected by immunoﬂuorescence staining with a speciﬁc antibody.
Nuclei were stained with DAPI. Scale bar: 100 mm. (C and D) Lengths of differentiating myotubes. Lengths of 10e12 myotubes obtained in experiments A and B were randomly
scored, and average values are displayed in panels C and D, respectively. **p < 0.01 (Welch's t-test).
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4. Discussion
In the early stage of the TLP research, TLP was regarded as a
development factor because TLP-knockdown and TLP-knockout
animals displayed abnormal developmental phenotypes [3e6].
However, the question of why TLP affects development has been
poorly resolved. In the present study, we addressed this issue.
C2C12 cells, which differentiate intomyotubes without difﬁculty by
a well-established differentiation protocol, are frequently used for
myogenic differentiation and development in culture. We found
that TLP gene expression in C2C12 cells is decreased in accordance
with the differentiation process (Fig. 1). TBP was also decreased
when cells were differentiating (Fig. 1B), being consistent with a
ﬁnding reported by Li et al. [22]. To clarify TLP function, we altered
the intracellular TLP level by overexpression experiment, and found
that the level of MHC protein is decreased by TLP overexpression
(Fig. 2A). Moreover, gene expression of myogenin and MHC was
downregulated by TLP (Fig. 2C and E). These results were conﬁrmed
by histochemical analyses because the population of MHC-positive
myotubes exhibited a negative correlation with amounts of intra-
cellular TLPs (Fig. 3). Consequently, we concluded that TLP func-
tions to repress or postpone differentiation. This repressive effect of
TLP may not be restricted to myogenesis but may be generalized
because TLP is also decreased in F9 cells when F9 embryonic car-
cinoma cells are differentiated (data not shown). TLP further
upregulates stem cell-related genes such as nanog, Oct3/4, and c-
Myc (data not shown). Therefore, it is speculated that abnormal
developmental phenotypes found in previous TLP knockdown and
knockout studies may be due to disturbed differentiation events
caused by a decreased amount of TLP.
The luciferase assay revealed that TLP depresses activity of the
myogenin promoter. Because myogenin is one of the most potent
myogenic transcription factors for myotube differentiation [21], it is
thought that depression of the myogenin promoter by TLP is
involved in TLP-mediated inhibition of myogenesis. It has been
demonstrated that TLP inhibits several TATA-containing promoters
[23,24]. One explanation of this phenomenon could be that TLP
stably binds and traps TFIIA, which is required for TBP-dependent
transcription initiation driven by TATA-box promoter [18],
because afﬁnity of TLP toTFIIA is about 10-times higher than to that
of TBP. We speculate that TLP-mediated repression of themyogenin
promoter is not a direct effect of TLP because TLP does not stably
bind to the myogenin promoter (data not shown) but that it is
mediated by TFIIA needed for TBP function. Because N37E mutant
TLP does not compete with TBP for TFIIA binding [19], this mutant
was not able to inhibit the myogenin promoter (Fig. 4B). We found
that, in addition to themyogenin promoter, the TIP120B promoter is
also downregulated by TLP during C2C12 myogenesis (Fig. 4C).
TIP120B [25,26], which is induced during myogenesis of
C2C12 cells, is an inhibitor of SCF ubiquitin ligase for myogenin and
MyoD to lead them to proteasome degradation [16]. Therefore, TLP
may inhibit myogenesis through a synergistic repressive effect on
several myogenesis-promoting genes.
In this study, we found that both distal and proximal AT-rich
sequences have a positive function for myogenin promoter activ-
ity because the net promoter activities of mutant1 (24%) and
mutant2 (12%) were considerably lower than that of the wild-type
promoter (Fig. 4B and C). The distal AT-rich sequence does not seem
to be a TATA-box element because the position of the element is far
from the transcription start site (!62) compared with the typical
TATA-box (around !30). The distal AT-rich element may interact
with some unknown positive transcription factors. On the other
hand, the proximal AT-rich motif, which competes with TBP for
TFIIA binding, was sensitive to TLP (Fig. 4) and was needed for TBP-
Fig. 4. Myogenin promoter activity is decreased by TLP. (A) Schematic representation of the promoter structure of the mouse myogenin gene used for luciferase assays. Sequences of
the AT-rich regions (underlined) at !62 and !28 are displayed. Mutated sequences in mutant1 and mutant2, in which distal and proximal AT-rich sequences respectively were
changed, are depicted with bold letters. (B) Luciferase assay for the myogenin promoter using C2C12 cells (aec) or HeLa cells (d) co-transfected with increasing doses of FH-TLP
expression vector or N37E expression vector. As for reporter plasmids, we used wild-type (a and d), mutant1 (b), and mutant2 (c) promoters. (C) Luciferase assays were pre-
formed by using siTLP-treated C2C12 cells and wild-type myogenin promoter. Reporter plasmid carrying a promoter sequence of TIP120B gene is previously described [26].
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dependent transcription repression of the myogenin promoter.
Therefore, we suggest that the proximal AT-rich motif works as a
TATA-box element.
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Ubiquitin-proteasome-dependent degradation of TBP-like
protein is prevented by direct binding of TFIIA
Momoko Isogai, Hidefumi Suzukia*, Ryo Maeda and Taka-aki Tamura
Department of Biology, Graduate School of Science, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba-shi, Chiba 263-8522, Japan
Although the majority of gene expression is driven by TATA-binding protein (TBP)-based
transcription machinery, it has been reported that TBP-related factors (TRFs) are also
involved in the regulation of gene expression. TBP-like protein (TLP), which is one of the
TRFs and exhibits the highest affinity to TFIIA among known proteins, has recently been
showed to have significant roles in gene regulation. However, how the level of TLP is main-
tained in vivo has remained unknown. In this study, we explored the mechanism by which
TLP protein is turned over in vivo and the factor that maintains the amount of TLP. We
showed that TLP is rapidly degraded by the ubiquitin-proteasome system and that tight inter-
action with TFIIA results in protection of TLP from ubiquitin-proteasome-dependent degra-
dation. The half-life of TLP was shown to be less than a few hours, and the proteasome
inhibitor MG132 specifically suppressed TLP degradation. Moreover, knockdown and over-
expression experiments showed that TFIIA is engaged in stabilization of TLP in vivo. Thus, we
showed a novel characteristic of TLP, that is, interaction with TFIIA is essential to suppress
proteasome-dependent turnover of TLP, providing a further insight into TLP-governed gene
regulation.
Introduction
TATA-binding protein (TBP) is the most common
general transcription factor (GTF), which is necessary
for transcription initiation (Greenblatt 1991; Pugh &
Tjian 1992; Pugh 2000). TBP recognizes and binds
to the TATA box motif, and other GTFs including
TFIIA and TFIIB are recruited to the promoter
regions of RNA polymerase II (Pol II)-driven genes
to form transcription initiation complexes (Imbalzano
et al. 1994). TBP-related factors (TRFs), TRF1,
TRF2 [also called TLP (TBP-like protein)] and
TRF3, have also been shown to participate in tran-
scription regulation (Reina & Hernandez 2007;
Zehavi et al. 2015). TRF1 and TRF3 have over 60%
similarity to TBP. They have TATA box-binding
ability as TBP does, and they are capable of replacing
TBP function in vitro. TRF1 functions as a regulator
of Pol III- and Pol II-driven transcription in Droso-
phila and Anopheles (Crowley et al. 1993). TRF3 has
been reported to be involved in embryogenesis and
development in vertebrates (Persengiev et al. 2003).
Thus, it is thought that TRF1 and TRF3 exhibit
their specific transcription regulatory function via
their structural and functional similarity to TBP.
However, TLP, which exists in most metazoans, has
the unique characteristic of having the lowest similar-
ity (approximately 40%) to TBP among TRF pro-
teins. Therefore, TLP has no TATA box-binding
ability, whereas its affinity to TFIIA and TFIIB is
preserved like other TRFs (Ohbayashi et al. 1999;
Berk 2000; Reina & Hernandez 2007; Zehavi et al.
2015). Notably, the affinity of TLP to TFIIA is one-
order higher than that of TBP to TFIIA (Teichmann
et al. 1999; Nakadai et al. 2004).
TFIIA is a well-known GTF that is required for
stabilization of TBP-DNA complex. TFIIA forms the
core machinery of the pre-initiation transcription
complex (PIC) together with TFIIB and TBP
(Greenblatt 1991; Pugh & Tjian 1992; Pugh 2000).
In vertebrates, holo-TFIIA complex consists of three
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subunits, a, b and c (Yokomori et al. 1993; Sun et al.
1994). The precursor of TFIIAa and b subunits is
generated from the TFIIA-L gene and is subsequently
processed into each subunit (Zhou et al. 2006; Høiby
et al. 2007). Both precursor (ab) and matured sub-
units (a/b) bind to the c subunit to form complexes
ab/c and a/b/c, respectively (Høiby et al. 2007;
Oyama et al. 2013). Although TLP is known to exhi-
bit affinity to each form of TFIIA, it exhibits higher
affinity, especially to the precursor form of TFIIA
(ab/c), than TBP does. The functional significance
of the highest affinity to TFIIA for TLP has long
been studied. We previously found that affinity of
TLP to TFIIA is required for transcriptional activa-
tion of TLP-target genes (Suzuki et al. 2012, 2014).
Moreover, we recently showed that affinity of TLP
with TFIIA is related to transcription repression
(Suzuki et al. 2015). Thus, our recent studies indicate
that TLP-TFIIA interaction plays a significant role in
transcriptional regulation in vivo.
The abundance of intracellular TLP has been
shown to fluctuate under given cellular conditions
such as exposure to DNA-damaging agents including
UV irradiation and etoposide (Shimada et al. 2003;
Suenaga et al. 2009). A change in TLP expression
level leads to transcriptional regulation of DNA dam-
age-responsive genes, suggesting that regulation of
TLP expression level in particular situations is crucial
for cell viability. However, it has not been deter-
mined how TLP expression is regulated. In this
study, we found that TLP is degraded by the ubiqui-
tin-proteasome pathway and that this degradation is
inhibited by TFIIA as its binding partner through
formation of a stable complex. This study suggested
the significance of a strong interaction between TLP
and TFIIA.
Results
TFIIA maintains the amount of TLP
It has long been known that TLP has the highest
affinity to TFIIA (Nakadai et al. 2004). Immunopre-
cipitation analysis confirmed that the affinity of TLP
to TFIIA is higher than that of TBP, and TLP pref-
erentially interacts with the precursor form of TFIIA
protein (Fig. 1A). We have reported that the TLP-
TFIIA interaction contributes to the regulation of a
subset of genes (Tanaka et al. 2007; Suzuki et al.
2014). In a previous study, we found that stable
TLP-TFIIA interaction affects promoter association
of TLP (Suzuki et al. 2014). Here, we investigated
the effect of TFIIA depletion by the siRNA method
on TLP abundance. We found that the partial
depletion of TFIIA decreased the amount of TLP
in HeLa cells (Fig. 1B). The same result was obtained
in HCT116 cells. Additionally, over-expression of
exogenous TFIIA weakened the TLP-siRNA-
induced decrease of TLP (Fig. 1C), implying that the
decrease of TLP by siRNA transfection is blocked by
TFIIA. As over-expression of TFIIA exhibited no
significant effect on TLP mRNA (Fig. 1D), it was
shown that TLP protein level is correlated with the
amount of TFIIA protein.
TLP is degraded by the ubiquitin-proteasome
pathway
The stability of TLP protein has not been investi-
gated. We therefore investigated the stability of TLP
protein in cells treated with cycloheximide (CHX).
In our experimental conditions, the half-life of TLP
was found to be 3–4 h (Fig. 2A). To identify the
pathway by which TLP is degraded, we used two
reagents, the proteasome inhibitor MG132 and the
autophagic degradation inhibitor bafilomycin A1.
The half-life of TLP protein was significantly pro-
longed by MG132 treatment, whereas it was not
affected by bafilomycin A1 treatment (Fig. 2B).
Moreover, the ubiquitination assay showed that TLP
is highly ubiquitinated in vivo (Fig. 2C). These results
indicate that TLP is degraded by the ubiquitin-pro-
teasome pathway.
TFIIA stabilizes TLP protein
Considering the fact that TLP is degraded in vivo
(Fig. 2) and the fact that TFIIA depletion decreased
the amount of TLP protein (Fig. 1), we suggested
that TFIIA stabilizes TLP. To evaluate this hypothe-
sis, we investigated the effect of TFIIA over-expres-
sion on the half-life of TLP. As shown in Fig. 3,
over-expression of TFIIA dramatically enhanced TLP
stability (Fig. 3A) without affecting TLP mRNA
(Fig. 3B). These results support our hypothesis. As it
is well known that the affinity of TLP-TFIIA is high,
we next examined whether the direct binding of
TFIIA to TLP is required for TLP stabilization. We
used deletion mutants of TLP, DN- and DC-TLP
(Fig. 4A). The N-terminal half of TLP has been
reported to be essential for TFIIA binding (Nakadai
et al. 2004). We confirmed that the DN-TLP mutant
did not exhibit significant affinity to TFIIA (Fig. 4B).
Wild-type TLP was stabilized by TFIIA dose-
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dependently, whereas DN-TLP was not stabilized by
TFIIA (Fig. 5A). Furthermore, the CHX treatment
experiment showed that the TFIIA-binding ability-
deficient DN-TLP mutant was not protected by
over-expressed TFIIA from degradation (Fig. 5C).
These results indicate that direct binding between
TLP and TFIIA is required for TLP stabilization by
TFIIA.
Our previous study showed that the cyclin G2
gene promoter is activated through TLP-TFIIA inter-
action (Tanaka et al. 2007). Consistent with our pre-
vious study, the cyclin G2 promoter was activated by
TLP, and the combination of TLP and TFIIA further
up-regulated the cyclin G2 promoter (Fig. 5B).
Moreover, consistent with the results of this study
showing that DN-TLP was not stabilized by TFIIA,
the combination of DN-TLP and TFIIA did not acti-
vate the promoter (Fig. 5B). As TLP has affinity to
TFIIB, we examined the possibility that TFIIA-
induced TLP stabilization affect protein level of
TFIIB. We checked the expression levels of proteins.
We confirmed that the processing of TFIIA was
inhibited by TLP but not by TFIIA affinity-depleted
DN-TLP (Fig. 5B, panel b), as we reported previ-
ously (Suzuki et al. 2015). The expression level of
TFIIB was not affected by stabilized TLP (Fig. 5B,
(A) (B)
(C) (D)
Figure 1 Amount of TLP is positively controlled by TFIIA. (A) Affinity of TFIIA to TLP or TBP. HCT116 cells were trans-
fected with expression plasmids for FH-TBP or FH-TLP, and the FH-tagged protein was immunoprecipitated with anti-Flag M2
beads. The eluates were analyzed by Western blotting. The values of percentage of input were shown below the panel. (B) Effect
of TFIIA knockdown on TLP protein expression. HeLa cells were transfected with siRNA for TFIIA (siTFIIA) or control siRNA
(scr), and the amounts of protein were determined by Western blotting. (C) and (D) effect of exogenous TFIIA on TLP under a
TLP-siRNA-transfected condition. FH-TFIIAab and FH-TFIIAc were introduced into HeLa cells together with siTLP or scr.
The amounts of protein and mRNA was determined by Western blotting (C) and RT-PCR (D), respectively. TLP, TBP-like
protein.
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panel b). These results suggest that TFIIA-induced
stabilization of TLP is required for promoter activa-
tion of cyclin G2 gene without affecting TFIIB pro-
tein level.
DC-TLP, which lacks the TFIIB-binding region,
was increased by TFIIA over-expression, but it is
degraded within several hours (Fig. 5C). This result
suggests that DC-TLP is slightly stabilized by TFIIA
and the affinity of DC-TLP to TFIIA is lower than
wild-type TLP. Consistently, we found that DC-TLP
shows lower TFIIA-binding ability than wild-type
TLP does and that DC-TLP has a little activation
function for cyclin G2 promoter (Fig. 5B). These
results imply that TFIIB binding to TLP is required
for stable TLP-TFIIA interaction.
The unprocessed form of TFIIAab-TFIIAc
complex has a function to stabilize TLP
TFIIA is a complex of a, b and c subunits (Høiby
et al. 2007). The TFIIAa and b subunits are gener-
ated from TFIIAab precursor by Taspase1-driven
proteolysis (Zhou et al. 2006). Thus, TFIIA can form
several molecular states including ab/c and a/b/c.
(A)
(B)
(C)
(a)
(b)
Figure 2 TLP protein is degraded by the ubiquitin-proteasome pathway. (A) Stability of TLP protein. HCT116 cells transfected
with an expression plasmid for FH-TLP were treated with CHX for the indicated time, and the protein was detected by Western
blotting (a). The signal intensity of FH-TLP or GAPDH was measured and is shown the right panel (b). (B) Effect of inhibitors of
proteasome and autophagy. FH-TLP-introduced HCT116 cells were treated with CHX in combination with MG132 or bafilomy-
cin A1 (BafA1) for the indicated times. (C) In vivo ubiquitination assay. HCT116 cells were transfected with plasmids for FH-TLP
and HA-tagged ubiquitin (HA-Ub) as indicated. After FH-TLP had been immunoprecipitated with a-Flag M2 beads, co-immuno-
precipitated HA-Ub was detected by Western blotting with a-HA antibody. TLP, TBP-like protein; CHX, cycloheximide.
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We wondered which state of TFIIA is able to stabi-
lize TLP. First, we tested whether TFIIAab or
TFIIAc subunit has a potential to stabilize TLP. The
results showed that TFIIAab or TFIIAc alone did
not stabilize TLP, but that the combination of
TFIIAab and TFIIAc stabilized TLP (Fig. 6A), sug-
gesting that the form of holo-TFIIA is required for
TLP stabilization.
Next, we examined the function of the TFIIAab
precursor for TLP stabilization. Generally, unpro-
cessed TFIIAab is thought to be an immature form
of TFIIA and to have no significant function.
However, as shown in Fig. 1A, TLP exhibited high
affinity to unprocessed TFIIAab (Fig. 1A). There-
fore, we investigated whether unprocessed TFIIAab
has a specific function for maintenance of TLP and
the subsequent transcriptional regulation. We found
that DGAA TFIIAab mutant, which is not processed
by Taspase1, stabilized TLP together with TFIIAc
(Fig. 6B), whereas DN-TLP was not stabilized by
DGAA (Fig. 6C), indicating that unprocessed
TFIIAab forms a complex with the c subunit and
stabilize TLP through directly binding to the N-
terminal part of TLP. Moreover, the luciferase
(A) (B)
Figure 3 TLP is stabilized by over-expressed TFIIA. (A) Effect of over-expressed TFIIA on stability of TLP protein. HCT116
cells into which FH-TLP and FH-TFIIA had been introduced were treated with CHX for the indicated times. (B) Effect of
TFIIA over-expression on transcription level of FH-TLP. HCT116 cells were transfected with FH-TLP and FH-TFIIA, and
mRNA expression was detected by RT-PCR. TLP, TBP-like protein; CHX, cycloheximide.
(A) (B)
Figure 4 TFIIA-binding capacity of mutant TLPs. (A) Schematic illustration of the structures of TLP deletion mutants. The
N-terminal and C-terminal parts of TLP, which are responsible for TFIIA binding and TFIIB binding, respectively, were deleted.
(B) The affinity of TLP mutant to TFIIA. HCT116 cells were transfected with expression plasmids for FH-TLP or FH-DN-TLP
together with TFIIA, and the FH-tagged protein was immunoprecipitated with anti-Flag M2 beads. The eluates were analyzed by
Western blotting. TLP, TBP-like protein.
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reporter assay showed that unprocessed TFIIAab acti-
vates the cyclin G2 promoter together with TLP
(Fig. 6D). The activation ability of unprocessed
TFIIA was similar to or higher than wild-type TFIIA
(Fig. 6D). These results suggest that unprocessed
TFIIAab has a potential to stabilize TLP protein and
direct subsequent promoter activation in vivo. From
the facts that unprocessed TFIIAab stabilizes TLP
(Fig. 6B,C) and that unprocessed TFIIAab alone
does not significantly activate cyclin G2 promoter
(Fig. 6D), the promoter activation by unprocessed
TFIIAab over-expression is likely to be caused by
accumulated TLP proteins.
Discussion
TLP was first identified as a development-related fac-
tor (Duttke et al. 2014). As a well-known phenotype
of TLP defect, its knockout causes a severe defect of
spermatogenesis of mouse development through
impaired spermatogenesis-related gene expression
(Zhang et al. 2001). However, the role of TLP in
human cells had remained obscure. Recent studies
showed that TLP is also involved in transcription reg-
ulation in human cells, and elucidation of how cellu-
lar TLP quantity is regulated must be important for
understanding TLP-regulated gene expression (Suzuki
(A)
(C)
(B) (a) (b)
Figure 5 Direct binding between TLP and TFIIA is required for TFIIA-mediated TLP stabilization. (A) Effect of over-expressed
TFIIA on DN-TLP mutant. HCT116 cells were transfected with expression plasmids for FH-TLP or FH-DN-TLP together with
increasing amounts of FH-TFIIAab and FH-TFIIAc. The amount of FH-TLP protein was determined by Western blotting. (B)
Luciferase reporter assay for mouse cyclin G2 promoter. HeLa cells were transfected with expression plasmids for FH-TFIIA and
FH-TLP or TLP mutants together with a cyclin G2 promoter reporter plasmid, and luciferase activity was determined (a). The
expression levels of proteins were determined by Western blotting (b). (C) Effect of over-expressed TFIIA on stability of TLP
mutants. HCT116 cells transfected with expression plasmids for FH-TLP and its mutants together with FH-TFIIA were treated
with CHX for the indicated times. The amounts of proteins were determined by Western blotting. TLP, TBP-like protein; CHX,
cycloheximide.
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et al. 2012, 2014). This study showed that TLP is a
target of the ubiquitin-proteasome system (Fig. 2)
and that TFIIA protects TLP protein from degrada-
tion. As results of stability analysis indicate, although
naked state TLP alone seems to be unstable, the
strongest binding partner TFIIA stabilizes TLP by
forming a stable complex. Structurally similar TBP
protein is also one of the TFIIA-interacting proteins.
However, TBP was not significantly stabilized by
TFIIA. Consistently, exogenously expressed TBP
exhibits little TFIIA-binding ability, whereas
exogenous TLP clearly exhibits TFIIA-binding capac-
ity (Fig. 1A), implying functional differences between
TBP and TLP in stabilization of TFIIA.
TBP generally potentiates the expression of TATA
box genes, whereas TLP represses TATA box genes
and activates a subset of TATA-less genes (Moore et al.
1999). Thus, control of the abundance of TBP and
TLP must be essential for determining gene expression
patterns from the chromosome. In a previous study,
we found that TFIIA works as a transcriptional co-acti-
vator of TLP (Suzuki et al. 2014). Additionally, the
(A) (B)
(C) (D)
Figure 6 TLP is stabilized by unprocessed TFIIAab-TFIIAc complex. (A) Effect of over-expressed TFIIA subunits on TLP sta-
bility. FH-TFIIA subunits were introduced into HCT116 cells together with FH-TLP as indicated, and the cells were treated with
CHX for the indicated times. The amount of protein was determined by Western blotting. (B) Effect of DGAA TFIIA mutant on
TLP. Increasing dose of wild-type FH-TFIIAab or FH-DGAA mutant was over-expressed in HCT116 cells together with TFIIAc
and FH-TLP as indicated, and the amount of protein was determined by Western blotting. (C) Effect of unprocessed TFIIA on
stability of wild-type TLP and DN-TLP. DGAA TFIIA mutant and TFIIAc were over-expressed in HCT116 cells together with
wild-type TLP or DN-TLP as indicated, and cells were treated with CHX for the indicated times. The amounts of proteins were
determined by Western blotting. (D) Luciferase reporter assay for mouse cyclin G2 promoter. The indicated combination of
expression plasmids together with the cyclin G2 promoter reporter were transfected into HeLa cells, and relative luciferase activity
was determined. TLP, TBP-like protein; CHX, cycloheximide.
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present study suggests that TFIIA-mediated control of
TLP turnover is involved in gene regulation. We
found that co-over-expression of TLP and TFIIA dra-
matically up-regulates the cyclin G2 TATA-less pro-
moter (Figs 5B and 6C), due to stabilization and
accumulation of TLP by TFIIA. A similar result was
obtained in another TATA-less promoter of the
CDKN1A gene (Suzuki et al. 2014). Consequently,
TFIIA activates gene promoters not only by stabilizing
TLP but also by exerting its co-activator function.
Notably, TLP is stabilized by TFIIA in its unpro-
cessed form (Fig. 6). Unprocessed TFIIAab protein is
subjected to Taspase1-mediated proteolysis, and this
process is critical for regulating the transcriptional acti-
vation function of TFIIA (Høiby et al. 2007; Oyama
et al. 2013). Generally, processed TFIIAa/b is func-
tional for activation of TBP-driven promoters. We
recently reported that this TFIIA maturation is inhib-
ited by TLP, which results in repression of TATA
box promoter activity (Suzuki et al. 2015), indicating
that interaction between TLP and the TFIIA precur-
sor has a negative effect on TBP-driven transcription.
In contrast, TLP exhibits an activation function for a
subset of TATA-less promoters including cyclin G2
promoter (Fig. 6C). Promoter activation by TLP and
the TFIIA precursor suggests that the TLP-TFIIA
precursor complex has a positive effect on a subset of
promoters. Taken together, the results indicate that
TLP-TFIIA interaction may function as a switch of
gene regulation through exerting a bivalent transcrip-
tional effect on distinct types of gene promoters.
It has been shown that genotoxic stress increases the
proportion of TFIIA-bound TLP (our unpublished
data) and the level of TLP (Suenaga et al. 2009; Suzuki
et al. 2012, 2014). Our conclusion that the interaction
with TFIIA stabilizes TLP protein implies that upon
DNA damage, increased TLP-TFIIA affinity increases
TLP abundance. As TLP plays an important role in the
DNA damage response through regulating a subset of
genes, the process that TLP expression is proteolyti-
cally regulated by TFIIA must be critical for DNA
damage response. The reason why DNA damage
enhances TLP-TFIIA interaction is not known. One
possible mechanism of enhanced TLP-TFIIA interac-
tion is posttranslational modification of TLP and
TFIIA. As TBP-TFIIA interaction has been reported
to be strengthened by phosphorylation (Solow et al.
1999), TLP-TFIIA interaction may also be affected by
phosphorylation. Whether the posttranslational modi-
fication model actually works for TLP stabilization is
an issue to be addressed for further investigation of
TLP-TFIIA interaction.
Experimental procedures
Cell culture, drug treatment and siRNA and DNA
transfection
Human HCT116 cells and HeLa cells were maintained in
Dulbecco’s modified MEM with high and low concentrations
of glucose, respectively, at 37 °C in the presence of 10% fetal
bovine serum. Fifty micrograms per milliliter of CHX and
100 nM bafilomycin A1 were used. siRNAs for human TLP
and TFIIA were described previously (Suzuki et al. 2014).
Transfection of plasmids or siRNA was carried out using
Lipofectamine 2000 reagent (Invitrogen).
Expression plasmids for mammalian cells
pCIneo-FH-TLP, an expression plasmid of flag/oligohistidine
(FH)-tagged mouse TLP, was described previously (Suzuki
et al. 2014). Mouse and human TLPs have identical amino
acid sequences. Plasmids for mutant TLPs (DN-TLP and DC-
TLP) were generated from pCIneo-FH-TLP by deleting its
amino or carboxyl terminus using the PCR method. TFIIA
expression plasmids, pCIneo-FH-TFIIAab and pCIneo-FH-
TFIIAc, have an open reading frame of human TFIIAab and
TFIIAc with an FH-tag at their amino termini. The plasmid
for mutant DGAA TFIIA was described previously (Suzuki
et al. 2015). pcDNA-HA-Ub has an open reading frame of
ubiquitin with an HA-tag as described previously (Shiraishi
et al. 2007).
Luciferase reporter assay
For construction of cyclin G2 promoter-containing reporter
plasmids for a luciferase assay, the promoter sequence of the
mouse cyclin G2 gene was amplified by PCR from mouse
genomic DNA and inserted into pGL3-basic (Promega). A
luciferase reporter assay was carried out as described previously
(Suzuki et al. 2014). Briefly, cells were inoculated into a 24-
well plate (8 9 104 cells/well). Twenty-four hours later, the
cells were transfected with the indicated amount of a reporter
plasmid and an effector plasmid and cultured for 24 h. Then,
the cells were disrupted with a Passive Lysis Buffer (Promega).
Luciferase activity in lysates was determined using a Single
Luciferase Reporter Assay System (Promega).
Western blotting and antibodies
Proteins were separated by 12.5% SDS-PAGE and transferred to
an Immobilon-P polyvinylidene difluoride (PVDF) membrane
(Millipore). Proteins on the PVDF membrane were incubated
with specific primary antibodies and appropriate horseradish
peroxidase-conjugated secondary antibodies, and the signals
were detected with ImmnoStar Zeta (Wako) as previously
described (Suzuki et al. 2015). As primary antibodies, we used
anti-(a)-GAPDH (Santa Cruz), a-p62 (Medical & Biological
Laboratories), a-p53 (Santa Cruz), a-b-actin (Santa Cruz) and
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a-HA antibodies. a-TLP, a-TBP and a-TFIIA antibodies are
antigen-purified antibodies (Suzuki et al. 2015).
Immunoprecipitation
Whole-cell extracts were prepared as previously described
method with some modifications (Nakadai et al. 2004).
Briefly, cells were lysed with the lysis buffer containing 1%
Triton X-100 and then mildly sonicated. Five hundred micro-
grams of the extract was used for immunoprecipitation. FH-
proteins in extracts were precipitated with anti-Flag M2 Affin-
ity Gel (Sigma-Aldrich). IgG-Sepharose 6 Fast Flow (GE
Healthcare Bioscience) was used as a control antibody. Bound
proteins were eluted with Flag peptide and analyzed by Wes-
tern blotting.
In vivo ubiquitination assay
A ubiquitination assay was carried out as described previously
with minor changes (Shiraishi et al. 2007). Briefly, HeLa cells
transfected with pcDNA-HA-Ub and pCIneo-FH-TLP were
treated with 25 lM MG132 for 4 h to accumulate ubiquiti-
nated proteins and then harvested. The cells were lysed in lysis
buffer with 20 lM N-ethylmaleimide, and the cell extract
containing 500 lg of proteins was used for immunoprecipita-
tion of FH-TLP with anti-Flag M2 Affinity Gel. FH-TLP-
bound proteins were eluted, and amount of co-immunopreci-
pitated ubiquitin was determined by Western blotting.
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